[Senate Hearing 108-218]
[From the U.S. Government Publishing Office]
DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, EDUCATION, AND RELATED
AGENCIES APPROPRIATIONS FOR FISCAL YEAR 2004
----------
WEDNESDAY, MARCH 19, 2003
U.S. Senate,
Subcommittee of the Committee on Appropriations,
Washington, DC.
The subcommittee met at 9:01 a.m., in room SD-124, Dirksen
Senate Office Building, Hon. Arlen Specter (chairman)
presiding.
Present: Senator Specter, Craig, Gregg, Harkin, Landrieu,
and Kohl.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
STATEMENT OF TOMMY G. THOMPSON, SECRETARY OF HEALTH AND
HUMAN SERVICES
opening statement of senator arlen specter
Senator Specter. Good morning, ladies and gentlemen. The
hearing of the Appropriations Subcommittee of Labor, Health,
Human Services, and Education will now proceed.
Our witness today will be the Secretary of HHS, Secretary
Tommy Thompson, the 19th Secretary of the Department which
oversees the health and welfare of the Nation.
The administration budget has proposed a discretionary
account for the Department of Health and Human Services of some
$60.7 billion which constitutes an increase of $514 million
over the fiscal year 2003 level, which, as obvious, does not
even account for an inflationary increase.
This Department has some of the most important funding in
our Nation, spanning medical research and Head Start and the
low-income health and energy costs, known as LIHEAP, and a
broad range of very, very important programs. It is, as usual,
a very difficult matter in allocating the resources which this
subcommittee has for three Departments, the Department of
Education, the Department of Labor, in addition to this
Department.
There is special concern about a number of lines. The
Centers for Disease Control, which is being asked to take on
additional responsibilities, as we speak, with this outbreak in
China. The National Institutes of Health, which have had
extraordinary results, have been limited in this year's
suggested funding by the administration to a $673 million
increase, which is a sharp decrease from the $3.5 billion
increase which the administration requested last year, which
really was a commentary on the phenomenal results which NIH
had. But we will be wrestling with these issues.
We appreciate the appearance of the Secretary today. To
give the maximum time for the Secretary's comments, we will
begin at this point.
Secretary Thompson began his public service back in 1966 as
a representative in the Wisconsin State Assembly. He served as
Governor of Wisconsin from 1987 to 2000, the longest-serving
Governor in Wisconsin history, well known for his innovative
activities in the welfare system and expanding health care
access to low-income children and families. He was chairman of
the National Governor's Association, the Education Commissioner
of the States and Midwestern Governors Conference. Both of his
degrees, bachelor and J.D., come from the University of
Wisconsin at Madison.
Thank you for joining us, Mr. Secretary, and we look
forward to your testimony.
SUMMARY STATEMENT OF HON. TOMMY G. THOMPSON
Secretary Thompson. Thank you so very much, Mr. Chairman. I
want to thank you at the outset for your passion, for your
leadership on so many issues that are very important to the
future of the health care and well-being of Americans, and I
thank you for that leadership.
I am sorry Mr. Harkin is not here, but I also want to
extend my appreciation to him as well.
Thank you so very much, Senator Specter, for inviting me to
testify today.
In my first 2 years at the Department, we have made, I
believe, tremendous progress in our efforts to improve the
health, the safety, and the well-being of the American people.
We continue to make extraordinary progress in providing health
care to lower-income Americans through waiver and State plan
amendments granted to States. We have been able to expand
access to health coverage for more than 2.2 million individuals
and have expanded the range of benefits offered to an
additional 6.7 million other Americans.
To build on this progress, the President proposed outlays
for HHS of $539 billion. $539 billion represents an increase of
$36.8 million, or 7 percent over last year's request, an
increase of more than $109 billion, or 25 percent, since 2001.
The discretionary part of the budget increases $1.64
billion, or 2.6 percent, to $65 billion of budget authority.
This would be $606 million, or 1.5 percent, higher than what
was enacted by the Congress in the fiscal year 2003
appropriation bill.
$539 billion is a large number, and I have a solemn
responsibility as Secretary to make sure that every one of
those dollars is put to good use. I owe it to the people who
pay the taxes, and I owe it to the people who consume the
services.
One way to ensure that these dollars are effective is to
work with you, Senator Specter, and Senator Harkin and other
committee members and other committees to improve and
strengthen our two largest health programs, Medicare and
Medicaid. I discuss these programs in my written testimony.
We are also making progress in keeping health care costs
down and preventing chronic diseases by encouraging Americans
to lead healthier lives. We have all heard the disturbing news
about the prevalence of diabetes, obesity, and asthma that
could be prevented through simple lifestyle changes. Diabetes
alone costs the Nation nearly $132 billion each year in direct
medical and indirect economic costs. Yet, modest lifestyle
changes, such as getting more exercise and losing weight, can
reduce the risk of this and other diseases dramatically.
The HHS budget, consistent with the President's HealthierUS
effort, proposes a coordinated Department-wide effort, Steps to
a HealthierUS, to promote healthier lifestyles, emphasizing
prevention of obesity, diabetes, asthma, heart disease, stroke,
and cancer. The fiscal year 2004 budget includes an investment
of $125 million for targeted disease prevention.
In order to improve patient safety, which I know, Senator
Specter, you have been an advocate and leader on, the Food and
Drug Administration is proposing two new rules to prevent
errors with medication.
The first of these proposals will require bar-coding on
almost all pharmaceuticals and blood products. This rule would
help reduce the number of medication errors by allowing health
care professionals to use bar-code scanning equipment to verify
that the right drug in the right dose is given to the right
patient at the right time.
We also support the creation of patient safety
organizations in order to collect data that can improve
procedures and prevent errors.
And thanks to your strong support, Mr. Chairman, we
recently completed a doubling of the budget of the National
Institutes of Health. This year we continue that commitment
with a budget of $27.7 billion, a net increase of $549 million
over last year.
But as a result of one-time projects that were funded in
fiscal year 2003 and not needing to be refinanced, actual NIH
research investment will rise by $1.9 billion, or 7.5 percent.
I would like to focus the remainder of my remarks this
morning on a topic that is probably on everyone's mind this
week, and that is bioterrorism. I would like to offer to you,
Mr. Chairman, and members of the committee, an opportunity to
come over to the Department at your choosing to see our new
bioterrorism communications center. It is state of the art, and
it is one that you would appreciate if you would come over and
have an opportunity to see.
The attacks on September 11 made it clear that the threat
of terror is more grave and more imminent than at any time in
modern history. Anthrax attacks make it clear that the threat
of terrorism includes weapons of unprecedented power and
ingenuity, and the proliferation of weapons of mass destruction
in the hands of outlaw regimes makes it even more urgent that
we prepare for a growing variety of threats.
We have already done a great deal, and the United States
today is better prepared than ever to meet and be able to
respond to the threat of a terrorist attack with a biological,
chemical, radiological, or nuclear agent.
The National Stockpile of Medical Countermeasures is large
and getting more extensive all the time. But that stockpile may
not be enough. Unfortunately, the medical treatment available
for many pathogens have improved very little in decades. The
smallpox vaccines available today hardly differ from those of
the 1960s. Some treatments for radiation and chemical exposure
have not changed much since the 1970s, and some diseases, such
as ebola, have never had an effective medical countermeasure.
These diseases lack effective or modern treatment in part
because they are so rare.
By contrast, the treatment of the vast majority of common,
naturally occurring illnesses have been able to be improved
dramatically as a result of ongoing innovations from biomedical
research and development. Heart attacks were often fatal in the
1970s, but they are much less so today. And better detection
and therapeutic options have significantly improved survival
rates for many kinds of cancer over the last 20 years.
We must bring that sort of progress to the rare, yet deadly
threats which are posed by bioterrorists, and that is why
President Bush, with the help of my Department, has been able
to announce Project Bioshield. He would spend roughly $6
billion over 10 years on new countermeasures to prepare America
for a bioterrorist attack. This proposal would speed up
research and approval of vaccines and treatments and ensure a
guaranteed funding source for their purchase, just the latest
in our forward-looking efforts to protect the homeland.
Our Department is doing well at getting bioterrorism money
out to State governments in many cases faster than they are
able to spend it.
So as we speak, Mr. Chairman, researchers are working to
identify the cause of the recent cases of what has been called
severe acute respiratory syndrome. While we have no reason to
think that this syndrome is related to influenza, the
appearance of similar symptoms in scattered locations reminds
us that this is the way an influenza pandemic might start.
The President's budget foresaw and prepared for an
influenza outbreak. It proposes to spend $100 million to ensure
the Nation has an adequate supply of influenza vaccine in the
event of a pandemic. And due to the constant changes in the
circulating influenza strains, we cannot stockpile influenza
vaccine, and the current manufacturing methods could not meet
the Nation's needs in the event of a pandemic. Funds will be
used for activities to ensure a year-around influenza vaccine
production capacity and development and implementation of
rapidly expandable production technologies. We will work
closely with industry to accomplish these goals.
The President has made improving our Nation's health and
health care one of his biggest priorities for this year. By
working together, we can make it one of our proudest
achievements.
I look forward to working with you, Mr. Chairman, Senator
Harkin, as well as Senator Craig, and all members of this
committee, and I know our discussion this morning will
certainly proceed and allow those things to be initiated.
PREPARED STATEMENT
I thank you, Mr. Chairman, and I would also, once again,
invite you and other members of the committee to come over to
the Department and see our very modern, state-of-the-art
communications system that will allow us to better respond to
any bioterrorist attack that may take place in this country.
Thank you again for giving me this opportunity to appear in
front of you, Senator.
[The statement follows:]
Prepared Statement of Tommy G. Thompson
Good morning Mr. Chairman, Senator Harkin and members of the
committee. I am honored to be here today to present to you the
President's fiscal year 2004 budget for the Department of Health and
Human Services (HHS). I am certain you will find that, viewed in its
entirety, our budget will help improve the health and safety of our
Nation. Before I discuss the fiscal year 2004 budget, I would like to
thank the committee for its hard work and dedication to the programs at
HHS.
Our fiscal year 2004 request totals $539 billion in outlays,
approximately 7.3 percent over the fiscal year 2003 budget. The
discretionary budget authority portion of the HHS budget, before this
committee, totals $60.7 billion, which is an increase of approximately
$1.5 billion, or 2.6 percent over the fiscal year 2003 President's
Budget and an increase of approximately $514 million, or 0.9 percent
over the fiscal year 2003 enacted appropriation. Mandatory outlays for
HHS total $475.9 billion in this budget proposal, an increase in excess
of 7 percent.
The budget proposed by the President for HHS will enable the
Department to continue its important work with our partners at the
State and local levels and the newly created Department of Homeland
Security. Working together, we will hold fast to our commitment to
protecting our Nation and ensuring the health and well-being of all
Americans. Many of our programs at HHS provide necessary services that
contribute to fighting the war on terrorism and provide us with a more
secure future. And, I am particularly focused on preparedness at the
State and local level, HHS's ability to respond rapidly to a
bioterrorist attack, research on and development of vaccines and other
therapies to counter potential bioterrorist attacks, and ensuring the
safety of our food supply.
The President's fiscal year 2004 budget request also continues to
support the needs of the American people by strengthening and improving
Medicare and Medicaid; enhancing Temporary Assistance for Needy
Families (TANF) and Foster Care; strengthening the Child Support
Enforcement Program; and furthering the reach of the President's New
Freedom Initiative.
The support of your committee is vital to achieving many of the
Administration's most important priorities. I am grateful for the close
partnership we have enjoyed in the past, and I look forward to working
with you again on an aggressive appropriations agenda to advance the
health and well being of millions of Americans. Today, I would like to
highlight for you the key issues in the President's budget.
SUPPORTING THE PRESIDENT'S DISEASE PREVENTION INITIATIVE
One of the most important issues on which we can work together is
chronic disease prevention. We all have heard the disturbing news about
the prevalence of diabetes, obesity, and asthma that could be prevented
through simple lifestyle changes. The statistics, I am sure, are as
alarming to you as they are to me. For example, the incidence of
diabetes and obesity among Americans is up sharply in the past decade,
putting millions more Americans at higher risk for heart disease,
stroke and other related medical conditions.
Diabetes alone costs the Nation nearly $132 billion each year in
direct medical costs and in indirect economic costs, including
disability, missed work, and premature death. Medical studies have
shown that modest lifestyle changes--such as getting more exercise and
losing weight--can reduce an individual's risks for developing this
serious health conditions.
The HHS budget, consistent with the President's HealthierUS effort,
proposes a coordinated, Department-wide endeavor--Steps to a
HealthierUS--to promote healthier lifestyles emphasizing prevention of
obesity, diabetes, asthma, heart disease, stroke, and cancer. The
fiscal year 2004 budget includes an investment of $125 million for
targeted disease prevention.
IMPROVING THE NATION'S HEALTH
Of all the issues confronting this Department, none has a more
direct impact on the well being of our citizens than the health of our
Nation. Our budget makes a concerted effort to improve the health of
the American people by taking significant steps that include: reducing
prescription drug-related medical costs, financing vaccines, investing
in hospital information technology, and continuing the effort to
increase and expand the number of Health Centers.
The budget includes initiatives that will carry out the Best
Pharmaceuticals for Children Act (BPCA) and alleviate drug-related
medical costs. My budget request for NIH includes an additional $25
million, for a total of up to $50 million, to improve information
available for prescribing pharmaceuticals to children. NIH is focusing
its efforts on drugs that are no longer under patent. The request for
the Food and Drug Administration (FDA) includes $12.3 million to
increase Americans' access to safe, effective, and less expensive
generic drugs and a $1 million increase to expand the range of drugs
available over-the-counter.
The HHS budget includes a series of improvements in the financing
of childhood vaccines to meet three goals--(1) improve vaccine access
for currently eligible children, (2) restore tetanus and diphtheria
booster vaccines (Td, DT) to the Vaccines for Children (VFC) program,
and (3) build a national stockpile of childhood vaccines. Legislation
will be proposed to improve access to VFC vaccines for children already
entitles to them. The budget proposes to expand the number of access
points for underinsured children--those whose private insurance does
not cover the immunizations--by allowing them to receive their VFC
vaccines at State and local public health clinics. To help protect
against future shortages, HHS will, starting in fiscal year 2003,
develop a stockpiling strategic plan and begin building a vendor-
managed, 6-month supply of all childhood vaccines to be completed by
2006. The budget includes $707 million in fiscal year 2003 to 2006 for
the stockpile. Under current-law we can stockpile these vaccines. I
also propose to restore the tetanus and diphtheria booster shots to the
VFC program by removing outdated price caps that are so low for some
vaccines that vendors will not bid on VFC contracts.
The budget also contains $100 million to ensure the nation has an
adequate supply of influenza vaccine in the event of a pandemic. Due to
the constant changes in the circulating influenza strains, we cannot
stockpile influenza vaccine, and the current manufacturing methods
could not meet the Nation's needs in the event of a pandemic. Funds
will be used for activities to ensure a year-round influenza vaccine
production capacity and the development and implementation of rapidly
expandable production technologies. We will work closely with industry
to accomplish these goals.
Senator Specter, you were instrumental in ensuring that patient
safety is a primary focus of AHRQ's research portfolio. In fiscal year
2001, we made awards to 94 grantees in five areas to begin the first of
three years of research to improve patient safety across healthcare
settings. Nearly half of these demonstration projects are focusing on
the use of computers and information technology to prevent medical
errors and to improve reporting of medical errors data Through these
projects, grantees are piloting potential error-reducing technologies
like personal digital assistants (PDAs) for electronic prescription
writing, as well as Computerized Physician Order Entry (CPOE), a
technology that helps to ensure that patients receive the right
medication, at the right dose, at the right time. As a result of these
projects, AHRQ's first step in improving patient safety has been to
demonstrate the efficacy of certain interventions in reducing medical
errors.
Our next step must be to take what we have learned and disseminate
it to healthcare providers and networks. We are putting $50 million
into a new program at AHRQ that will improve patient safety by
increasing investments in hospital information technology. We are also
making a commitment to help implement these technologies in health
systems that otherwise may not be able to make the capital investment.
A focus on small community and rural hospitals will help to bridge the
so-called ``digital divide'' by helping these hospitals catch up with
those that are further along.
AHRQ's budget proposal also includes $24 million for ongoing
activities such as the work of the Patient Safety Task Force and the
Patient Safety Data Reporting System integration efforts, as well as
plans to initiate challenge grants and a patient safety improvement
corps; a $10 million increase for the expansion and enhancement of
information collected in the U.S. Census Bureau's Current Population
Survey; and a $2 million increase to improve the usability and
timeliness of Medical Expenditure Panel Surveys (MEPS) data and help
sustain prior year enhancements to the sample size and content of
surveys that collect information from medical providers, insurers, and
households.
We must do everything within our abilities to address the
disparities in health care in this Nation. The fiscal year 2004 budget
proposes numerous activities to address and alleviate health
inequities. Programs that cut across various HHS agencies strive toward
bettering the health of our Nation.
The fiscal year 2004 budget continues the third year of the
President's multi-year initiative to expand access to care for millions
of Americans especially those who are uninsured. The budget includes
$1.6 billion, a $122 million increase, to provide primary and
preventive health care services to nearly 14 million individuals.
Almost 40 percent of the patients treated at health centers have no
insurance coverage and many others have inadequate coverage. These
health centers are located in our most underserved communities. Over
half are in rural America. In support of the Health Center Initiative,
the President is also seeking to expand the National Health Service
Corps by adding $42 million to increase the number of health care
providers in rural and underserved areas, to a total field strength of
4,300 people; and provide for 2,400 loan repayments and scholarships.
In addition to childhood immunization, the fiscal year 2004
President's budget for the Centers for Disease Control and Prevention
(CDC) requests programmatic increases in several areas. I am seeking a
$12 million increase for the breast and cervical cancer program, which
supports screenings for low-income, underinsured, and uninsured women
between the ages of 50-64, and $5 million to expand School Health
Programs to reduce health risks such as tobacco use, poor eating habits
and obesity. The budget also includes an increase of $10 million for a
Public Health Information Network (PHIN) to integrate and expand CDC's
existing networks to establish a consistent exchange of information
between public health partners.
The Substance Abuse and Mental Health Services Administration's
proposed budget is $3.4 billion, a net program level increase of $198
million over fiscal year 2003. As part of the President's Drug
Treatment Initiative, the budget includes $200 million in fiscal year
2004, a total of $600 million over three years, to establish a new
competitive State substance abuse voucher program. This program will
assist 100,000 Americans in the first year in obtaining the critical
alcohol and drug treatment services they need but lack access to. This
effort complements existing alcohol and drug abuse treatment programs
by providing consumer choice and broadening the base of treatment
providers to include more faith-based providers. Through this new
program individuals seeking drug and alcohol treatment and support
services will be assessed and then receive a voucher to pay for
appropriate community treatment programs. This program will require
accountability by linking payment to providers to demonstrated
treatment effectiveness measured by abstinence from alcohol and drug
use after treatment.
The fiscal year 2004 request also includes an increase of $31
million for the Substance Abuse Block Grant. The Block Grant will
provide drug treatment services to 400,000 persons. In the area of
mental health, we propose $107 million, an increase of $9 million, for
Children's Mental Health Services to serve a total of 17,000 children
and adolescents with serious mental and emotional disorders along with
their families. We are also requesting $50 million, an additional $7
million, for Projects for Assistance in Transition from Homelessness to
serve a total of 147,000 homeless individuals. These funds link efforts
to move homeless individuals off the streets by providing them with
mental health services and substance abuse treatment.
FIGHTING HIV/AIDS
HIV/AIDS is one of the most serious challenges facing humanity. No
country has been spared. Some have faced widespread devastation. All
have citizens whose lives have been destroyed by this horrible disease.
Our commitment to ending this pandemic is strong and unwavering. The
fiscal year 2004 budget for HHS includes $6.4 billion in discretionary
funds within HHS to combat HIV/AIDS. Within this level is $680 million
to support a variety of efforts to fight HIV/AIDS in developing
nations. For example, our budget includes $150 million to support the
Mother-to-Child transmission of HIV/AIDS prevention initiative. This
initiative seeks to treat approximately one million women annually in
developing countries in order to reduce transmission of HIV to their
children by 40 percent. This is an integral part of the President's
Emergency Plan for AIDS Relief, which seeks to stem the death toll from
AIDS. Currently, demographers project that, absent strong action, life
expectancy will fall from 66 to 33 years in Zambia and from 70 to 40
years in Zimbabwe.
The budget also, includes $2 billion for life sustaining care and
services for over 530,000 Americans under the Ryan White CARE Act. The
Ryan White programs target our resources toward the development of an
effective service delivery system by partnering with States, heavily
impacted metropolitan areas, faith-based and community-based providers
and academic institutions. Our budget includes $739 million to provide
drug therapies to approximately 159,000 individuals. These funds will
provide Americans living with HIV/AIDS a lifeline to care who might
otherwise have to choose between expensive medical treatments and other
necessities. These funds will help eliminate those difficult decisions.
MAINTAINING OUR INVESTMENT IN BIOMEDICAL RESEARCH
I commend you, Mr. Chairman, Senator Harkin, and this Subcommittee,
for your unwavering commitment to doubling the budget for the National
Institutes of Health. After five years of outstanding growth that
doubled the NIH budget, the fiscal year 2004 Budget provides a
significant investment to ensure that the momentum gained over the last
five years is sustained. We have developed a plan that would increase
funding for on-going research by about $2 billion, approximately +7
percent. The fiscal year 2004 budget totals $27.9 billion, a net
increase of $718 million above the fiscal year 2003 enacted
appropriation. Within the NIH Budget, research grows much more rapidly,
as a result of redirecting one-time project cost savings into new
biomedical research funding. NIH will fund a record number of new and
competing research grants. Advances in scientific knowledge have
provided the foundation for improvement in public health and have led
to enhanced health and quality of life for all Americans. Much of this
can be attributed to the ground breaking work carried on by, and funded
by, the National Institutes of Health. Some additional highlights of
NIH funding include:
--Over $15 billion to fund an expected record number of research
project grants (at least 10,500 for competing grants and a
total of approximately 39,500 grants);
--An increase of $25 million for a total of $50 million for pediatric
drug use studies;
--An increase of $50 million for Type 1 diabetes research ($150
million total in mandatory appropriation); and
--An increase of $25 million for NIH's new strategic biomedical
research ``roadmap''.
FIGHTING BIOTERRORISM
Mr. Chairman, as Americans confront the realities of terrorism and
hostilities around us, it is imperative that the Federal Government be
prepared to keep our citizens safe and healthy.
HHS's $3.6 billion bioterrorism budget substantially expands
ongoing medical research, strengthens State and local preparedness and
targets investments to protect our food supply. State and local public
health preparedness activities funded by the Centers for Disease
Control and Prevention (CDC) and hospital preparedness efforts
supported by the Health Resources and Services Administration (HRSA)
would receive a total of $1.5 billion. The President's proposal
significantly increases ongoing biodefense research at the National
Institutes of Health (NIH). The budget includes a total of $1.6 billion
for basic research on the biology of microbial agents with bioterrorism
potential and applied research on the development of new or improved
diagnostics, vaccines, and therapies. We propose increasing support for
bioterrorism education for clinicians by $32 million, for a total of
$60 million, to provide incentives for 25 medical and health
professions curricula reform projects and provide continuing education
to 65,000 health care providers on the diagnosis, treatment, and
reporting of diseases that can be caused by the intentional release of
a biological agent. The bioterrorism budget also includes initiatives
to improve food safety: $15.5 million targeted on newly authorized
activities, including registration of domestic and foreign food
facilities and State grants to improve state food laboratories,
monitoring and inspections; and an additional $5 million for improving
information exchange with State food laboratories on food pathogens.
HHS, in cooperation with the Department of Homeland Security, will
spearhead the development of Project Bioshield. This project, which the
President recently announced, will bring together the scientific and
fiscal resources of the United States government in an innovative
effort to develop medical countermeasures against bioterror before they
are ever needed. Project Bioshield will have three (3) major goals:
--To ensure that sufficient resources are available to procure the
next-generation countermeasures. A guaranteed funding source
must be available to enable the government to purchase vaccines
and other therapies as soon as experts believe they can be made
and will be safe and effective, and spur industry investment in
the development of these vaccines/therapies.
--To Accelerate NIH research and development. This involves providing
more flexible contracting process and procurement authorities
for critical biodefense work.
--To make promising treatments available more quickly for use in
emergencies. This means establishing a new FDA Emergency Use
Authorization that would permit greater flexibility and
latitude than the current Investigational New Drug (IND)
authority in the use of promising medical countermeasures that
are under development in emergency situations.
While funding for the next generation countermeasures will be in
the new Department of Homeland Security (DHS), HHS will provide the
scientific direction, and will be responsible for the actual
procurements. Furthermore, HHS will continue to manage the Strategic
National Stockpile and provide the scientific and public health
direction needed to ensure that the pharmaceutical stockpiles include
appropriate amounts of vaccines, other therapeutics and emergency
equipment/supplies. New mandatory funding will also be included in DHS
which will ensure that adequate resources are available to procure new
medical countermeasures once sufficient research has been conducted to
demonstrate that the products will be proven safe and effective. A
guaranteed funding source must be made available to industry to
stimulate interest and investment in the development of these products.
This authority would be invoked only if there is no significant
commercial market for the products.
HEAD START
Never has there been such a clear commitment on the part of Federal
and State governments to enhance the well being of children and
families. Never have we known so much about what children need for
healthy growth and development. Never have so many programs been
focused on meeting these needs of our most vulnerable citizens. There
are more resources currently available for low-income children and
families than at any other time in our nation's history. The
President's budget continues this commitment with a budget of $6.8
billion to provide 923,000 children Head Start services. However, not
all the news is good. Children in Head Start enter school further ahead
than other economically disadvantaged children. But unfortunately--even
after 30 years--Head Start children do not enter school at the same
level as more economically advantaged children.
To strengthen the Head Start program, improve services to low-
income children, and promote the coordination and integration of
comprehensive early care and education services, President Bush is
asking Congress to include in the reauthorization of the Head Start Act
a provision that will allow interested states to include Head Start in
their preschool plans. Under the President's proposal, states are
offered the opportunity to coordinate preschool programs with Head
Start programs in exchange for meeting certain accountability
requirements. States wishing to participate must submit a state plan
that addresses several fundamental issues concerning preschool
education.
FAITH BASED AND COMMUNITY INITIATIVES
In support of the President's Faith-Based and Community Initiative,
the HHS fiscal year 2004 budget supports programs that link faith- and
community-based organizations, State and local governments, and Federal
partners to provide effective substance abuse treatment and positive
youth development.
Another important program that helps some of our most vulnerable
children is the Mentoring Children of Prisoners program. We are asking
for funds to be increased to a total of $50 million, which would in
turn be made available to faith-based, community-based, state and local
governments, tribes, and public organizations for programs that provide
supportive one-on-one relationships with caring adults to children who
are more likely to succumb to substance abuse, gang activity, early
childbearing and delinquency. This down payment will help more than
30,000 adolescent children of prisoners receive guidance, have positive
role models, and give them a fighting chance to succeed.
The President's budget also proposes $20 million for promotion and
support of responsible fatherhood and healthy marriages. This funding
will promote and support involved, committed, and responsible
fatherhood and encourage the formation and stability of healthy
marriages.
In addition, the budget request for the Compassion Capital Fund is
$100 million, an increase of $65 million above the fiscal year 2003
appropriation. These funds would continue to be used to provide
technical assistance to faith- and community-based organizations to
expand and emulate model social programs.
STRENGTHENING AND IMPROVING MEDICARE
Even though Medicare is not under the jurisdiction of this
Committee, we are all aware that our Nation's Medicare program needs to
be modernized and improved to provide seniors with more choices and
better benefits. While we remain steadfastly committed to ensuring that
America's seniors and individuals with disabilities can keep their
current, traditional Medicare, the President is dedicating $400 billion
over ten years to provide access to subsidized prescription drug
coverage, better private options for those beneficiaries who want them,
full coverage for disease prevention, and better protection from high
out-of-pocket costs.
Under the President's framework, seniors happy with their coverage
under traditional Medicare will be able to keep it, with added
protection against high out-of-pocket drug expenses at no additional
premium. Seniors who want better coverage will be offered the same
types of plan choices available to members of Congress and federal
employees. Private plans will be available in each region of the
country, including rural areas. Plans will provide full coverage of
preventive care, protection against high out-of pocket medical costs,
and cost sharing that does not penalize the sick. Comprehensive,
subsidized prescription drug coverage will be available to those who
want it for an additional premium. Low-income seniors will face no
premium for drug coverage and will have only nominal cost-sharing
requirements. Seniors who enroll in these plans will maintain the
ability to choose any doctor and any hospital.
Seniors willing to accept a more selective provider panel will be
able to enroll in the same type of low-cost, high-coverage managed care
plans available today. These plans will offer a subsidized,
comprehensive drug benefit, as well as all the additional benefits I
just described. Plans can also offer extra benefits and broader
coverage.
STRENGTHENING AND IMPROVING MEDICAID AND SCHIP
State Health Care Partnership Allotments
Another of our mandatory initiatives that I would like to briefly
highlight is our plan to strengthen and improve Medicaid and SCHIP.
Building on the successes of the State Children's Health Insurance
Program (SCHIP) and the Health Insurance Flexibility and Accountability
(HIFA) demonstrations have shown in increasing coverage while providing
flexibility and reducing the administrative burden on States, the
Administration proposes optional State Health Care Partnership
Allotments. Under this proposal, States would have the option of
electing to continue the current Medicaid program or to choose
partnership allotments. The allotment option provides States an
estimated $12.8 billion over seven years in extra funding over the
expected growth rate in the current Medicaid and SCHIP budgets. If a
State elects the allotments, the federal portion of the SCHIP and
Medicaid funding would be combined and states would receive two
individual allotments: one for long-term care and one for acute care.
States would be required to maintain their current levels of spending
on Medicaid and SCHIP, but at a lower rate of increase than the federal
allotment.
States electing a partnership allotment would have to continue
providing current mandatory services for mandatory populations. For
optional populations and optional services, the increased flexibility
of these allotments will allow each State to tailor its provision of
health benefit packages for its low-income residents. Let me stress
that this is an OPTION we are proposing for States.
New Freedom Initiative
Promoting home and community-based care as an alternative to
nursing homes for the elderly and disabled is a priority of this
Administration. The New Freedom initiative represents part of the
Administration's effort to allow Americans with disabilities to be more
fully integrated into their communities. Under this initiative, we are
committed to promoting the use of at-home and community-based care as
an alternative to nursing homes. The Administration will invest $350
million in fiscal year 2004, and $1.75 billion over 5 years on this
important initiative to help seniors and disabled Americans live in the
setting that best supports their needs.
Transitional Medicaid Assistance (TMA)
TMA provides health coverage for former welfare recipients after
they enter the workforce. TMA allows families to remain eligible for
Medicaid for up to 12 months after they lose welfare-related Medicaid
eligibility due to earnings from work. This budget proposal would
authorize the TMA program for five more years, at a cost of $400
million in fiscal year 2004, and $2.4 billion over five years. We are
also proposing modifications to TMA provisions to simplify it and make
it work better in coordination with private insurance. These
modifications cost $20 million in fiscal year 2004 and $290 million
over five years.
EMPOWERING AMERICA'S FAMILIES
Reauthorization of Temporary Assistance for Needy Families (TANF) and
the Child Care Development Fund
Building on the considerable success of welfare reform in this
great Nation, the President's fiscal year 2004 budget follows the
framework proposed in the fiscal year 2003 request, which includes the
reauthorization of TANF. We applaud passage of H.R. 4 and are committed
to working with both the House and the Senate to ensure the legislation
moves quickly and is consistent with the President's Budget. The
President's proposal includes five years of funding for the TANF Block
Grants to States, and Tribes; Matching Grants to Territories; and
Tribal Work Programs at current levels. In addition, the Budget
proposes to reauthorize state-based abstinence education grants for
five years at $50 million annually, to further assist with reducing the
number of out-of-wedlock births, reducing the spread of STDs among
teens, and helping teens make healthy life choices.
Increasing Support for Children in Foster Care
In a continuing effort to improve the lives of children who are at
risk of abuse and neglect, this Administration is proposing a child
welfare program option that States can use to improve their child
welfare service systems. This plan would allow States to choose a fixed
allocation of funds over a five-year period rather than the current
entitlement funding for the title IV-E Foster Care program.
Participating States would receive their funds in the form of flexible
grants which could be used for a wide array of child welfare-related
purposes, such as child abuse and neglect prevention, maintenance and
administrative payments for foster care, child welfare training, and
family support. The flexible funding will allow States to develop
innovative ways to ensure the safety, permanency and well-being of
children, tailed to meet the needs of their child welfare populations.
States which elect this option and experience emergencies affecting
their foster care systems may access additional funding from the TANF
contingency fund.
The Administration is proposing a nearly $5 billion budget for
Foster Care in fiscal year 2004, a $90 million increase over last
year's request. Not only will these funds support a child welfare
program option, but they also will be used to provide payments for
maintenance and administrative costs for more than 240,000 children in
foster care each month, as well as payments for training and child
welfare data systems. The President's budget also requests $200 million
for the Foster Care Independence Program.
Additionally, the Administration continues its commitment to the
Promoting Safe and Stable Families Program by requesting to $505
million to assist States in coordinating services related to child
abuse prevention and family preservation. This important program also
promotes adoption and provides post-adoption support to families.
Child Support Enforcement
The President's fiscal year 2004 budget will build on the
considerable success of the Child Support Enforcement program.
Legislation will be proposed to enhance and expand the existing
automated enforcement infrastructure at the Federal and State level and
increase support collected on behalf of children and families. When
combined with the opportunities to increase child support outlined in
the President's fiscal year 2003 budget (expanded passport denial,
offset of certain Social Security benefits, optional pass through of
child support to families on TANF, among others) these proposals offer
an impressive $7.5 billion in increased child support payments to
families over 10 years. The budget also recognizes that healthy
families need more than just financial support and increases resources
for the Access and Visitation Program to support and facilitate non-
custodial parents' access to and visitation of their children.
PRESIDENT'S MANAGEMENT AGENDA
I realize that as we work to improve the heath and well-being of
every American citizen, we also need to improve ourselves. I am
committed to improving the management of the Department of Health and
Human Services. The fiscal year 2004 budget supports the President's
Management Agenda and includes cost savings from consolidating
administrative functions; organizational delayering to speed decision
making processes; competitive sourcing; implementation of effective
workforce planning and human capital management strategies; and
adoption of other economies and efficiencies in administrative
operations. We have also included savings in information technology
(IT) which will be realized from ongoing IT consolidation efforts and
spending reductions made possible through the streamlining or
elimination of lower priority projects. The IT infrastructure
consolidation will further reduce infrastructure expenditures for
several HHS agencies and should be fully implemented by October 2003.
IMPROVING THE HEALTH AND SAFETY OF OUR NATION
Mr. Chairman, the budget I bring before you today contains many
different elements of a single proposal. What binds these fundamental
elements together is the desire to improve the lives of the American
people. All of our proposals, from building upon the successes of
welfare reform to protecting the nation against bioterrorism; from
increasing access to healthcare, to strengthening Medicare; all these
proposals are put forward with the simple goal of ensuring a safe and
healthy America. I know this is a goal we all share, and with your
support, we are committed to achieving it.
Senator Specter. Thank you, Mr. Secretary.
Our practice is to have 5-minute rounds, and we will adhere
to that. Obviously, there will be a number of rounds for you
because of the very many issues which are involved here.
SEVERE ACUTE RESPIRATORY SYNDROME
The most immediate concern, among many immediate concerns--
it is hard to put anything ahead of bioterrorism today when the
48-hour period for President Bush's ultimatum will expire in
just a few hours. But there is grave concern about the
respiratory infection which has triggered a global health
alert, and in an era where everybody is worried about plots and
plans, some speculation has arisen as to whether this virus
might have been planted in China to see what the results would
be. And there is some grave concern that this could have
enormous implications as an infectious disease.
How serious is it, Mr. Secretary, as a potentially
infectious disease that could present an enormous health threat
around the world?
Secretary Thompson. Senator, we are very concerned about
it. It started in Guangdong Province, we think, but we are not
sure that there is actually a continuation of that. But
basically we think that there is a possibility that is where it
started. There were 300 cases there. I have met with the
Minister of Health here in Washington from China. At the
beginning he was not as cooperative as we would like, but
subsequently we have been working very closely with China, with
the World Health Organization. In fact, almost on a daily basis
I----
Senator Specter. Mr. Secretary, what are the details? The
reports were that they would not cooperate with us. Is that
true?
Secretary Thompson. That was true at the beginning,
Senator, but that has subsequently changed and we are now going
into Guangdong Province, as we speak, with CDC people and WHO
people.
Senator Specter. What was the cause for their initial
reluctance to be cooperative?
Secretary Thompson. They were in the process of changing
their government. They were also reluctant to have outsiders
from the United States come in and assist them at the
beginning. They thought they had it controlled and did not
think they needed any further help. And those were basically
the reasons given to me when I talked to the Deputy Minister of
Health when he appeared here in Washington about 12 days ago.
Senator Specter. Is there realistically potential for a
worldwide epidemic from this respiratory ailment?
Secretary Thompson. There is that possibility. We are not
certain it is a probability, but it is certainly a possibility.
It has showed up now in Hong Kong, Bangkok, Singapore, Sweden,
possibly in Germany, definitely in Canada. We are investigating
approximately 40 cases in the United States. Forty cases were
reported. We are looking at 11 cases, but nothing has been
confirmed. Two scientists in Germany have indicated from nasal
swabs that there is the possibly of the paramyxo virus, but
that has not been confirmed by either WHO laboratories or CDC.
Senator Specter. If so, what would that mean?
Secretary Thompson. It would mean that it would be a virus
that we could identify and would have some way then to control
and treat it. But so far, we have not been able, Senator
Specter, to make an accurate confirmation from CDC if it is
even a virus. We think it is, but we are not sure, and what
virus it is has not been confirmed. Therefore, until CDC's
laboratories confirm it, we do not make any kind of
speculations as to what this particular disease is.
Senator Specter. To the extent that you can answer this
question--and it may be impossible to answer--what causes
something like this?
Secretary Thompson. We are not sure, Senator. That is one
of the questions that we are still trying to find an answer
for.
[The information follows:]
Severe Acute Respiratory Syndrome
The cause of Severe Acute Respiratory Syndrome (SARS) is not known
at this time. Some researchers have reported finding paramyxovirus-like
particles in respiratory specimens from a few cases of SARS.
Paramyxovirus is a family of viruses that cause respiratory infections
and childhood illnesses including measles, mumps, and croup. The
Paramyxovirus family also includes a recently identified virus called
metapneumovirus. These are preliminary findings and at this time we
cannot say for certain that a paramyxovirus is the cause of SARS. Some
of the paramyxoviruses that cause respiratory infections are
widespread, especially during the winter season, so it is not
unexpected to see them in an upper respiratory specimen. Analysis of
laboratory specimens to identify a cause for SARS is ongoing both by
CDC researchers and by researchers from other countries.
Information currently available about SARS indicates that people
who appear to be most at risk are either health care workers taking
care of sick people or family members or household contacts of those
who are infected with SARS. That pattern of transmission is what would
typically be expected in a contagious respiratory or flu-like illness.
However, as the investigation continues, we will continue to consider
all possibilities.
Senator Specter. Well, it is obviously very difficult to
answer that kind of a question, but that is on everybody's
mind. Is there any possibly, however remote, that this could be
a virus planted as part of biological warfare?
Secretary Thompson. It is certainly possible, Senator. We
think it is very, very doubtful. We think this is some sort of
a virus, but we are not even certain of that.
All I can tell you is that the laboratory scientists and
technicians and analysts at CDC are working around the clock.
We have just received the specimens from Hong Kong late
yesterday afternoon. We needed those specimens. We have got the
specimens and the autopsy report in from Canada. We are
reviewing all of those things. The scientists are working
extremely hard. I meet either in person or by teleconferences
with Dr. Gerberding and the staff at CDC on a daily basis, and
we will have a conference at 9:30 a.m. tomorrow for an update
as to what the scientists were able to analyze over the
evening.
But at this point in time, there is nothing new to report
to you, Senator, but I will be more than happy, this afternoon,
when I get the update to call you and Senator Harkin so that
you can let the other members of the committee know what the
results are. We will give you up-to-date information on a daily
basis from my office as to what is transpiring, but right now
we do not know for sure where it really started. We think
probably Guangdong Province, but we are not certain. We are not
certain if it is a virus, and as soon as we do find answers to
those questions, I will give you a call and let you know
directly.
Senator Specter. Okay.
During your last answer, my red light went on, so I will
not ask another question until the next round.
I would note very briefly that in Pittsburgh recently we
see efforts made to get reports from doctors and hospitals to
try to see if there is any pattern of an illness which might
portend of a biological attack, and at a time when there is
such anxiety worldwide, to have this suddenly crop up, it is an
avenue which needs to be explored.
Then we are going to come back in the next round, as far as
I am concerned, to the CDC, a very important agency undergoing
enormous renovations with their laboratory facilities and the
budget cuts them at a time when they are an agency of
importance second to none. But I will await round two.
OPENING STATEMENT OF SENATOR TOM HARKIN
Now my distinguished colleague, Senator Harkin, Democrat of
Iowa.
Senator Harkin. Thank you very much, Mr. Chairman.
Mr. Secretary, thank you very much for your great
leadership at the Department on so many areas.
First, on the budget end, I just want to commend you for
your leadership in putting in the systems change grants. We
have talked about that in the past. You have taken great
leadership on that. This is one where it is going to make a
real difference in States in getting people out of institutions
and getting them in the community. So thank you very much for
that and for including these grants in your budget.
Again, I also want to compliment you on your great emphasis
on prevention in the budget and what you are doing on
preventative health care. I know you personally spearheaded
this new emphasis. I wish we had more dollars in there; I am
sure you do too.
But I would just make note that on another committee on
which I sit, the Agriculture Committee, this year we are
reauthorizing the school lunch, school breakfast WIC program,
summer feeding program. I hope there is a good cross-
fertilization between your Department and Agriculture on some
of these issues. There is a blending here, and we need, I
think, to start promoting, as you said in your own budget
proposal, healthier lifestyles, cutting down on childhood
obesity, getting kids more exercise programs, getting them
learning how to eat right in the beginning. So I guess I am
just making a plea for you to help us as much as you can in
another Department----
Secretary Thompson. I would love to.
Senator Harkin [continuing]. Because I think this is a
merge here and we need your help on these matters as we move
ahead.
After all those accolades, I will say I am disappointed in
the 2.5 percent increase for NIH. I do not know what we are
going to do about that, but that really is not acceptable. We
have got to have a bigger increase in NIH than that 2.5 percent
increase.
HEAD START
Lastly, again on Head Start, Mr. Secretary, you have been a
great leader in Head Start. I know your devotion to the
program. I know you have been very supportive of it. For years
now, I think for the 18, 19 years I have been on this committee
and on the authorizing committee, there have been at various
times proposals to take Head Start and move it into Education.
People think that this is an education program and we are going
to teach kids how to read. Well, that is a part of Head Start.
But as you have pointed out in your own document statement,
these kids come from low-income families. They do not have the
kind of family support. They do not even have the health
support. Their health matters are usually worse. Their living
conditions and socialization skills are worse. Head Start is
something that reaches into all these areas. So rather than
trying to move this to the Department of Education, I think we
need to put more emphasis on Early Head Start, the 0 to 3, and
getting more into that area.
So I say to you as a great friend and an admirer of yours,
Mr. Secretary, please go back and tell your boss and the other
people around that there are a number of us here who are not
going to let it be transferred to the Department of Education.
It ain't gonna happen.
Secretary Thompson. I have already said that, Senator.
Senator Harkin. Okay, well, then tell him you have got
backing up here. It is not going to happen. So we are on your
side on that, and we will do everything we can to support your
budget in that area.
CENTERS FOR DISEASE CONTROL AND PREVENTION INITIATIVE
Lastly, my time is about to run out. I made a statement,
but I guess my question would be getting back to CDC, the
Centers for Disease Control. You have that new $100 million
prevention initiative at CDC. Again, I just hope that we can
put a lot of emphasis on that and that we can focus some more
attention on building up CDC. We have done NIH. We got it
doubled. We need to keep it going. The 2.5 percent is too low.
But, Mr. Secretary, I just need your thoughts on CDC and
where we are headed this year in terms of getting them up to
speed and getting the kind of budget that they need both for
the prevention, which you are aimed at, which is good, but also
for the public health aspect that we need in America to build
up our public health infrastructure that I think--well, I do
not know if you agree or not--I think really went downhill over
the last 40 years, and we need to build it up again. So just
your thoughts on that.
Secretary Thompson. Thank you so very much. Can I just
quickly go through a lot of the points you raise?
Senator Harkin. Sure.
Secretary Thompson. First, on the Freedom Initiative and on
the grants initiative, thank you for your leadership. It is the
right thing to do to keep people in their own home, and I am
fully behind it, enthusiastic, glad we put the extra money in
because it is the right thing to do.
In regards to prevention, $152 billion a year spent on
tobacco-related illnesses. 400,000 people die. $132 billion a
year on diabetes. Seventeen million Americans are diabetic.
Sixteen million are pre-diabetic, and 200,000 people die a
year. We have done an exhaustive study in which 60 percent can
be prevented if, in fact, we walk 30 minutes a day and lose 10
to 15 pounds.
Senator Harkin. Can I interrupt you right there, Mr.
Secretary?
Secretary Thompson. Sure.
Senator Harkin. A recent study showed that 80 percent of
elementary school kids in America do not even get 1 hour of PE
a week at the schools--80 percent.
Secretary Thompson. It is not the right thing to do. And we
have got to get people out--$117 billion on obesity and 300,000
people die. Senator, we have to do it. Ninty-five percent of
the money in Medicare goes to waiting for people to get sick
and then getting them well, and only 5 percent on preventative
health. We need to put more money into it.
NIH, granted it is 2.5 percent. But the actual research
dollars will be $1.9 billion, or a 7.5 percent increase because
we put more money in fiscal year 2003 into buildings in one-
time costs, such as $250 million in anthrax expenditures, plus
the extramural capital expenditures. So actually we are going
to have a 7.5 percent increase in the research. There will be
more research grant dollars than ever before.
On CDC, in regards to preventative health and on State
health, you are absolutely correct. We let it go downhill.
But thanks to your leadership and that of Senator Specter
and this committee on a bipartisan basis in Congress, we put $1
billion last year in fiscal year 2002 in building up the State
health departments. And I want to tell you one of my concerns
is the States have only drawn down 19 percent of that money. We
got it out there and the States have only drawn down--we got an
additional $1,418,000,000 to send out this year, and we are in
the process of sending it out. So if you could help me get the
State of Iowa to draw more of their money down and use it, it
would be very helpful. We need to do it. Plus, we are asking an
additional $1.5 billion for fiscal year 2004 to do it. We have
the greatest opportunity, Senator, to be able to build up local
State health departments the way you envision it, the way I
envision it, than we have ever had before. The money is there.
The money is out the door and it has been allocated. It just
has not been drawn down by the States.
Senator Harkin. Fascinating. Thank you, Mr. Secretary. We
will look into that.
Senator Specter. Senator Craig.
OPENING STATEMENT OF SENATOR LARRY CRAIG
Senator Craig. Well, Mr. Chairman, thank you very much.
Mr. Secretary, great to have you with us this morning.
Secretary Thompson. Thank you, Senator.
COMMUNITY HEALTH CENTERS
Senator Craig. I have some comments and you may want to
react to them much like Senator Harkin, but let me commend you
first for your continued support of community health centers.
The budget proposal takes another positive step toward
improving the health care in rural America. Most of my State
still gets the definition of being rural. And the inclusion of
$122 million to provide primary and preventative health
services to nearly 14 million individuals is a great advance, I
think, for our Nation's health centers.
NATIONAL HEALTH SERVICE CORPS
In addition, your focus on the National Health Service
Corps I think would provide much needed scholarship and loan
assistance to additional health care providers in underserved
and rural areas.
AGING
I have a fun experience and a unique opportunity now,
serving as the chairman of the Special Committee on Aging. I
have got a great staff. We are doing a lot of exploratory
overview of the aging of America, Mr. Secretary. I must tell
you that it is, without question, time to modernize and improve
Medicare. All of us understand that. The prescription drug item
in it is going to be important if we can work out our
differences.
CHRONIC ILLNESS
But you have talked about the way health care is delivered.
We have got some excellent pilot programs going on at CMS as it
relates to managing chronic illnesses. We could literally take
all of those who have that situation, pay for their full health
care if they would simply adhere to the protocols, and we would
save billions and billions of dollars a year in health care
costs and certainly in their ability to conduct and live in
society.
OBESITY
But the thing that fascinates me most in this process--and,
Senator Harkin was talking about the growing epidemic of
obesity in this country. We have got 60,000-plus centenarians
in our country today. That is 100 years old or older. With
current trends, we are going to be over 1 million in 60 years.
And if we find the cure for cancer--and we know we are
certainly on the threshold of major breakthroughs--that number
skyrockets. Thank goodness, a positive sign in the lives of
Americans.
At the same time, those people are going to be able to live
a great deal better if they exercise and if they have good
nutritional advice and understand the value of nutrition. We
have held several hearings in that area today. It is dramatic
what happens in the senior community as it relates to the cost
of health care when they simply exercise and eat right. The
cost goes down dramatically and they live longer and they are
much healthier.
While we are not teaching our kids to exercise anymore, we
know that most people do exercise better, at least if they are
learning to, in groups. In certainly our seniors we are finding
that to be the case also. They will tend to exercise if they
can exercise together. That is some work we are going to spend
a good deal more time with. But it is something that, clearly,
as we look at our health care delivery systems, we ought to be
a lot more interested in preventative than maintenance. If we
can get at that, the costs involved will be dramatic.
I am pleased to see the President's Disease Preventative
Initiative and the support that is going on there. But it is
obvious to me that we have got to modernize our health care
delivery system or that part of it that we are participating
in--it is lagging by about 30 years, and it makes good sense to
get us active in promoting all of these things.
I think your budget certainly goes in that direction. It is
going to be a tight budget year. We all understand that. There
is a good deal more we would like to do, but this is probably a
year when we will not be able to do all we would want to do. I
am quite sure Americans will agree if we are in a time of war
and we have certain responsibilities there, there is going to
have to be an understanding of allocation.
But I thank you very much, and I am pleased to see the
direction we are headed in.
Secretary Thompson. Senator Craig, thank you so very much
for your comments. I appreciate them tremendously and I can
only say that I want to work with you on all of the subjects.
Community health centers, absolutely doing an awesome job. They
are serving the underinsured and the uninsured and a lot of
minorities. We are expanding them thanks to the cooperation on
a bipartisan basis. We are very appreciative of that support.
The National Health Service Corps. Very important to get
doctors graduated, get them out into underserved areas like
your State and my State and the States of the members on this
committee. I want to work with you on that. It is something
that we need to do more of.
Medicare-strengthening and prescription drug coverage.
Absolutely vital this year. You have certainly heard about the
trustees' report. Certainly I was very concerned when we met
this past Monday. Medicare is going to stop having a surplus in
the year 2013, 3 years sooner than it was before. This is going
to cause all kinds of problems. It will be absolutely broke by
the year 2026, 4 years earlier than it was estimated last year.
So it is accelerating, and that means that at the present time,
2 percent of the dollars that go into the budget come from
loans from Social Security and Medicare. It will no longer
happen after fiscal year 2009. A big concern of the Congress
and of mine.
Medicaid needs to be improved and strengthened, and that is
what we are trying to do with the new Medicaid proposal.
In regards to the individuals that are living longer, there
is no question about that. The demographics show that we must
start addressing that issue--and I do not think we have done a
very good job in the past.
Senator Craig. I agree.
Secretary Thompson. And I thank you so very much for taking
the leadership in this area.
We have got to find ways in which we can get some tax
credits for people to purchase long-term insurance. We have to
get more people involved. We have to figure out a way to get
tax credits, I think, for individuals who start leading
healthier lifestyles. It is going to be very difficult and
complex, but it is something that I think we should do.
I am setting up a summit with the National Institutes of
Health and the University of North Carolina Medical School in
which we are going to have a summit of health insurance
companies, of fast food industries and businesses, as well as
individual organizations around the America to talk about
preventative health and how we might be able to work together
in America to start changing lifestyles. That is why the $125
million is the request in there from my Department, from me
personally because I really believe that this is something we
have to do.
Unless we start exercising, unless we start eating properly
and losing some weight, we are going to continue to cause a
tremendous rupture in the health care delivery system because
$152 billion a year on tobacco-related illnesses, $132 billion
on diabetes, $117 billion on obesity, all of these can be
changed dramatically by watching what we eat and exercising.
That is why the $125 million is going to be put out there.
We are going to try and declare certain cities ``healthy
cities'' and have them vie for it. They have to show a
reduction in asthma and diabetes. They have to show that they
are improving their walking trails for families in their
communities. I think it is going to be a very well thought and
well received program. I have talked to the League of Cities
across America. They have been very supportive of it because
they can see what it would mean to their city if they are
designated as a healthy city.
I think that these are the kinds of things that we can work
together on a bipartisan basis and really improve the quality
of health, hold down on dollar amounts because we are spending
so much on waiting for people to get sick and then trying to
get them well when we could spend a lot less and keep people
healthier and lead a better quality of life for all Americans.
So I thank you and want to work with you on these
particular subjects, and we will, hopefully, be able to start
programs that are really going to accomplish these objectives.
Senator Craig. Well, Mr. Secretary, thank you for those
comments. I find it ironic, as we have worked over the last
several decades to take fat out of our diet, that we created an
obesity epidemic.
Secretary Thompson. We really have.
Senator Craig. I think we better revisit our nutritional
patterns.
Thank you.
Secretary Thompson. Thank you very much. I put the whole
Department of Health and Human Services on a diet and I want to
tell you that we are doing well.
Senator Craig. Good.
Senator Specter. Senator Landrieu.
OPENING STATEMENT OF SENATOR MARY L. LANDRIEU
Senator Landrieu. Thank you, Mr. Chairman.
Let me just begin by welcoming you, Mr. Secretary, and I
look forward to working with you on many of the issues that we
have worked well together on in the past and look forward to
some more progress in adoption and foster care and Head Start,
early childhood education, et cetera.
TAX CUTS
But just a couple of comments. I agree with the Senator
from Idaho about the sacrifices that we need to make at this
particular time with the war looming and with great challenges
on the home front. But I would hope that those sacrifices could
be equally shared and not borne disproportionately by the poor
children of this country and by the vulnerable elderly. So when
sacrifices have to be made, I hope perhaps some tax cuts for
certain segments could be postponed or put on hold while we
make sure that we are covering the essential services to poor
children and their families so that the sacrifices made do not
fall disproportionately on just those in uniform and their
families and the poor children and the vulnerable seniors. So
that is going to be a major debate as we frame the budget that
you are able to operate.
Second, with the modest increase that you are given, you
have got quite a challenge before you in terms of meeting the
challenges that you have just stated in answering many of the
questions: medical, Medicare, the obesity issue, substance
abuse, the number of children in foster care, the health care
system that you could claim in some ways is in a crisis
situation because we are not particularly geared right now to
handle just the regular medical challenges of this Nation, but
the bioterrorism challenges, which of course is homeland
defense, but nonetheless important.
FOSTER CARE
But let me, having just opened with that, ask you a couple
of questions about your budget. I noticed with great interest
your comments, although they were brief in the budget, about an
``alternative funding system for foster care.'' Would you just
take a moment to maybe elaborate on some of your ideas
regarding more flexibility in the foster care system in that we
are spending I think somewhere, including the State portion,
about $8 billion trying to--I do not know how you describe what
we are trying to do. I guess we are trying to keep families
together, but when they cannot be kept together, promote
adoption. In the meanwhile, we support the sort of temporary
foster care system that in my mind has gotten quite expensive.
I think that there would be ways to actually do a better
job servicing our families, saving children, promoting adoption
for maybe less money if we could rethink the way this funding
stream is put together. So could you just give a brief--and I
want to just give a minute to this if you could about what some
of your thoughts might be.
Secretary Thompson. I certainly will try, Senator Landrieu.
First off, let me thank you for your leadership in this
area because you have definitely been a leader on adoption and
foster care, and it is well recognized. And I want to work with
you. Senator Clinton and Congressman----
Senator Landrieu. DeLay.
Secretary Thompson [continuing]. Tom DeLay have contacted
me and want to work with me on this, and I would appreciate you
also working with me on it.
Right now, as you probably know, the foster care system is
somewhat arcane in that you can only use the Federal 4(e)
dollars in foster care for children who are defined under the
old AFDC formula, which was eliminated in 1996. So you have to
go back and compute the children under that formula, which is
no longer in existence, and you can only use the Federal
dollars for that and then you can only use the Federal dollars
after the family has broken up or has caused problems and the
child is removed and placed in a temporary foster home.
We think we should be able to spend the money, hopefully,
at the preventive stage. I am big on this prevention because I
think that is where we need to go as a Government, is to start
preventing things before they happen. If we could use some of
the Federal dollars in a preventative stage, on a voluntary
basis, I think we could cause a lot better outcome. I think the
families could stay together. The children could stay in the
families instead of being removed and going into the foster
care system. That is the thrust of our proposal and that is the
alternative funding, is to go into the preventative stage on a
voluntary basis. It would not be mandatory. It would be a
voluntary thing.
We are hopeful that we are going to be able to get
bipartisan support on this. It appears that the Governors are
very supportive so far, and it appears that we are getting
bipartisan support. I would certainly solicit your support in
this as well.
Senator Landrieu. I look forward to working with you. I
have got one more question, but I want to just encourage you
along that line because with the new legislation that has been
supported on a bipartisan basis to really promote unification
where possible, but then move quickly to adoption when it is
not, and focus also on the preventive aspects, which is
substance abuse treatment for some of these families that, if
treated, could potentially continue to raise their children and
do a good job. So I really encourage you and look forward to
working with you.
HEAD START
But my second point would be on Head Start. I would say to
the chairman and the ranking member while there are
disagreements right now or different views, I should say, about
this program, I hope that we would not establish victory for
either side as to whether it stays in the Department of
Education or just stays in the Department of Health and Human
Services. That should not be what we decide is victory. What
victory should be is having an early childhood education
program in this Nation that is up to the task of getting
children basically ready to learn when they hit that
kindergarten door.
That is going to take a combination of efforts, Mr.
Secretary, as you know, combining the resources of the cities,
the States, of the Department of Health and Human Services, and
the Department of Education. So I would like to really think
about using this not to create a fight between agencies, but
use it as an opportunity to really strengthen a signature
program that could have a dramatic impact, Mr. Secretary, if we
do it right, on all the things that you outlined and could be a
tremendous legacy for you and for your administration to get
that in place.
So I look forward to working with you and the members of
this committee to fund the reform efforts that you put down.
Thank you.
Secretary Thompson. Senator Landrieu, thank you so very
much for your comments, but thank you so very much for your
willingness to help on this Heat Start. I could not agree more
enthusiastically with what you want to have as the outcome. If
we can develop a better program--that is why you are in
Government. That is why I am in the administration. We should
work for that. I am confident that Secretary Paige and I will
work on a collaborative basis with you. Any suggestions you
might have on how to improve the program I will take very
seriously I know, and I know Secretary Paige will.
I think we can develop a much better program. What we are
trying to do is allowing for the States to be able to integrate
their early childhood dollars, because I think really there is
a disconnect there. And I would like to be able, on a voluntary
basis, to allow Governors to have more involvement in the early
childhood stages.
Second, I would like to put a lot more emphasis on the
earliest childhood, the 0 to 3. That is where we really need to
put some more emphasis. And I know you agree with that, and I
thank you so very much.
OPENING STATEMENT OF SENATOR HERB KOHL
Senator Specter. Senator Kohl, your timing is impeccable.
You arrived just in time for your round of questions.
ABUSE AND NEGLECT IN LONG-TERM CARE FACILITIES
Senator Kohl. Thank you, Senator Specter.
Welcome, Mr. Secretary. Mr. Secretary, at last year's
hearing we talked about how important it is to make sure that
State survey agencies and ombudsmen have enough funding so they
can inspect nursing homes and other long-term care facilities,
also to investigate complaints of abuse and neglect.
As you know, every year I have worked hard to increase
funding for these programs, and so I was disappointed to see
that the President's budget for this year actually cut survey
funding by $6 million from 2003 levels that we just enacted,
and it flat-lines the ombudsmen funding.
I cannot imagine how we can cut these programs when abuse
and neglect complaints jumped by nearly 14 percent least year.
So to me it is clear that we need an increase and certainly not
a decrease in our efforts to make sure that all patients in
long-term care are safe.
So I ask you, how can we expect States and ombudsmen to
carry out these critical duties if we cut their funding, and
can we do something about it?
Secretary Thompson. Senator Kohl, thank you so very much
and thank you for your leadership in this area. As you know,
when you and I worked together in the State of Wisconsin, we
got a mandatory proposal through, and I think it is probably
one of the best laws in the country in regards to that. I know
it was signed into law, and I know you were very supportive of
that.
Senator Kohl. Very much so.
Secretary Thompson. You know that I agree with you.
Second, it was not a cut, when we introduced it, Senator.
The problem was when we introduced the budget, the Congress had
not passed the fiscal year 2003 appropriation, and you were
very successful in getting additional money put in. So our
budget was in when the fiscal year 2003 budget was in, which
increased it by $6 million, which we had level funded it. We
had not cut it. We had level-funded it from the year before.
Third, it was a tough budget. This is one of the items I
had appealed, but I lost on the appeal to OMB. I understand
your concern. I just want to work with you to build the best
surveillance as we possibly can.
As you probably know, we have started nursing home quality
standards, and we started an experimental program with six
States. Now it is national. And it is working out very well.
The nursing home industry has bought into it, and we are now on
the CMS web page. We are able to allow people to look at the
comparisons of nursing homes within their State so that they
can find out which nursing homes are doing the best job in
various areas. This is also something I am sure you would
approve of. These are the things that we are trying to do to
improve the quality in our nursing homes for our senior
citizens.
Senator Kohl. I know how much you care about the issue and
I know that we will be able to continue working on it.
One other question in this area. As you know, Mr.
Secretary, over the years Congress has held many hearings on
abuse in nursing homes and we heard stories from people about
patients being beaten, raped, and even killed by employees who
are supposed to be caring for them. We know that the vast
majority of nursing home workers do a very good job, but as we
know, it only takes a few to corrupt a whole system.
I have introduced legislation to create a national registry
of abusive workers and require FBI criminal background checks
before hiring. The bill is supported by patient advocates, as
well as the nursing home industry. As we debate Medicare reform
this year, we will hear a lot of ideas about what exactly
reform means. But it seems to me at the very least one of the
most important reforms we should pass is to ensure the basic
safety of those who are already in nursing homes and already
covered by Medicare. Nursing homes receive more than $11
billion in Medicare funding in 2001, and I believe we have an
obligation to make sure that these dollars are well spent.
So will the administration support legislation to get a
national registry of potential nursing home employees and will
the administration, will you, work with me and others to get it
passed this year?
Secretary Thompson. As you know, I worked with you when we
got it passed in State of Wisconsin, and I will continue to
work with you, Senator. I think it is the right thing and I
hope that we can get it done.
Senator Kohl. I thank you so much. It is good to see you.
Secretary Thompson. It is always a pleasure.
Are the Bucks going to make it?
Senator Kohl. It is going to be tough.
Secretary Thompson. Well, let us do a little bit more in
that area too, Senator.
Senator Kohl. Well, I will but I want to assure you,
Governor, it is not because I am not paying them enough.
Secretary Thompson. I know that, Senator. Let us just hope
they make it to the playoffs.
Senator Kohl. All right.
Senator Specter. Senator Gregg, like Senator Kohl, your
timing is impeccable. You arrived just in time for your round
of questioning.
OPENING STATEMENT OF SENATOR JUDD GREGG
Senator Gregg. Well, I appreciate that. Unfortunately, I
have to head off to carry the Secretary's water at the markup
that I am starting on bioshield, respite care, and a variety of
other things he sent to us to do. So my only question would be
to the Secretary--well, I am going to reserve my questions
because it will take too long to answer, and I would have to
leave in the middle of the answer. But it is a pleasure to see
the Secretary here and I look forward to continuing to work
with him.
Secretary Thompson. Thank you, Senator Gregg, for your
tremendous support on the smallpox and bioshield initiatives.
And thank you for coming over and viewing the Department's new
communications center. I extended that invitation to all
members. I would like to have them come over because I think
you would attest that it is one of the most modern in the
Government.
Senator Gregg. An extremely impressive facility. I think it
could be of value to every Senator to have a chance to look at
it and see the resources there.
CENTERS FOR DISEASE CONTROL AND PREVENTION
Senator Specter. Secretary Thompson, on my first round I
was focused on what the CDC was doing on the China virus, and
the very broad responsibilities which CDC has on bioterrorism.
But I note that CDC has been cut by $160 million on their
overall budget and $152 million on CDC's buildings and
facilities.
Starting first with the $160 million cut, is that wise,
appropriate in the context where we consistently call on the
CDC to do more, illustrated by the current Chinese virus?
Secretary Thompson. The CDC budget, Senator, as you know,
is very important to you. It is very important to me. It is
very important to our country. During the process of give and
take with OMB, you are given so much money. You try and do the
best job possible.
In regards to the building program, I requested $250
million, which was sort of the glide path in order to get----
Senator Specter. You are talking on the building program
now?
Secretary Thompson. Yes.
Senator Specter. I am about to come to that. The building
program has been cut by $152 million.
Secretary Thompson. $152 million out of the $250 million.
Senator Specter. The facilities had been in a longstanding
state of disrepair which had not been focused on by your
predecessors until members of this committee went down and took
a look. You know that story.
Secretary Thompson. I know it very well.
Senator Specter. We had an emergency appropriation that
year, about 3 years ago, of $170 million, and we added $250
million and $250 million. We have had very vociferous
complaints from the community which is really up in arms. When
I was there, I saw distinguished scientists with desks in the
halls--you know about that--and very important chemical
substances unprotected, unsafeguarded. When was the last time
you saw the CDC, Mr. Secretary?
Secretary Thompson. I go to the CDC about every 6 months. I
am going down there again----
Senator Specter. Well, how was it when you saw it last? Are
the conditions still pretty bad?
Secretary Thompson. Conditions are improving. We are making
a lot of progress. We still have a long ways to go.
Senator Specter. They are improving, but are they still
pretty bad?
Secretary Thompson. The laboratories should be finished up
this year, and that was our highest concern. Our laboratories,
as well as for the security of them. That has come along very
nicely, but there are some other buildings.
The problem is we have three campuses, and we have 24 other
buildings that we are renting around the City of Atlanta. It
really causes a disconnect. There is not the synergism that we
could have if we could relocate those 24 buildings on campus
and have the building program go.
I understand your position, Senator. Oz Nelson and Bernie
Marcus have been leaders down there, and I think they met with
you yesterday. They have talked to me. I talk to them on a very
regular basis. We are trying to get $250 million which was the
glide path----
Senator Specter. Well, I hope you talk to them as regularly
as they call me.
Secretary Thompson. Well, I am sure they probably call you
more.
Senator Specter. I'm going to give WATS line with those
folks.
But we ask them to do so much.
My time is close to expiring, and I want to stick to the
time limits here.
NATIONAL INSTITUTES OF HEALTH FUNDING
CDC is tied very closely with the NIH funding, and the NIH
funding--you know what this subcommittee has done. When you
present a budget like this to us, Mr. Secretary, you really
leave us in a position of adding to the CDC and adding to the
NIH and taking away from other programs. And I know your
problems with OMB, but I suggest to you there has to be a
tougher level of advocacy on these lines.
The subcommittee would like to know how many grants have
been awarded by NIH, what will happen with the flow of grants
when the increase is only a figure of $673 million. I will ask
as the final question before my red light goes on, why does the
administration request only $673 million for NIH when last year
it was $3.7 billion?
Secretary Thompson. First off, Senator, I do not know how I
could be a stronger advocate than what I have been in the past.
Senator Specter. Well, you can take over OMB, Mr.
Secretary.
Secretary Thompson. Well, I suppose I could, but I was not
asked to do that, Senator, and I do not think they are going to
ask me to do it either.
I am a strong advocate. I am passionate about it. And I
thank you for you passion because it has been yours and Senator
Harkin's and members' of this committee that have been able to
do it.
In regards to NIH funding, it is a 2.5 percent increase
over what the fiscal year 2003 request was, but----
Senator Specter. How do you figure a 2.5 percent increase?
Do you have a different slide rule than I do?
Secretary Thompson. No, I do not. Subsequent to the
introduction of our budget, Congress passed the fiscal year
2003 appropriation bill which increased the amount of money
over and above what we had requested. Therefore, instead of a
2.6, it was about a 1.6 percent increase over what you
appropriated. But what we put in over what was in the fiscal
year 2002, it is a 2.6 percent increase. That is the
difference.
In regards to that, there was $250 million put in for the
purchase of anthrax which is no longer there. That has been
purchased. There was a one-time capital cost in the NIH budget
for building laboratories at Fort Detrick and also on the
campus, and also the remodeling of a laboratory in Montana.
Those things have been done. There was approximately $375
million put in for capital improvements on campuses, on
universities for bioterrorism laboratory advancements, as well
as other things. Those were one-time costs. When they are taken
out, you add that back into the research. Those one-time
dollars will no longer be going for the expenditure of anthrax
and for capital costs. They will be going back into research.
So the total amount of money going for research over last year
will be $1.9 billion, or a 7.5 percent increase, which will
allow us to send out more grants and more dollars than ever
before. And that is just how it works out, Senator.
Senator Specter. Senator Harkin.
Senator Harkin. Thank you, Mr. Chairman.
Mr. Secretary, I am shifting a little bit here. I just
again wanted to focus on this new Freedom Initiative, the
disability grants, which I compliment you for moving ahead on
that.
There are enough people who want to ask questions. Why do I
not write you a letter on this and discuss this with you? I am
concerned about what happens after the first year. You have got
these grants in there for the first year. What happens after
that? I mean, they cannot just drop off a cliff someplace. And
there is a match there for that first year. Then after that, we
do not know. So I am greatly concerned that States may go into
this, and then after the first year, they have nothing. And I
do not know what the plan is for that. But maybe I should write
you. Maybe you could respond to me on that basis.
[The information follows:]
New Freedom Initiative
There are several components to the New Freedom Initiative
proposal, the following are items with fiscal impact in the fiscal year
2004 and beyond (many of these demonstrations were also proposed in the
President's fiscal year 2003 Budget):
--Medicaid Spousal Exemption.--$95 million over five years, with $16
million proposed for fiscal year 2004. This proposal would give
States the option to continue Medicaid eligibility for spouses
of disabled individuals who return to work. Under current law,
individuals with disabilities might be discouraged from
returning to work because the income they earn could jeopardize
their spouse's Medicaid eligibility. This proposal would extend
to the spouse the same Medicaid coverage protection now offered
to the disabled worker.
--New Freedom Initiative Demonstrations.--$220 million over 5 years,
with $11 million proposed for fiscal year 2004. This initiative
would fund four demonstrations that promote home and community-
based care alternatives. Two of the demonstrations provide
respite care services for adults and substantially disabled
children. Another demonstration provides community-based care
alternatives for children who are currently residing in
psychiatric residential treatment facilities. The President
proposed these demonstrations for fiscal year 2003. Also
included is $3 million in discretionary spending for the CMS
Research and Demonstrations Budget that will fund the Direct
Service Worker National Demonstration.
--``Money Follows the Individual'' Rebalancing Demonstration.--$1.75
billion over 5 years, with $350 million proposed for fiscal
year 2004. This 5-year demonstration would finance Medicaid
services for individuals who transition from institutions to
the community. Federal grant funds would pay the full cost of
home and community-based waiver services for 1 year, after
which the participating States would agree to continue care at
the regular Medicaid matching rate. This demonstration would
also provide incentives to States for increased use of home and
community-based services and would help provide information on
costs of different approaches.
The fiscal year 2004 budget will also include $40 million for
``Systems Change Grants'' to support States in their planning to create
new systems to support people with disabilities in the community
instead of in institutions.
Secretary Thompson. Senator, I really think that the
evidence is going to show that this is the right thing to do. I
think that you have recognized that for many years and have
been pushing for this thing. It is something I did when I was
in Wisconsin. I moved people from nursing homes and left them
in their own homes.
Senator Harkin. I am aware of that.
Secretary Thompson. Also, for the disabled community, we
did the same thing. It is so much better--a quality of life
issue--that I just do not think, once you start down this path,
that you would ever be able to stop it. I think the advocates,
I think the Senators like you, Senator Harkin, and I think the
administration have made a commitment, and I think they have
made a commitment to the community and I think we are going to
stand by that. As long as I am here, I know I am going to be
pushing for it, and I know I am going to have your support in
order to accomplish that.
Senator Harkin. Thank you, Mr. Secretary.
Senator Specter. Senator Craig.
Senator Craig. Mr. Chairman, I have no further questions.
Senator Specter. Senator Landrieu.
SUBSTANCE ABUSE
Senator Landrieu. Yes. Mr. Secretary, let me just follow up
with our substance abuse focus, if we could, because as you
know, the record speaks clearly about the reason that I think
maybe 70 to 80 percent of children in foster care are there
because a parent or both parents have a serious substance abuse
problem. I do not have to share with you the statistics about
our prisons being full of people who have substance abuse
problems and for whatever reason--not that those reasons are
excused--turn to a life of crime, et cetera. My point being
that since we spend I think $30,000 or $40,000 per year to
incarcerate someone, it would seem to me that one of the
smartest investments we could make as a nation is trying to
find and continuing to pursue, even though it is difficult, a
very effective remedy or program for substance abuse.
Your budget here, the block grant that we provide to our
States, provides treatment services to 400,000 people. Do we
know how many people in the country are suffering from
substance abuse that could potentially be helped by a block
grant like this? Do we have a figure that we are shooting for?
Secretary Thompson. I am sure we do, but I do not have it
at the tip of my----
Senator Landrieu. Could anyone on your staff share with us?
Do we know what the universe is that we are dealing with?
Secretary Thompson. I know we have that information. I will
get it for you, Senator Landrieu.
Senator Landrieu. Because I think it is huge.
Secretary Thompson. It is.
Senator Landrieu. I think it is millions and millions and
millions of people that are suffering from substance abuse. And
I point out to the committee and to the chairman that the block
grant only provides for services for 400,000 people in the
country. So we are just woefully short in that line item. So if
you could provide for me the universe that we have at least
identified as the numbers of people who have serious substance
abuse--you know, chronic--I would just ask.
Secretary Thompson. We will get that information for you.
[The information follows:]
President's Drug Treatment Initiative
In fiscal year 2004, we are requesting a total of $2.6 billion for
the President's Drug Treatment Initiative to provide drug treatment
services to approximately to 725,000 individuals, an increase of
135,000 individuals over fiscal year 2003. We are requesting an
increase of $31 million for the Substance Abuse Prevention and
Treatment Block Grant and $200 million for a new voucher program,
Access to Recovery, to increase treatment options and expand access to
services to 100,000 individuals, including services provided by faith-
based organizations.
We believe that these increases in substance abuse treatment will
help us reach those people who need treatment. According to the 2001
National Household Survey on Drug Abuse, 5 million people needed but
did not receive treatment in 2001. Of this 5 million people, an
estimated 377,000 reported that they felt they needed treatment for
their drug problem. This includes an estimated 101,000 who reported
that they made an effort but were unable to get treatment and 276,000
who reported making no effort to get treatment.
Senator Landrieu. And then try to provide me, if you would,
in your opinion what are the one or two or three most effective
either statewide or regional programs. And by effective, I mean
a record, an objective record, of people entering the program
with problems, exiting the program cured, which is I know very
difficult. Because if we could identify some of those effective
programs, I would like to work with you on moving some of the
money out of corrections and out of foster care and into drug
abuse treatment and prevention so as to save this Government a
tremendous amount of money and, needless to say, a lot of
heartache in the process. So if you could provide that for me.
[The information follows:]
Substance Abuse Programs
Numerous studies have shown substance abuse treatment to be
effective in reducing substance use, crime, and infectious diseases,
while increasing employment and social functioning. For example, in
Louisiana, the Department of Health and Hospitals, Office for Addictive
Disorders administers substance abuse prevention and treatment services
in 10 regions throughout the State. The Office for Addictive Disorders
requires substance abuse treatment programs to screen, assess, and
place individuals in need of substance abuse treatment using
standardized assessment instruments such as The Diagnostic and
Statistical Manual (DSM-IV-R) of Mental Disorders, the Addiction
Severity Index, 5th Edition, and the Patient Placement Criteria for the
Treatment of Substance Related Disorders, 2nd Edition Revised. The
appropriate assessment and placement of individuals in need of
substance abuse treatment is critically important to the desired
treatment outcomes of achieving and maintaining abstinence and
recovery.
The Office for Addictive Disorders has identified two exemplary
programs:
1. Rainbow Social Detoxification, Alexandria, Louisiana (Region VI)
The program reported: 98.5 percent occupancy rate for the last
calendar year; 63 percent of clients admitted showed improvement in the
first two quarters of the current fiscal year according to exit data;
and 78 percent of the clients completed the treatment program in the
last fiscal year.
2. Infinity Women With Dependent Residential Program, New Orleans,
Louisiana (Region I)
This is a collaborative effort between the Office for Addictive
Disorders and the Office of Family Support utilizing TANF funding to
provide substance abuse treatment to women and their children.
Of the women who completed treatment: (1) 100 percent are enrolled
in school or employed at 1-month follow-up post discharge; (2) 100
percent reported a reduction in drug/alcohol usage at 1-month follow-up
post discharge; 92 percent of the children ages 0-5 demonstrated
improvement in their developmental assessments from admission to
discharge; and 53 percent of school aged children demonstrated improved
academic performance admission to discharge.
Additionally, the following programs have reported promising
treatment outcomes for their respective targeted population in need of
substance abuse treatment.
City of Boise Collaborative Methamphetamine Treatment Services Project,
Boise, Idaho
Target population: The target population for this SAMHSA-funded
project is adults ages 18 and up, methamphetamine users, male and
female, and their families in Boise and the surrounding community of
Ada County. The project will serve between 50-75 clients per year.
Outcomes: The project is estimating that a minimum of 75 percent of
all clients admitted will graduate from the treatment program with
client outcomes similar to those of other comparable Matrix model
programs in relation to being drug free, employed, or engaged in
productive activity; living in a permanent place within the community;
and having little or no involvement with the criminal justice system.
After fiscal year 2003, the project will determine the program's impact
on the following: (a) decreased crime, arrest, convictions, and
incarcerations; (b) decreased emergency room/medical/hospital visits;
(c) decreased foster care placements; and (d) reduced health and social
costs from associated drug use.
The Pinal Hispanic Council Adolescent Treatment Project, Eloy, Arizona
Target population: The target population for this Substance Abuse
Prevention and Treatment block grant-funded project are Chicano,
American Indian, and African American adolescent males and females
between the ages of 10-18.
Outcomes: Pinal Hispanic Council receives Federal and State funds
and is a multiethnic, adolescent treatment improvement project which
provides comprehensive substance abuse treatment services to a tri-
county rural community in southern Arizona. Their main office, located
in Eloy, is ``Centro de Ayuda'' (Help Center) and two satellite
offices, ``Centro de Unidad'' (Unity Center) are located in Coolidge
and Casa Grande. The program receives the majority of its patients from
the various public schools, families, and the juvenile justice
department. The drugs of choice are primarily alcohol, methamphetamine,
inhalants, marijuana, and crack cocaine. A home-based approach to
treatment is used and a bilingual multi-cultural staff ensures cultural
sensitivity. Approximately 85 percent of the 48 clients completed
treatment in the last fiscal year. This program is a model for both
delivering services in a rural community and in coalition building in a
rural community.
Secretary Thompson. Senator, thank you so very much. You
know we have also put in this new program for mentoring and
counseling children of prisoners because they are going to get
out and we want to be able to try to get them reintegrated back
in the family if it is possible and if there is not going to be
any kind of spousal abuse or anything like this. This is a
program that we think will be very effective. But there are
many demonstration programs out there that we would certainly
like to work with you on and see if we could make it a national
program.
Senator Landrieu. And the reason that I bring that up, is
because I think the public has a sense that there are no cures
or that they are so difficult, people just throw their hands up
and say what is the use of funding it, it does not work. So
what we have to do is give people hope that there are, in fact,
effective programs that do work, that can be put into place,
and that we can really make a serious advancement here on this
particular subject. So, thank you.
One other thing for the record. If you could supply me with
the grants that either universities or scientists, doctors,
physicians, the medical infrastructure in Louisiana has
received from NIH, I would appreciate that. I know that there
are records to that effect, and if your staff could get that
for me, that would be very helpful.
Secretary Thompson. For all the universities----
Senator Landrieu. For all universities in Louisiana in the
last 3 years.
Secretary Thompson. From NIH?
Senator Landrieu. From NIH. Thank you.
Secretary Thompson. I would be more than happy to. And if
you do not get it within 10 days, call me. Will you please?
[The information follows:]
NIH Grants and Contracts Awarded for the State of Louisiana
A list of all NIH grants and contracts awarded to recipients in the
State of Louisiana for the past 3 years is being provided under
separate cover. In summary, NIH made 334 grant and contract awards for
$78.6 million to recipients in Louisiana in fiscal year 2000; 324
awards for $85.8 million in fiscal year 2001; and 344 awards for $117.5
million in fiscal year 2002--a dollar increase of more than 49 percent
over fiscal year 2000.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
GRANT NUMBER NAME ORGANIZATION TITLE AWARDED
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
FISCAL YEAR 2000
D43TW001086-02................. MATHER, FRANCES J................. TULANE UNIVERSITY OF LOUISIANA............... INTERNATIONAL TRAINING IN MEDICAL INFORMATICS.................. $146,438
D43TW001142-02................. BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... ACTIONS FOR BUILDING CAPACITY.................................. 100,000
D43TW001142-02S1............... BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... IMPACT OF MID-GUT BACTERIA ON ANOPHELES MOSQUITOES............. 40,000
F30DA005743-05................. MARTIN-SCHILD, SHERYL B........... TULANE UNIVERSITY OF LOUISIANA............... TYR-W-MIF-1 AND OPIATE TOLERANCE............................... 53,903
F31DA005907-02................. HORNER, KRISTEN A................. TULANE UNIVERSITY OF LOUISIANA............... CHANGES IN ENDOMORPHINS DURING OPIATE TOLERANCE................ 19,145
F31DA005926-02................. BRADLEY, AMY L.................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... SYNTHESIS AND DEVELOPMENT OF NEW COCAINE MEDICATIONS........... 21,189
F31DA005948-02................. CZAPLA, MARC A.................... TULANE UNIVERSITY OF LOUISIANA............... ENDOMORPHIN AND CARDIORESPIRATORY CONTROL...................... 20,452
F31DA005968-02................. SMITH, REBECCA R.................. TULANE UNIVERSITY OF LOUISIANA............... ENDOMORPHIN PLASTICITY IN CHRONIC PAIN MODELS.................. 34,115
F31DA006010-01................. BEYER, CHAD E..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MEDIAL PREFRONTAL CORTEX'S ROLE IN COCAINE SENSITIZATION....... 18,654
F31DA006040-01................. GREENWELL, THOMAS N............... TULANE UNIVERSITY OF LOUISIANA............... ENDOMORPHIN-NEUROIMMUNE INTERACTIONS........................... 19,935
F31GM019387-03................. HAMILTON, KIMBERLY Y.............. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... CHIRAL SELECTOR IN CAPILLARY ELECTROPHORESIS................... 21,210
F31GM019876-02................. BURSE, JEANINE R.................. TULANE UNIVERSITY OF LOUISIANA............... PAST AND PRESENT BIOINDICATION OF RIVER POLLUTION.............. 23,805
F31GM020437-02................. CEDILLO, BERTHA M................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... DEVELOPMENT OF A CHIRAL SELECTOR SYSTEM........................ 25,470
F31GM020603-01................. WILLIAMS, BRIDGET D............... TULANE UNIVERSITY OF LOUISIANA............... THE ROLE OF TRACT STABILITY IN TELOMERE MAINTENANCE............ 33,994
F31GM020686-01................. ROBINSON, TERI L.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... DENDRIMERS/POLYMERIC SURFACTANTS IN CHIRAL SEPARATIONS......... 25,573
F31GM020928-01................. AUSTIN, JOSEPH.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MINORITY PRE-DOCTORAL FELLOWSHIP PROGRAM....................... 22,512
F31HG000207-02................. SIMMONS-WILLIS, TRACEY A.......... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MINORITY PRE-DOCTORAL FELLOWSHIP PROGRAM....................... 13,896
F31NS011180-01................. CLAYTON BAUCOM, CATHERINE A....... TULANE UNIVERSITY OF LOUISIANA............... HUMAN HAND PREFERENCE--STRUCTURAL FUNCTIONAL MRI STUDIES....... 20,830
F32AA005543-02................. ZHANG, ZILI....................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... POSTTRANSLATIONAL INHIBITION OF TNF ALPHA BY ALCOHOL........... 40,936
F32DA005877-03................. STAFFORD, DAVID A................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... DRUG EFFECTS ON COCAINE PAIRED CONDITIONED REINFORCERS......... 40,936
F32DK009931-02................. ROSS, DONNA M..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... RENAL CAPILLARY FAILURE IN DIABETIC NEPHROPATHY................ 32,416
F32EY006996-02................. LOUTSCH, JEANNETTE M.............. LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HSV1 REACTIVATION--CONTROL BY THE LAT DOMAIN............ 39,232
F32HD008390-03................. GULLEDGE, CYNTHIA C............... TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF OPIOID MODULATION OF MATERNAL BEHAVIOR........... 37,516
G11HD034961-03................. ISLAND, GLENDA J.................. GRAMBLING STATE UNIVERSITY................... GSU RESEARCH ADMINISTRATION INFRASTRUCTURE PROGRAM............. 91,749
G11HD038437-01................. OSAGIE, EMMANUEL I................ SOUTHERN UNIV A&M COL BATON ROUGE............ EXTRAMURAL RESEARCH DEVELOPMENT AWARD.......................... 1
G20RR015079-01................. BAKER, DAVID G.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... TRANSGENIC FACILITIES FOR NUTRITIONAL RESEARCH................. 141,322
K01CA078318-02................. HEMENWAY, CHARLES S............... TULANE UNIVERSITY OF LOUISIANA............... BMI1 INTERACTING PROTEINS IN NEOPLASTIC TRANSFORMATION......... 109,982
K01GM000707-01................. CHETTY, KOTHAPA N................. GRAMBLING STATE UNIVERSITY................... HYPERCHOLESTEROLEMIA AND REPERFUSION INJURY.................... 22,803
K02DA000204-08................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOID PEPTIDE PROCESSING ENZYMES.............................. 112,160
K02DA000211-07................. FRANCE, CHARLES P................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... BEHAVIORAL PHARMACOLOGY OF OPIOIDS............................. 37,261
K02DK002605-02................. KAPUSTA, DANIEL R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOIDS AND CENTRAL NEURAL REGULATION OF RENAL FUNCTION........ 94,955
K02MH000967-07................. HAYCOCK, JOHN W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HUMAN TYROSINE HYDROXYLASE AND SCHIZOPHRENIA................... 106,040
K02MH001231-06A1............... O'DONNELL, JAMES M................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... NOVEL MECHANISMS OF ANTIDEPRESSANT ACTIVITY.................... 69,863
K07HL003327-05................. ALI, JUZAR........................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... TUBERCULOSIS ACADEMIC AWARD--COMPREHENSIVE EDUC PROGRAM........ 71,033
K08AI001438-05................. CHANG, WUN-LING................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... CD4+ T CELL REGULATION--EFFECTOR CELLS IN BLASTOMYCOSIS........ 118,800
K08AI001467-03................. MASON, ANDREW L................... OCHSNER CLINIC FOUNDATION.................... RETROVIRAL ETIOLOGY OF PRIMARY BILIARY CIRRHOSIS............... 118,800
K08AI049790-01................. PARADA, NEREIDA A................. TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF IL-2 RECEPTOR BY THE CD4 LIGAND IL-16............ 110,700
K08EY000414-02................. COLITZ, CARMEN M.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... TELOMERASE FUNCTION AND REGULATION IN THE LENS................. 104,674
K08HL003569-05................. Ortiz, Luis A..................... TULANE UNIVERSITY OF LOUISIANA............... APOPTOSIS IN PULMONARY FIBROSIS--ROLE FOR TNF AND P53.......... 114,080
K08MH001706-03................. SCHEERINGA, MICHAEL S............. TULANE UNIVERSITY OF LOUISIANA............... TRAUMATIZED YOUNG CHILDREN--RISK FOR MALADAPTATION............. 150,627
K23DC000135-04................. FOUNDAS, ANNE L................... TULANE UNIVERSITY OF LOUISIANA............... NEUROBIOLOGIC SUBSTRATES OF STUTTERING......................... 80,271
K30HL004521-01................. FRIEDMAN, MITCHELL................ TULANE UNIVERSITY OF LOUISIANA............... CLINICAL RESEARCH CURRICULUM AWARD............................. 200,000
M01RR005096-11................. CORRIGAN, JAMES J................. TULANE UNIVERSITY OF LOUISIANA............... GENERAL CLINICAL RESEARCH CENTER............................... 2,223,025
N01AI075327-005................ Didier, Elizabeth Schmidt......... TULANE UNIVERSITY OF LOUISIANA............... PRECLINICAL EVAL. OF THERAPIES FOR MICROSPORIDIAL INFECT....... 397,907
N01HG065404-000................ ROTHSCHILD, HENRY................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DETERM. OF GEN. SUSCEPTIBILITY LUNG CANCER FAM. S.O.LA......... 184,570
N01HG065404-006................ ROTHSCHILD, HENRY................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DETERM OF GEN SUSCEPTIBILITY LUNG CANCER....................... 237,874
N01HG065404-007................ ROTHSCHILD, HENRY................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DETERM OF GEN SUSCEPTIBILITY LUNG CANCER....................... 237,675
P01CA028842-17................. CORREA, PELAYO.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ETIOLOGIC STUDIES OF GASTRIC CARCINOMA......................... 683,011
P01DK043785-10................. GRANGER, D NEIL................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PATHOPHYSIOLOGY OF INTESTINAL ISCHEMIA/REPERFUSION............. 1,243,529
P30EY002377-22................. KAUFMAN, HERBERT E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... CORE GRANT FOR VISION RESEARCH................................. 432,575
P50AA009803-07................. SPITZER, JOHN J................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, HIV INFECTION AND HOST DEFENSE........................ 1,707,894
P50AA009803-07S1............... SPITZER, JOHN J................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, HIV INFECTION AND HOST DEFENSE........................ 105,817
P51RR000164-39................. LAROSA, JOHN C.................... TULANE UNIVERSITY OF LOUISIANA............... REGIONAL PRIMATE RESEARCH CENTER............................... 5,731,111
R01AA008846-08................. Bautista, Abraham P............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... LIVER AND THE IMMUNODEFICIENCY OF ALCOHOLICS................... 169,292
R01AA009505-05................. PRUETT, STEPHEN B................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF IMMUNOSUPPRESSION BY ONE DOSE OF ETHANOL......... 154,003
R01AA009876-06................. WOLCOTT, ROBERT M................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... FETAL ALCOHOL EFFECTS AND IMMUNE DEVELOPMENT................... 205,594
R01AA011224-04................. GILES, THOMAS D................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITS........ 235,882
R01AA011760-04................. MASON, CAROL M.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, TB AND AIDS........................................... 181,995
R01AG016592-01A1............... BERENSON, GERALD S................ TULANE UNIVERSITY OF LOUISIANA............... EVOLUTION OF CARDIOVASCULAR RISK WITH NORMAL AGING............. 715,752
R01AG017887-01................. JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NUTRITIONAL AND METABOLIC MECHANISMS OF AGING.................. 336,000
R01AG017981-01................. MCLAUGHLIN, MARK L................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... BETA-SHEET MIMICS FROM CONSTRAINED DIPEPTIDE UNITS............. 180,930
R01AG017983-01................. HAMMER, ROBERT P.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... INHIBITION OF FIBRILLOGENESIS WITH B-STRAND MIMICS............. 316,180
R01AG017983-01S1............... HAMMER, ROBERT P.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... INHIBITION OF FIBRILLOGENESIS WITH B-STRAND MIMICS............. 66,802
R01AG018239-01................. GEISELMAN, PAULA J................ LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... OBESITY PREVENTION AFTER SMOKING CESSATION IN MENOPAUSE........ 183,750
R01AG018648-01................. VANLANDINGHAM, MARK J............. TULANE UNIVERSITY OF LOUISIANA............... SOCIO-DEMOGRAPHIC IMPACT OF AIDS ON OLDER PERSONS.............. 109,678
R01AI019199-16................. KLEI, THOMAS R.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... LYMPHATIC LESION PATHOGENESIS IN BRUGIA INFECTED JIRDS......... 222,143
R01AI022001-16................. O'CALLAGHAN, DENNIS J............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NUCLEIC ACIDS OF HERPES VIRUS INFECTED CELLS................... 330,781
R01AI031567-06................. CHERVENAK, ROBERT P............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DEVELOPMENTAL BIOLOGY OF T CELL PRECURSORS..................... 178,096
R01AI032556-06A1............... FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... MUCOSAL CELL MEDIATED IMMUNITY IN VAGINAL CANDIDIASIS.......... 203,750
R01AI034754-07................. Garry, Robert F................... TULANE UNIVERSITY OF LOUISIANA............... ALTERATIONS OF ION TRANSPORT BY HIV............................ 236,098
R01AI040667-05................. VAN DER HEYDE, HENRI C............ LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS WHEREBY CD4 T CELLS ACTIVATE AMI AND CMI............ 194,558
R01AI041693-03................. FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HORMONAL REGULATION OF VIGINAL IMMUNITY TO C ALBICANS.......... 200,347
R01AI042146-02................. MUGGERIDGE, MARTIN I.............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... ROLES OF HSV2 MEMBRANE PROTEINS IN MEMBRANE FUSION............. 173,012
R01AI042350-03................. LANDRY, SAMUEL J.................. TULANE UNIVERSITY OF LOUISIANA............... HELPER T CELL EPITOPE IMMUNODOMINANCE.......................... 199,020
R01AI042400-01A2............... DAVISON, BILLIE B................. TULANE UNIVERSITY OF LOUISIANA............... A RHESUS MONKEY MODEL OF MALARIA IN PREGNANCY.................. 566,402
R01AI042777-03................. CLEMENTS, JOHN D.................. TULANE UNIVERSITY OF LOUISIANA............... MECHANISM OF CHOLERA TOXIN AND E COLI LT ADJUVANTICITY......... 195,482
R01AI043000-02................. KOUSOULAS, KONSTANTIN GUS......... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... GENETICS & FUNCTIONS OF HSV1 GK IN VIRUS ENTRY & EGRESS........ 279,406
R01AI044424-03................. STACZEK, JOHN..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... CHIMERIC VIRUS VACCINES FOR P AERUGINOSA INFECTION............. 183,600
R01AI045151-01A1............... FREYTAG, LUCIA C.................. TULANE UNIVERSITY OF LOUISIANA............... MUCOSAL IMMUNIZATION--PREVENTION OF SYSTEMIC CANDIDIASIS....... 222,750
R01AI045725-01A1............... GILLIS, THOMAS P.................. NATIONAL HANSEN'S DISEASE PROGRAM............ DEVELOP AND EVALUATE NEW LEPROSY AND TB VACCINES............... 110,275
R01AI046275-02................. Robinson, JAMES E................. TULANE UNIVERSITY OF LOUISIANA............... RHESUS MABS FROM SHIV INFECTED MACAQUES........................ 220,613
R01AI048499-01................. ROOP, ROY M....................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... BRUCELLA STATIONARY PHASE GENE EXPRESSION AND VIRULENCE........ 315,000
R01AR045982-03................. ALA-KOKKA, LEENA M................ TULANE UNIVERSITY OF LOUISIANA............... MUTATIONS CAUSING DISC DISEASE AND SCIATICA.................... 280,549
R01AR046976-02................. KIMPEL, DONALD L.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NOVEL IMAGING TECHNOLOGIES FOR RHEUMATOID ARTHRITIS............ 286,000
R01CA054152-09................. HILL, STEVEN M.................... TULANE UNIVERSITY OF LOUISIANA............... NEUROENDOCRINE INFLUENCES ON MAMMARY CANCER.................... 178,276
R01CA054576-07................. Dash, Srikanta A.................. TULANE UNIVERSITY OF LOUISIANA............... HEPATITIS C VIRUS AND HEPATOCELLULAR CARCINOMA A............... 244,525
R01CA065600-04................. SPARKS, RODNEY L.................. TULANE UNIVERSITY OF LOUISIANA............... CARCINOGENESIS AND LOSS OF DIFFERENTIATION CONTROL............. 173,347
R01CA075190-03................. BERKEL, HANS J.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... CHEMOPREVENTION OF ADENOMATOUS COLORECTAL POLYPS............... 651,800
R01CA075613-02................. HWANG, DANIEL H................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... CYCLOOXYGENASE AND TUMORIGENESIS............................... 189,257
R01CA078335-02................. GNARRA, JAMES R................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HGF/SF SIGNALING BY THE VHL TUMOR SUPPRESSOR................... 216,802
R01CA078335-02S1............... GNARRA, JAMES R................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HGF/SF SIGNALING BY THE VHL TUMOR SUPPRESSOR................... 70,117
R01CA080149-02................. MATHIS, J MICHAEL................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER........... 107,690
R01CA081125-02................. SCHWARZENBERGER, PAUL O........... LOUISIANA STATE UNIV HSC NEW ORLEANS......... IL-17 AND HEMATOPOIESIS........................................ 137,290
R01CA081506-01A1............... EHRLICH, MELANIE.................. TULANE UNIVERSITY OF LOUISIANA............... DNA HYPOMETHYLATION AND CANCER................................. 219,564
R01CA082689-02................. OCHOA, AUGUSTO C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... INDUCTION OF ANERGY AND ALTERED SIGNAL TRANSDUCTION............ 201,812
R01CA083823-01................. Levy, Laura S..................... TULANE UNIVERSITY OF LOUISIANA............... SELECTIVE FORCES OPERATIVE IN FELV INFECTION................... 237,309
R01CA085693-01................. HARRISON, LYNN.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DNA REPAIR OF MULTIPLY DAMAGED SITES IN CELLS.................. 218,250
R01DA005084-13................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOID PEPTIDE SYNTHESIZING ENZYMES............................ 175,109
R01DA006013-08................. GOEDERS, NICHOLAS E............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... ENVIRONMENTAL INFLUENCES ON COCAINE SELF ADMINISTRATION........ 207,513
R01DA008255-06................. VARNER, KURT J.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CHRONIC COCAINE/STIMULANTS--CARDIOVASCULAR CONSEQUENCES........ 170,943
R01DA009157-05................. FRANCE, CHARLES P................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DISCRIMINATIVE EFFECTS OF BENZODIAZEPINE WITHDRAWAL............ 31,209
R01DA009820-05................. GLOWA, JOHN R..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DETERMINANTS OF DRUG EFFECTS ON DRUG MAINTAINED BEHAVIOR....... 318,520
R01DA009820-05S1............... GLOWA, JOHN R..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DETERMINANTS OF DRUG EFFECTS ON DRUG MAINTAINED BEHAVIOR....... 58,144
R01DA011417-02................. Moerschbaecher, Joseph M.......... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CANNABINOID ABUSE EFFECTS ON LEARNING AND MEMORY............... 189,130
R01DA011528-04................. TRUDELL, MARK L................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... SYNTHESIS OF POTENTIAL COCAINE ABUSE THERAPEUTICS.............. 251,372
R01DA011655-03................. ZADINA, JAMES E................... TULANE UNIVERSITY OF LOUISIANA............... NEUROBIOLOGY OF ENDOMORPHINS................................... 134,463
R01DA011939-01A2............... Harlan, Richard E................. TULANE UNIVERSITY OF LOUISIANA............... THALAMOSTRIATAL MECHANISMS OF MORPHINE ACTION.................. 187,166
R01DA012267-02................. HARRISON, MURELLE G............... SOUTHERN UNIV A&M COL BATON ROUGE............ PREVENTING SUBSTANCE USE IN RURAL AFRICAN-AMERICAN YOUTH....... 571,834
R01DA012427-01A1............... WINSAUER, PETER J................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... COCAINE SELF-ADMINSTRATION: EFFECTS ON LEARNING................ 91,369
R01DA012427-01A1S1............. WINSAUER, PETER J................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... COCAINE SELF-ADMINSTRATION: EFFECTS ON LEARNING................ 10,010
R01DA012703-02................. TRUDELL, MARK L................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... NOVEL NICOTINIC RECEPTOR MEDIATED THERAPEUTIC AGENTS........... 287,756
R01DC000303-13................. GUTH, PAUL S...................... TULANE UNIVERSITY OF LOUISIANA............... PHARMACOLOGY OF VESTIBULAR NEUROTRANSMISSION................... 212,969
R01DC003679-02................. Hood, Linda Jean.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... AUDITORY GENETIC STUDIES OF HEREDITARY HEARING LOSS............ 201,335
R01DC003792-02................. CAPRIO, JOHN T.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... ENCODING OF BIOLOGICALLY RELEVANT ODOR SIGNALS................. 310,659
R01DC003896-02................. Ricci, Anthony J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... ENDOGENOUS FACTORS REGULATING TRANSDUCER ADAPTATION............ 169,287
R01DC003896-02S1............... Ricci, Anthony J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... ENDOGENOUS FACTORS REGULATING TRANSDUCER ADAPTATION............ 19,770
R01DC004196-02................. Keats, Bronya J................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ID OF THE MOUSE DEAFNESS (DN) GENE ON CHROMOSOME 19............ 217,521
R01DE008851-10................. BLOCK, MICHAEL S.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... PROSPECTIVE EVALUATION OF IMPLANT SUPPORTED BRIDGES............ 109,415
R01DE008911-09................. WISE, GARY E...................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MOLECULAR BASIS OF TOOTH ERUPTION.............................. 168,830
R01DE012178-03................. FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ORAL IMMUNE DYSFUNCTION AND CANDIDIASIS IN HIV INFECTION....... 222,477
R01DE012178-03S1............... FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ORAL IMMUNE DYSFUNCTION AND CANDIDIASIS IN HIV INFECTION....... 105,767
R01DE012178-03S2............... FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ORAL IMMUNE DYSFUNCTION AND CANDIDIASIS IN HIV INFECTION....... 25,622
R01DE012187-05................. SIXBEY, JOHN W.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DETERMINANTS OF EPSTEIN BARR VIRUS MUCOSAL PATHOGENESIS........ 219,839
R01DE012329-02................. CHEN, YIPING...................... TULANE UNIVERSITY OF LOUISIANA............... MOLECULAR MECHANISMS OF VERTEBRATE TOOTH INITIATION............ 175,255
R01DE012916-02................. AMEDEE, ANGELA M.................. TULANE UNIVERSITY OF LOUISIANA............... SIV MACAQUE MODEL FOR BREAST MILK TRANSMISSION OF HIV.......... 284,210
R01DK034286-16................. RABON, EDWIN C.................... TULANE UNIVERSITY OF LOUISIANA............... GASTRIC ACID SECRETION: CATION BINDING IN H,K-ATPASE........... 188,931
R01DK039232-11................. CARDELLI, JAMES A................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... REGULATION OF PHAGOCYTOSIS..................................... 179,990
R01DK041868-10................. HWANG, DANIEL H................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DIETARY N 3 FATTY ACIDS AND EXPRESSION OF CYCLOOXYGENASE....... 185,627
R01DK042714-08S1............... HORNBY, PAMELA J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... CNS AUTONOMIC PATHWAYS AND GASTROINTESTINAL FUNCTION........... 10,000
R01DK042714-09................. HORNBY, PAMELA J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... CNS AUTONOMIC PATHWAYS AND GASTROINTESTINAL FUNCTION........... 177,080
R01DK043337-08................. KAPUSTA, DANIEL R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOIDS AND CENTRAL NEURAL REGULATION OF RENAL FUNCTION........ 142,501
R01DK044628-06................. Inscho, Edward W.................. TULANE UNIVERSITY OF LOUISIANA............... PURINERGIC REGULATION OF THE RENAL MICROVASCULATURE............ 231,761
R01DK045278-08................. York, David A..................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... ENTEROSTATIN REGULATION OF FAT INTAKE.......................... 213,473
R01DK045449-07................. BARICOS, WILLIAM H................ TULANE UNIVERSITY OF LOUISIANA............... PA/PLASMIN/GELATINASE CASCADE IN DIABETIC NEPHROPATHY.......... 208,020
R01DK046935-06................. Lancaster, Jack R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... NITROGEN AND OXYGEN RADICAL INTERACTIONS IN SURGERY............ 193,177
R01DK047211-06................. VEDECKIS, WAYNE V................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... REGULATION OF GLUCOCORTICOID RECEPTOR GENE EXPRESSION.......... 175,335
R01DK047348-07................. BERTHOUD, HANS-RUDOLF............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... AUTONOMIC REGULATION OF FOOD INTAKE AND METABOLISM............. 174,607
R01DK047663-06................. GRISHAM, MATTHEW B................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... ADHESION MOLECULE EXPRESSION IN CHRONIC GUT INFLAMMATION....... 180,366
R01DK049703-05................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CONTROL OF PEPTIDE HORMONE BIOSYNTHESIS BY PC2 AND 7B2......... 169,680
R01DK049703-05S1............... LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CONTROL OF PEPTIDE HORMONE BIOSYNTHESIS BY PC2 AND 7B2......... 65,780
R01DK049703-05S2............... LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CONTROL OF PEPTIDE HORMONE BIOSYNTHESIS BY PC2 AND 7B2......... 28,749
R01DK050736-04................. LOVEJOY, JENNIFER C............... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MENOPAUSE EFFECT ON OBESITY, ENERGY BALANCE AND INSULIN........ 221,244
R01DK051392-04................. HAMMOND, TIMOTHY G................ TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF URINARY BLADDER ENDOSOMAL FUSION................. 226,264
R01DK052968-02................. Stephens, Jacqueline M............ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... REGULATION AND ACTIVATION OF STATS IN ADIPOCYTES............... 176,467
R01DK053113-02................. SMITH, BRENDA K................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... TASTE AND GENETIC MECHANISMS OF MACRONUTRIENT SELECTION........ 210,114
R01DK053697-04................. CORREA, PELAYO.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HELICOBACTER INFECTION AND GROWTH OF CHILDREN.................. 116,698
R01DK053903-02................. Harris, Ruth B.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... LEPTIN AND PERIPHERAL GLUCOSE METABOLISM....................... 178,683
R01DK054880-02................. KASTIN, ABBA J.................... TULANE UNIVERSITY OF LOUISIANA............... BLOOD/BRAIN BARRIER AND LEPTIN TRANSPORT IN OBESITY............ 318,730
R01DK054952-01A2............... HAMM, L. LEE...................... TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF CITRATE TRANSPORT................................ 198,450
R01DK055626-01A2............... AWAYDA, MOUHAMED S................ TULANE UNIVERSITY OF LOUISIANA............... KINASE REGULATION OF THE EPITHELIAL NA CHANNEL................. 210,625
R01DK056264-01A1............... El-Dahr, Samir S.................. TULANE UNIVERSITY OF LOUISIANA............... INDUCIBLE DYSPLASTIC NEPHROPATHY IN B2-DEFICENT MICE........... 267,300
R01DK057242-01................. BERTHOUD, HANS-RUDOLF............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... FUNCTIONAL ORGANIZATION OF THE VAGAL-ENTERIC INTERFACE......... 191,743
R01DK057446-02................. LOVEJOY, JENNIFER C............... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... INTERNET-AIDED PREVENTION OF PREGNANCY-INDUCED OBESITY......... 226,282
R01DK057476-02................. MARTIN, PAMELA D.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... PRIMARY CARE OFFICE MANAGEMENT OF OBESITY...................... 190,358
R01DK058152-01................. KOZAK, LESLIE P................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... GENETICS OF DEVELOPMENTAL PLASTICITY IN THE ADIPOCYTE.......... 419,610
R01ES004344-10................. BACKES, WAYNE L................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... TOXICOLOGICAL SIGNIFICANCE OF ALKYLBENZENE METABOLISM.......... 197,329
R01ES006766-07................. Brody, Arnold R................... TULANE UNIVERSITY OF LOUISIANA............... GROWTH FACTORS IN ASBESTOS INDUCED PULMONARY FIBROSIS.......... 246,479
R01ES007815-05................. Deutsch, Walter A................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... OXIDATIVE DNA DAMAGE AND THE ANALYSIS OF 8-OXOG REPAIR......... 239,906
R01ES008663-04................. FRIEDMAN, MITCHELL................ TULANE UNIVERSITY OF LOUISIANA............... BIOCHEMICAL MECHANISM FOR OZONE PATHOLOGY...................... 190,024
R01ES009158-04................. PRUETT, STEPHEN B................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF IMMUNOTOXICITY OF CHEMICAL STRESSORS............. 113,432
R01ES009870-01A1............... MEHENDALE, HARIHARA M............. UNIVERSITY OF LOUISIANA AT MONROE............ DIETARY RESTRICTION AND TOXICANT-INDUCED LIVER DISEASE......... 224,993
R01ES010046-01A1............... LASKY, JOSEPH A................... TULANE UNIVERSITY OF LOUISIANA............... DISRUPTION OF PDGF SIGNAL TRANSDUCTION IN LUNG FIBROSIS........ 222,750
R01EY002672-22................. KAUFMAN, HERBERT E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HERPES SIMPLEX.......................................... 446,207
R01EY003311-21................. KLYCE, STEPHEN D.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... INTEGRATED ASSESSMENT OF CORNEAL FORM AND FUNCTION............. 254,318
R01EY004928-18................. BAZAN, HAYDEE E................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CORNEAL LIPID METABOLISM AND RESPONSE TO INFLAMMATION.......... 191,428
R01EY006311-14................. HILL, JAMES M..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HSV--LATENCY, REACTIVATION, AND RECURRENCE.............. 225,251
R01EY006635-14................. BAZAN, HAYDEE E................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELL SIGNAL TRANSDUCTION IN CORNEAL WOUND HEALING.............. 216,772
R01EY007380-11A2............... MENERAY, MICHELE A................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... INTERACTIVE CELLULAR CONTROLS LACRIMAL GLAND FUNCTION.......... 277,869
R01EY008871-10................. HILL, JAMES M..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR PATHOGENESIS AND THERAPY OF BACTERIAL KERATITIS......... 286,084
R01EY010974-05................. O'CALLAGHAN, RICHARD J............ LOUISIANA STATE UNIV HSC NEW ORLEANS......... STAPH KERATITIS--MECHANISMS/ARRESTING OF CORNEAL DAMAGE........ 249,898
R01EY011610-03................. BURGOYNE, CLAUDE F................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... IOP RELATED FORCE AND FAILURE IN THE OPTIC NERVE HEAD.......... 274,018
R01EY012367-02................. JACOB, JEAN T..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... EPITHELIALIZATION OF TISSUE ENGINEERED CORNEAS................. 186,119
R01EY012416-02................. BEUERMAN, ROGER W................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... REGULATION OF PROTEIN SYNTHESIS IN THE LACRIMAL GLAND.......... 220,278
R01EY012540-02................. PALKAMA, ARTO K................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... AQUEOUS OUTFLOW AND STRUCTURAL CORRELATIONS.................... 332,155
R01EY012602-03................. ALLIEGRO, MARK C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... CONTROL OF VEGF STIMULATED ENDOTHELIAL PROLIFERATION........... 170,373
R01EY012701-01A1............... CHANDRASEKHER, GUDISEVA........... LOUISIANA STATE UNIV HSC NEW ORLEANS......... GROWTH FACTOR RECEPTOR MEDITATED SIGNAL MECHANISMS LENS........ 174,794
R01EY012887-01................. KHOOBEHI, BAHRAM.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... RETINAL AND CHOROIDAL BLOOD FLOW IMAGING....................... 213,024
R01EY012961-01................. O'CALLAGHAN, RICHARD J............ LOUISIANA STATE UNIV HSC NEW ORLEANS......... MECHANISMS AND THERAPY OF BACTERIAL KERATITIS.................. 284,555
R01GM020818-27................. RHOADS, ROBERT E.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... REGULATION OF EUKARYOTIC PROTEIN SYNTHESIS INITITATION......... 311,655
R01GM039844-09S1............... WARNER, ISIAH M................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... BIOANALYTICAL SEPARATIONS USING CHIRAL POLYMERS................ 18,277
R01GM039844-10................. WARNER, ISIAH M................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... BIOANALYTICAL SEPARATIONS USING CHIRAL POLYMERS................ 243,454
R01GM045668-08................. DEININGER, Prescott L............. TULANE UNIVERSITY OF LOUISIANA............... HUMAN DIMORPHISMS BY SINE MASTER GENES......................... 234,512
R01GM045842-08................. Gross, David S.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... STRUCTURE/REGULATION OF THE YEAST HSP90 GENES.................. 161,768
R01GM047789-16................. TATCHELL, Kelly G................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... GENETIC ANALYSIS OF PROTEIN PHOSPHATASE I IN YEAST............. 192,414
R01GM051261-04................. WALDROP, GROVER L................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... CATALYTIC MECHANISM OF BIOTIN DEPENDENT ENZYMES................ 92,391
R01GM051521-07................. WITT, STEPHEN N................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... KINETICS AND MECHANISM OF THE HEAT SHOCK 70 PROTEIN DNAK....... 194,117
R01GM056526-04................. LUSTIG, ARTHUR J.................. TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF TELOMERE DYNAMICS IN YEAST....................... 228,650
R01GM056835-03................. MCLAUGHLIN, MARK L................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... PEPTIDES ACTIVE AGAINST INTRACELLULAR PATHOGENIC DISEASE....... 166,651
R01GM058843-02................. LIMBACH, PATRICK A................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... IDENTIFICATION OF MODIFIED NUCLEOSIDES IN RIBOSOMAL RNA........ 126,851
R01HD008431-25................. KOZAK, LESLIE P................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MOLECULAR GENETICS OF THERMOGENESIS............................ 302,854
R01HD035245-04................. Muneoka, Ken...................... TULANE UNIVERSITY OF LOUISIANA............... MSX GENES IN WOUND HEALING AND REGENERATION.................... 152,788
R01HD036822-02................. WANG, YU-PING..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PLACENTAL FUNCTION IN PREECLAMPSIA............................. 137,077
R01HD037811-01A1............... GASSER, RAYMOND F................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... HUMAN EMBRYO SECTIONS ON COMPUTER DISKS FOR EDUCATION.......... 367,391
R01HD039104-01................. WILLIAMSON, DONALD A.............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... INTERNET-BASED OBESITY PREVENTION FOR BLACK ADOLESCENTS........ 157,972
R01HG001499-04................. SOPER, Steven A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... HIGH THROUGHPUT DNA SEQUENCING USING NANO-REACTORS............. 430,128
R01HG001777-03................. LIMBACH, PATRICK A................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... DNA SEQUENCING BY MASS SPECTROMETRIC METHODS................... 136,475
R01HL018426-26S1............... Navar, L. Gabriel................. TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF RENAL HEMODYNAMICS............................... 10,434
R01HL018426-27................. Navar, L. Gabriel................. TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF RENAL HEMODYNAMICS............................... 281,221
R01HL026371-19................. Navar, L. Gabriel................. TULANE UNIVERSITY OF LOUISIANA............... RENAL FUNCTIONAL DERANGEMENTS IN HYPERTENSION.................. 231,372
R01HL026371-19S1............... Navar, L. Gabriel................. TULANE UNIVERSITY OF LOUISIANA............... RENAL FUNCTIONAL DERANGEMENTS IN HYPERTENSION.................. 73,309
R01HL026441-20................. GRANGER, D NEIL................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... TRANSCAPILLARY FLUID EXCHANGE.................................. 243,130
R01HL045670-08S1............... BOUCHARD, CLAUDE.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... HERITAGE-GENETICS, RESPONSE TO EXERCISE, RISK FACTORS.......... 284,054
R01HL045670-09................. BOUCHARD, CLAUDE.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... HERITAGE-GENETICS, RESPONSE TO EXERCISE, RISK FACTORS.......... 915,078
R01HL054797-07A1............... KORTHUIS, RONALD J................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... PRECONDITIONING: PMN ADHESION AND MICROVASCULAR INJURY......... 290,000
R01HL056241-03................. LEFEVRE, MICHAEL.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... EFFICACY OF DIET THERAPY IN SUBJECTS AT RISK FOR CHD........... 323,842
R01HL058409-04................. AGRAWAL, KRISHNA C................ TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF HEMATOLOGIC ABNORMALITIES IN AIDS................ 274,486
R01HL058610-04................. HOYLE, GARY W..................... TULANE UNIVERSITY OF LOUISIANA............... PULMONARY FIBROSIS IN PDGF TRANSGENIC MICE..................... 263,426
R01HL059699-03................. IMIG, JOHN D...................... TULANE UNIVERSITY OF LOUISIANA............... OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY.............. 92,972
R01HL059724-04................. SHELLITO, JUDD E.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... T LYMPHOCYTE SUBSETS AND HOST DEFENSE AGAINST P CARINII........ 335,478
R01HL059879-02................. CLAYCOMB, WILLIAM C............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NOVEL GENE DISCOVERED IN THE HEART............................. 206,942
R01HL060300-04................. HE, JIANG......................... TULANE UNIVERSITY OF LOUISIANA............... EPIDEMIOLOGY STUDIES OF DIETARY FIBER AND BLOOD PRESSURE....... 129,736
R01HL060532-04................. Brody, Arnold R................... TULANE UNIVERSITY OF LOUISIANA............... EPITHELIAL GROWTH FACTORS IN ENVIRONMENTAL LUNG DISEASE........ 280,370
R01HL060849-02................. LEFER, DAVID J.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF MYOCARDIAL REPERFUSION INJURY--DIABETES.......... 176,994
R01HL061271-02................. Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NON CD4 HOST DEFENSE AGAINST P CARINII PNEUMONIA............... 73,902
R01HL061934-04................. MORRIS, CINDY A................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS................ 214,500
R01HL062000-01A2............... HYMAN, ALBERT L................... TULANE UNIVERSITY OF LOUISIANA............... CARDIOPULMONARY SURGERY RESEARCH............................... 257,450
R01HL062052-03................. Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA............. 250,250
R01HL062147-03................. PANDEY, KAILASH N................. TULANE UNIVERSITY OF LOUISIANA............... ANP RECEPTOR GENE--TARGETING AND EXPRESSION.................... 155,714
R01HL063128-01A2............... AGRAWAL, KRISHNA C................ TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF CARDIOVASCULAR COMPLICATIONS IN AIDS............. 283,597
R01HL063195-02................. TRAYANOVA, NATALIA A.............. TULANE UNIVERSITY OF LOUISIANA............... CARDIAC TISSUE STRUCTURE IN THE DEFIBRILLATION PROCESS......... 147,940
R01HL064555-02................. CLARKSON, CRAIG W................. TULANE UNIVERSITY OF LOUISIANA............... MOLECULAR BASIS FOR DRUG INDUCED CARDIOTOXICITY IN AIDS........ 183,546
R01HL064577-02................. JOHNSON, ROBERT A................. TULANE UNIVERSITY OF LOUISIANA............... HEMODYNAMIC ROLES OF ENDOGENEOUS CARBON MONOXIDE............... 166,277
R01MH051175-06................. O'DONNELL, JAMES M................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS........... 197,207
R01NS009626-30................. LI, YU-TEH........................ TULANE UNIVERSITY OF LOUISIANA............... GLYCOSIDASES AS RELATED TO SPHINGOLIPIDOSES.................... 334,553
R01NS023002-15................. BAZAN, NICOLAS G.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... PHOSPHOLIPIDS AND ARACHIDONIC ACID AND EP...................... 265,361
R01NS025134-11................. HAYCOCK, JOHN W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR REGULATION OF TYROSINE HYDROXYLASE.................... 207,349
R01NS025987-12S1............... PHELPS, CAROL J................... TULANE UNIVERSITY OF LOUISIANA............... HYPOPHYSIOTROPIC NEURON DIFFERENTIATION--TARGET FEEDBACK....... 50,000
R01NS025987-13................. PHELPS, CAROL J................... TULANE UNIVERSITY OF LOUISIANA............... HYPOPHYSIOTROPIC NEURON DIFFERENTIATION--TARGET FEEDBACK....... 207,159
R01NS034926-04................. TASKER, JEFFREY G................. TULANE UNIVERSITY OF LOUISIANA............... GLUTAMATE MODULATION OF HYPOTHALAMIC NEURONS................... 177,854
R01NS036936-03................. ERICKSON, JEFFREY D............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... VESICULAR TRANSPORTER SPECIFICITY.............................. 201,699
R01NS036936-03S1............... ERICKSON, JEFFREY D............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... VESICULAR TRANSPORTER SPECIFICITY.............................. 50,000
R01NS037070-03................. ERZURUMLU, REHA S................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR MECHANISMS UNDERLYING PATTERN FORMATION............... 127,909
R01NS037963-03................. CANAVIER, CARMEN C................ LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... FIRING PATTERN REGULATION IN MIDBRAIN DOPAMINE NEURONS......... 147,768
R01NS039050-01A1............... ERZURUMLU, REHA S................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SOMATOSENSORY CORTICAL DEVELOPMENT AND PLASTICITY.............. 167,305
R01NS039099-01A1............... TASKER, JEFFREY G................. TULANE UNIVERSITY OF LOUISIANA............... HYPOTHALAMIC SYNCHRONIZATION BY LOCAL GLUTAMATE CIRCUITS....... 311,088
R01NS039458-01................. MAGEE, JEFFERY C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DENDRITIC INTEGRATION IN HIPPOCAMPAL PYRAMIDAL NEURONS......... 207,276
R03AG018034-01................. CHERRY, KATIE E................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... PERCEPTIONS OF FORGETFULNESS IN ADULTHOOD...................... 69,247
R03AG018187-01................. Inscho, Edward W.................. TULANE UNIVERSITY OF LOUISIANA............... RENAL MICROVASCULAR FUNCTION IN AGED RATS...................... 74,250
R03AG018600-01................. REDDIX, RHODA A................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... GLIAL CELL DERIVED NEUROTROPHIC FACTOR AND THE AGING GUT....... 71,500
R03AI042077-03................. Malone, John B.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... GEOGRAPHIC INFORMATION SYSTEMS & SCHISTOSOMIASIS............... 72,787
R03CA081602-02................. HAGENSEE, MICHAEL E............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NONINVASIVE DETECTION OF ANTIBODIES AGAINST HPV................ 65,284
R03CA083050-02................. YU, HERBERT H..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... ESTROGEN AND INSULIN LIKE GROWTH FACTORS IN BREAST CANCE....... 71,195
R03CA083095-02................. CORREA, PELAYO.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HOST RESPONSE TO HELICOBACTER PYLORI INFECTION................. 66,985
R03CA083632-02................. ESPINOZA-DELGADO, IGOR............ LOUISIANA STATE UNIV HSC NEW ORLEANS......... TRIAL OF BRYOSTATIN/IL-2 TO ENHANCE ANTIGEN PRESENTATION....... 71,474
R03CA086378-01................. HAGENSEE, MICHAEL E............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... DEVELOPMENT OF A URINE PCR ASSAY FOR HPV DNA DETECTION......... 69,350
R03CA088135-01................. SU, L. J.......................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... DIETARY SURVEY INSTRUMENT DEVELOPMENT FOR AN ETHNIC MINO....... 71,210
R03DA012547-01A1............... ROERIG, SANDRA C.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... SPINAL NITRIC OXIDE IN CHRONIC INFLAMMATORY PAIN............... 69,978
R03DA013421-01................. LAHOSTE, GERALD J................. LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... GAP JUNCTIONS AND DOPAMINE PLASTICITY.......................... 71,000
R03DA013546-01................. HUANG, TIEN L..................... XAVIER UNIVERSITY OF LOUISIANA............... NOVEL ANTI-PCP AGENTS WITH NEUROPROTECTIVE PROPERTIES.......... 69,975
R03DC003609-03................. OETTING, JANNA B.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... SLI WITHIN THE CONTEXT OF DIALECT DIVERSITY.................... 55,926
R03DE012944-02................. DEE, KAY C........................ TULANE UNIVERSITY OF LOUISIANA............... ADHESION/GROWTH-PROMOTING PROACTIVE DENTAL BIOMATERIALS........ 36,473
R03DK054971-03................. ABDEL-MAGEED, ASIM B.............. TULANE UNIVERSITY OF LOUISIANA............... METALLOTHIONEIN AND PROSTATE TUMORIGENESIS..................... 73,992
R03MH061944-01................. NORTHUP, JOHN A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... STAR PROGRAM: EARLY & PREVENTIVE INTERVENTION OF ADHD.......... 73,500
R13GM061083-01................. MOUDGIL, GIRISH C................. TULANE UNIVERSITY OF LOUISIANA............... ALLERGY, IMMUNOLOGY, AND ANESTHETIC ACTION..................... 3,000
R15AI047297-01................. ENNIS, D G........................ UNIVERSITY OF LOUISIANA AT LAFAYETTE......... ANALYSIS OF DNA REPAIR AND SOS REGULATION IN BRUCELLA.......... 117,628
R18AI033449-06................. FREY, DANIEL J.................... LOUISIANA ORGAN PROCUREMENT AGENCY........... ENHANCING DONOR REGISTRY TO INCREASE DONATION.................. 282,669
R21AR047796-01................. PROCKOP, DARWIN J................. TULANE UNIVERSITY OF LOUISIANA............... EXPANSION OF STEM CELLS FOR SKELETAL TISSUES................... 74,250
R21CA078693-02................. EHRLICH, MELANIE.................. TULANE UNIVERSITY OF LOUISIANA............... PROGENITOR COLONY RT-PCR ANALYSIS IN CML TREATMENT............. 148,421
R21CA082618-02................. NATHAN, CHERIE-ANN O.............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... MOLECULAR ANALYSIS OF SURGICAL MARGINS WITH EIF4E IN CAN....... 122,714
R21CA083198-01A1............... OCHOA, AUGUSTO C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... T CELL SIGNAL TRANSDUCTION TO MONITOR HPV VACCINES............. 141,426
R21CA084095-01................. HYMAN, LINDA E.................... TULANE UNIVERSITY OF LOUISIANA............... ELONGIN C: FUNCTION AND ROLE IN VHL DISEASE.................... 148,500
R21CA091785-01................. MATHIS, J MICHAEL................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... ROLE OF CYSTATIN M IN BREAST TUMOR PROGRESSION................. 99,863
R24CA084625-01................. SOPER, Steven A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MICRO-INSTRUMENT PLATFORMS FOR GENETIC-BASED ANALYSES.......... 591,505
R24DA007970-08................. KOMISKEY, HAROLD L................ XAVIER UNIVERSITY OF LOUISIANA............... MIDARP AT XAVIER UNIVERSITY OF LOUISIANA....................... 393,470
R24HL060808-03................. STRONG, JACK P.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... PDAY CARDIOVASCULAR SPECIMEN AND DATA LIBRARY.................. 124,343
R24RR012545-02................. BASKIN, GARY B.................... TULANE UNIVERSITY OF LOUISIANA............... ANIMAL MODEL FOR GENE THERAPY OF INHERITED DISORDERS........... 503,804
R25CA047877-13................. LOPEZ-S, ALFREDO.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SHORT RESEARCH EXPERIENCES IN CANCER........................... 63,123
R25GM051773-03A1............... HIMAYA, M A....................... GRAMBLING STATE UNIVERSITY................... PARTNERSHIP FOR MINORITY ACCESS TO BACCALAUREATE DEGREES....... 468,130
R25MH058560-03................. SAXENA, KRISHAN M................. GRAMBLING STATE UNIVERSITY................... NIMH HONORS MINORITY HIGH SCHOOL PROGRAM AT GSU................ 26,001
R29AI039023-05................. HOYLE, GARY W..................... TULANE UNIVERSITY OF LOUISIANA............... NEUROGENIC INFLAMMATION IN ASTHMA AND OZONE LUNG INJURY........ 110,151
R29CA069148-05................. DE BENEDETTI, ARRIGO.............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... PROTO-ONCOGENE EIF-4E IN BREAST CANCER......................... 101,454
R29CA076186-03................. MEYERS, SHARI L................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MOLECULAR MECHANISM OF TRANSFORMATION BY AML1/ETO.............. 100,955
R29DC003280-02S1............... Garcia, Meredith M................ TULANE UNIVERSITY OF LOUISIANA............... PROTEIN KINASE C IN CENTRAL AUDITORY PLASTICITY................ 20,000
R29DC003280-03................. Garcia, Meredith M................ TULANE UNIVERSITY OF LOUISIANA............... PROTEIN KINASE C IN CENTRAL AUDITORY PLASTICITY................ 98,502
R29DK052148-04................. KALOGERIS, THEODORE J............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NEUROHORMONAL CONTROL OF INTESTINAL APOLIPOPROTEIN A IV........ 100,588
R29ES007856-05................. MORRIS, GILBERT F................. TULANE UNIVERSITY OF LOUISIANA............... P53 IN ASBESTOS INDUCED LUNG DISEASE........................... 113,433
R29ES009055-03................. MILLER, CHARLES A................. TULANE UNIVERSITY OF LOUISIANA............... ARYL HYDROCARBON RECEPTOR STRUCTURE AND INTERACTIONS........... 87,585
R29EY012204-03................. GLEASON, EVANNA L................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... METABOTROPIC GLUTAMATE RECEPTORS ON AMACRINE CELLS............. 96,588
R29HD036310-05................. VEAZEY, RONALD S.................. TULANE UNIVERSITY OF LOUISIANA............... ONTOGENY OF THE NEONATAL MACAQUE IMMUNE SYSTEM................. 115,261
R29HD036421-04................. KUBISCH, HANS M................... TULANE UNIVERSITY OF LOUISIANA............... MARKER ASSISTED SELECTION OF BOVINE BLASTOCYSTS................ 57,093
R29HL051306-05................. MAJID, DEWAN S.................... TULANE UNIVERSITY OF LOUISIANA............... NITRIC OXIDE AND MEDIATING PRESSURE NATRIURESIS................ 116,625
R29HL058806-04................. CRUMB, WILLIAM J.................. TULANE UNIVERSITY OF LOUISIANA............... CHARACTERIZATION ION CURRENT IN PEDIATRIC HUMAN ATRIA A........ 84,322
R29MH055654-04................. FRICK, PAUL J..................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... CALLOUS/UNEMOTIONAL TRAITS AND CONDUCT PROBLEMS................ 95,780
R29NS033671-05................. ELMSLIE, KEITH S.................. TULANE UNIVERSITY OF LOUISIANA............... CALCIUM CHANNELS IN SYMPATHETIC NEURONS........................ 106,366
R29NS035865-04................. MAGEE, JEFFERY C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DENDRITIC K+ AND IH CHANNELS IN HIPPOCAMPAL NEURONS............ 104,280
R37AG006168-15................. JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR AGING IN A YEAST MODEL SYSTEM......................... 411,022
R37AG006168-15S1............... JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR AGING IN A YEAST MODEL SYSTEM......................... 5,000
R37AG006168-15S2............... JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR AGING IN A YEAST MODEL SYSTEM......................... 120,640
R37DK032089-19................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DIETARY OBESITY................................................ 293,153
R37DK036013-14................. ORLANDO, ROY C.................... TULANE UNIVERSITY OF LOUISIANA............... ESOPHAGEAL CYTOPROTECTION--AGENTS AND MECHANISMS............... 202,749
R37EY002580-20S2............... KAUFMAN, HERBERT E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... CORNEAL PRESERVATION AND KERATOPLASTY.......................... 165,943
R37MH051853-07................. MCCANN, SAMUEL M.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MECHANISM OF ACTION OF CYTOKINES ON BRAIN AND PITUITARY........ 290,105
R42CA083756-03................. Pincus, Seth H.................... NORION DIAGNOSTIC INNOVATIONS, INC........... HIV INFECTIVITY TEST FOR ANTIVIRAL SUSCEPTIBILITY.............. 245,461
R43AI042464-01A2............... LO, WAI-CHUN J.................... ANOMERIC, INC................................ RAPID SCREENING OF MICROBES IN URINE........................... 100,000
R43DC004378-01................. JUNEAU, ROGER P................... SOFTEAR TECHNOLOGIES, LLC.................... BENEFITS OF A SOFT-SOLID HEARING INSTRUMENT.................... 99,237
R43GM061508-01................. SINHA, SUDHIR K................... RELIAGENE TECHNOLOGIES, INC.................. DIMORPHIC ALU REPEATS-APPLICATION IN IDENTITY TESTING.......... 100,000
R43NS038358-01A2............... NARDUCY, KENNETH W................ ST CHARLES PHARMACEUTICALS................... DEVELOPMENT OF ANALGESICS WITH FEWER SIDE EFFECTS.............. 99,999
R44CA083552-02................. MORGAN, LEE R..................... DEKK-TEC, INC................................ ISOPHOSPHORAMIDE MUSTARD--A PHASE 1 STUDY...................... 225,894
R44CA085021-01................. MORGAN, LEE R..................... DEKK-TEC, INC................................ DERIVATIVES OF DEMETHYLPENCLOMEDINE: ANTICANCER AGENTS......... 126,956
S06GM004531-11................. IFEANYI, FELIX I.................. GRAMBLING STATE UNIVERSITY................... MBRS SCORE PROGRAM AT GRAMBLING STATE UNIVERSITY............... 83,072
S06GM004531-11S1............... IFEANYI, FELIX I.................. GRAMBLING STATE UNIVERSITY................... MBRS SCORE PROGRAM AT GRAMBLING STATE UNIVERSITY............... 112,668
S06GM008008-29................. STEVENS, CHERYL L................. XAVIER UNIVERSITY OF LOUISIANA............... MBRS SCORE PROGRAM AT XAVIER UNIVERSITY........................ 587,409
S11ES009996-02................. BLAKE, ROBERT C................... XAVIER UNIVERSITY OF LOUISIANA............... ALTERATION OF GENE REGULATION BY ENVIRONMENTAL COMPOUNDS....... 1,103,872
S11ES010018-02................. MUGANDA, PERPETUA M............... SOUTHERN UNIV A&M COL BATON ROUGE............ CELLULAR & MOLECULAR TOXICOLOGY OF BUTADIENE................... 880,496
T32AA007577-02................. BAGBY, GREGORY J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM................... 186,499
T32CA065436-04................. JAFFE, BERNARD M.................. TULANE UNIVERSITY OF LOUISIANA............... RESEARCH TRAINING IN SURGICAL ONCOLOGY (T32)................... 35,288
T32DA007311-02................. GOEDERS, NICHOLAS E............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... STRESS AND THE NEUROBIOLOGY OF DRUG AND ALCOHOL DEPENDE........ 260,724
T34GM007716-22................. BIRDWHISTELL, TERESA.............. XAVIER UNIVERSITY OF LOUISIANA............... MARC UNDERGRADUATE STUDENT TRAINING IN ACADEMIC RESEARCH....... 512,916
T34GM008714-03................. HIMAYA, M A....................... GRAMBLING STATE UNIVERSITY................... U STAR PROGRAM FOR MARC AT GRAMBLING STATE UNIVERSITY.......... 169,093
T34MH017102-18................. SAXENA, KRISHAN M................. GRAMBLING STATE UNIVERSITY................... NIMH COR HONORS UNDERGRADUATE PROGRAM AT GSU................... 78,921
U01AI032913-09................. VAN DYKE, RUSSELL B............... TULANE UNIVERSITY OF LOUISIANA............... TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT................. 869,072
U01AI038844-04S1............... Lertora, Juan J. L................ TULANE UNIVERSITY OF LOUISIANA............... AIDS CLINICAL TRIALS UNIT...................................... 656,013
U01AI042178-08S2............... BESCH, CERYL L.................... TULANE UNIVERSITY OF LOUISIANA............... LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM...................... 201,108
U01AI042178-09................. MUSHATT, DAVID M.................. TULANE UNIVERSITY OF LOUISIANA............... LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA).............. 734,999
U01CA083014-02................. ZAKRIS, ELLEN L................... TULANE UNIVERSITY OF LOUISIANA............... TULANE AIDS-ASSOCIATED MALIGNANCY CONSORTIUM................... 146,641
U01DK046636-06S1............... HENDRICKS, JAMES B................ CHILDREN'S HOSPITAL (NEW ORLEANS)............ DIABETES PREVENTION TRIAL-IDDM (DPT-1)......................... 32,167
U01DK048377-07................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... NIDDM PRIMARY PREVENTION TRIAL (DPT 2)......................... 647,180
U01DK056990-02................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Clinical Center for Look AHEAD: Health in Diabetes............. 864,842
U01HD031315-07................. WILSON, JOHN T.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PEDIATRIC PHARMACOLOGY RESEARCH UNIT........................... 299,009
U01HD032844-06................. ABDALIAN, SUE E................... TULANE UNIVERSITY OF LOUISIANA............... ADOLESCENT MEDICINE HIV/AIDS RESEARCH NETWORK.................. 178,365
U01HL038844-14................. BERENSON, GERALD S................ TULANE UNIVERSITY OF LOUISIANA............... EARLY NATURAL HISTORY OF ARTERIOSCLEROSIS...................... 1,153,179
U01HL057190-04................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DIETARY PATTERNS, SODIUM INTAKE AND BLOOD PRESSURE............. 169,185
U01HL060571-03................. HARSHA, DAVID W................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... PREMIER--LIFESTYLE INTERVENE FOR BLOOD PRESSURE CONTRL......... 594,383
U01HL066855-01................. Webber, Larry S................... TULANE UNIVERSITY OF LOUISIANA............... TRIAL OF ACTIVITY FOR ADOLESCENT GIRLS (TAAG).................. 504,822
U10CA035272-17................. KARDINAL, CARL G.................. OCHSNER CLINIC FOUNDATION.................... OCHSNER COMMUNITY CLINICAL ONCOLOGY PROGRAM.................... 531,345
U10CA058658-08................. MILLS, GLENN M.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... SOUTHWEST ONCOLOGY GROUP....................................... 244,025
U10CA063845-06S3............... VEITH, ROBERT W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... LSUMC MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM....... 160,768
U10CA063845-06S4............... VEITH, ROBERT W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... LSUMC MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM....... 94,893
U10CA063845-06S5............... VEITH, ROBERT W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... LSUMC MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM....... 77,070
U19AI045511-02................. BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... AFRICAN MALARIA VECTORS........................................ 592,666
U42RR003583-14S1............... ROWELL, THOMAS J.................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... ESTABLISHMENT OF A CHIMPANZEE BREEDING/RESEARCH PROGRAM........ 335,000
U42RR009895-05S2............... DRUILHET, ROBERT E................ UNIVERSITY OF LOUISIANA AT LAFAYETTE......... DEVELOPMENT OF A SPF PIGTAIL MACAQUE BREEDING COLONY........... 412,500
U42RR015087-01................. ROWELL, THOMAS J.................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... ESTABLISHMENT/MAINTENANCE OF BIOMEDICAL RESEARCH COLONY........ 820,281
U45ES010664-01................. WRIGHT, BEVERLY H................. XAVIER UNIVERSITY OF LOUISIANA............... WORKER HEALTH AND SAFETY TRAINING COOPERATIVE AGREEMENT........ 955,608
------------
TOTAL FY 2000............ .................................. ............................................. ............................................................... 78,633,407
============
FISCAL YEAR 2001
D43TW001086-03................. MATHER, FRANCES J................. TULANE UNIVERSITY OF LOUISIANA............... INTERNATIONAL TRAINING IN MEDICAL INFORMATICS.................. 149,371
D43TW001142-03................. BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... ACTIONS FOR BUILDING CAPACITY.................................. 100,000
F06TW005588-01................. BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... Vector ecology of urban malaria in Africa...................... 29,700
F31DA005907-03................. HORNER, KRISTEN A................. TULANE UNIVERSITY OF LOUISIANA............... CHANGES IN ENDOMORPHINS DURING OPIATE TOLERANCE................ 20,585
F31DA005926-03................. BRADLEY, AMY L.................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... SYNTHESIS AND DEVELOPMENT OF NEW COCAINE MEDICATIONS........... 23,099
F31DA005948-03................. CZAPLA, MARC A.................... TULANE UNIVERSITY OF LOUISIANA............... ENDOMORPHIN AND CARDIORESPIRATORY CONTROL...................... 21,892
F31DA005968-03................. SMITH, REBECCA R.................. TULANE UNIVERSITY OF LOUISIANA............... ENDOMORPHIN PLASTICITY IN CHRONIC PAIN MODELS.................. 35,818
F31DA006040-02................. GREENWELL, THOMAS N............... TULANE UNIVERSITY OF LOUISIANA............... ENDOMORPHIN-NEUROIMMUNE INTERACTIONS........................... 21,431
F31DA014155-01................. BANNER, EDITH J................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... Total Synthesis of Novel Decahydroquinolines................... 22,271
F31DC005116-01................. MCINVALE, ANDREW C................ TULANE UNIVERSITY OF LOUISIANA............... PSD Proteins: Functional Morphology at Auditory Synapses....... 21,500
F31GM019387-04................. HAMILTON, KIMBERLY Y.............. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... CHIRAL SELECTOR IN CAPILLARY ELECTROPHORESIS................... 22,650
F31GM019876-03................. BURSE, JEANINE R.................. TULANE UNIVERSITY OF LOUISIANA............... PAST AND PRESENT BIOINDICATION OF RIVER POLLUTION.............. 15,274
F31GM019876-03S1............... BURSE, JEANINE R.................. TULANE UNIVERSITY OF LOUISIANA............... PAST AND PRESENT BIOINDICATION OF RIVER POLLUTION.............. 5,575
F31GM020437-03................. CEDILLO, BERTHA M................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... DEVELOPMENT OF A CHIRAL SELECTOR SYSTEM........................ 24,737
F31GM020686-02................. ROBINSON, TERI L.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... DENDRIMERS/POLYMERIC SURFACTANTS IN CHIRAL SEPARATIONS......... 27,013
F31GM020915-01A1............... GUTIERREZ, YANIRA I............... TULANE UNIVERSITY OF LOUISIANA............... PI3K-Mediated Hypoxia Survival Signaling Pathways.............. 24,470
F31HL068296-01................. ANDERSON, KIMBERLY M.............. TULANE UNIVERSITY OF LOUISIANA............... Studies of a novel A and B blood group cleaving enzyme......... 19,000
F31MH012816-01A1............... SANTUZZI, ALECIA M................ TULANE UNIVERSITY OF LOUISIANA............... PREDOCTORAL FELLOWSHIP PROGRAM (DISABILITY).................... 21,080
F32DA014162-01................. DANIEL, JILL M.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Effects of Estrogen and Cannabinoids on Learning............... 33,260
F32DK009931-03................. ROSS, DONNA M..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... RENAL CAPILLARY FAILURE IN DIABETIC NEPHROPATHY................ 40,196
F32DK010151-01................. WHITE, CHRISTY L.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... LEPTIN RESPONSIVENESS IN A DIETARY MODEL OF OBESITY............ 43,772
F32EY013651-01................. MARQUART, MARY E.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... Pseudomonas proteases as ocular virulence factors.............. 41,996
G08LM007108-01A1............... PERNOTTO, DENNIS A................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... USING A LOUISIANA NETWORK TO TRAIN/SEARCH NLM DATABASES........ 49,489
G11HD034961-04................. ISLAND, GLENDA J.................. GRAMBLING STATE UNIVERSITY................... GSU RESEARCH INFRASTRUCTURE--PHASE II.......................... 81,148
G20RR016930-01................. BLANCHARD, JAMES L................ TULANE UNIVERSITY OF LOUISIANA............... BLDG D RENOV-ANIMAL RESOURCES IMPROVEMENTS..................... 699,950
K01CA078318-03................. HEMENWAY, CHARLES S............... TULANE UNIVERSITY OF LOUISIANA............... BMI1 INTERACTING PROTEINS IN NEOPLASTIC TRANSFORMATION......... 136,197
K01ES000358-01A1............... HUNT, JAY D....................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Mutation and Environmental Exposures........................... 101,962
K01GM000707-02................. CHETTY, KOTHAPA N................. GRAMBLING STATE UNIVERSITY................... HYPERCHOLESTEROLEMIA AND REPERFUSION INJURY.................... 23,390
K02DA000204-09................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOID PEPTIDE PROCESSING ENZYMES.............................. 115,525
K02DK002605-03................. KAPUSTA, DANIEL R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOIDS AND CENTRAL NEURAL REGULATION OF RENAL FUNCTION........ 100,440
K02MH000967-08................. HAYCOCK, JOHN W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HUMAN TYROSINE HYDROXYLASE AND SCHIZOPHRENIA................... 109,220
K08AI001438-06................. CHANG, WUN-LING................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... CD4+ T CELL REGULATION--EFFECTOR CELLS IN BLASTOMYCOSIS........ 118,800
K08AI001467-04................. MASON, ANDREW L................... OCHSNER CLINIC FOUNDATION.................... RETROVIRAL ETIOLOGY OF PRIMARY BILIARY CIRRHOSIS............... 118,800
K08AI049790-02................. PARADA, NEREIDA A................. TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF IL-2 RECEPTOR BY THE CD4 LIGAND IL-16............ 110,700
K08MH001706-04................. SCHEERINGA, MICHAEL S............. TULANE UNIVERSITY OF LOUISIANA............... TRAUMATIZED YOUNG CHILDREN--RISK FOR MALADAPTATION............. 153,733
K22ES011025-01................. DUGAS, TAMMY R.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... COX-2 Mediated Vascular Toxicity of Methylenedianiline......... 106,080
K22HD001339-01................. DONZE, DAVID...................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... ANALYSIS OF CHROMOSOMAL INSULATOR/BOUNDARY ELEMENTS............ 133,960
K23DC000135-05................. FOUNDAS, ANNE L................... TULANE UNIVERSITY OF LOUISIANA............... NEUROBIOLOGIC SUBSTRATES OF STUTTERING......................... 74,925
K30HL004521-02................. FRIEDMAN, MITCHELL................ TULANE UNIVERSITY OF LOUISIANA............... CLINICAL RESEARCH CURRICULUM AWARD............................. 200,000
M01RR005096-12................. WHELTON, PAUL K................... TULANE UNIVERSITY OF LOUISIANA............... GENERAL CLINICAL RESEARCH CENTER............................... 2,378,343
P01DK043785-10S1............... GRANGER, D NEIL................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PATHOPHYSIOLOGY OF INTESTINAL ISCHEMIA/REPERFUSION............. 201,214
P20RR016456-01................. WISCHUSEN, EVERETT W.............. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... Louisana Biomedical Research Network........................... 1,928,797
P30EY002377-23................. KAUFMAN, HERBERT E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... CORE GRANT FOR VISION RESEARCH................................. 490,104
P50AA009803-08................. NELSON, STEVE..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, HIV INFECTION AND HOST DEFENSE........................ 1,733,863
P50AA009803-08S1............... NELSON, STEVE..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, HIV INFECTION AND HOST DEFENSE........................ 95,126
P51RR000164-40................. WHELTON, PAUL K................... TULANE UNIVERSITY OF LOUISIANA............... REGIONAL PRIMATE RESEARCH CENTER............................... 5,984,645
R01AA009505-06................. PRUETT, STEPHEN B................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF IMMUNOSUPPRESSION BY ONE DOSE OF ETHANOL......... 175,929
R01AA009876-07................. WOLCOTT, ROBERT M................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... FETAL ALCOHOL EFFECTS AND IMMUNE DEVELOPMENT................... 211,762
R01AA010384-06A1............... Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, IMMUNOSUPPRESSION, AND TACE........................... 286,000
R01AA011224-05................. GILES, THOMAS D................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITS........ 243,652
R01AA011760-05................. MASON, CAROL M.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, TB AND AIDS........................................... 184,376
R01AA012865-01................. KASTIN, ABBA J.................... TULANE UNIVERSITY OF LOUISIANA............... PEPTIDES AND ALCOHOL INTERACT AT THE BLOOD-BRAIN BARRIER....... 214,000
R01AG016592-02................. BERENSON, GERALD S................ TULANE UNIVERSITY OF LOUISIANA............... EVOLUTION OF CARDIOVASCULAR RISK WITH NORMAL AGING............. 713,391
R01AG017887-02................. JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NUTRITIONAL AND METABOLIC MECHANISMS OF AGING.................. 336,000
R01AG017981-02................. MCLAUGHLIN, MARK L................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... BETA-SHEET MIMICS FROM CONSTRAINED DIPEPTIDE UNITS............. 182,340
R01AG017983-02................. HAMMER, ROBERT P.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... INHIBITION OF FIBRILLOGENESIS WITH B-STRAND MIMICS............. 291,180
R01AG018031-01A1............... LUKIW, WALTER J................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Gene Expression in Alzheimer's Disease......................... 237,738
R01AG018239-02................. GEISELMAN, PAULA J................ LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... OBESITY PREVENTION AFTER SMOKING CESSATION IN MENOPAUSE........ 183,749
R01AG018648-02................. VANLANDINGHAM, MARK J............. TULANE UNIVERSITY OF LOUISIANA............... SOCIO-DEMOGRAPHIC IMPACT OF AIDS ON OLDER PERSONS.............. 111,375
R01AG018648-02S1............... VANLANDINGHAM, MARK J............. TULANE UNIVERSITY OF LOUISIANA............... SOCIO-DEMOGRAPHIC IMPACT OF AIDS ON OLDER PERSONS.............. 55,688
R01AG018869-01................. SUITOR, JILL J.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... PARENT-ADULT CHILD RELATIONS: WITHIN FAMILY DIFFERENCES........ 545,893
R01AG018869-01S1............... SUITOR, JILL J.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... PARENT-ADULT CHILD RELATIONS: WITHIN FAMILY DIFFERENCES........ 29,106
R01AI022001-17................. O'CALLAGHAN, DENNIS J............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NUCLEIC ACIDS OF HERPES VIRUS INFECTED CELLS................... 336,305
R01AI024030-14................. Robinson, JAMES E................. TULANE UNIVERSITY OF LOUISIANA............... HIV-1 Neutralizing Human MAbs.................................. 309,163
R01AI031567-07................. CHERVENAK, ROBERT P............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DEVELOPMENTAL BIOLOGY OF T CELL PRECURSORS..................... 183,440
R01AI032556-07................. FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... MUCOSAL CELL MEDIATED IMMUNITY IN VAGINAL CANDIDIASIS.......... 214,500
R01AI033325-10................. KHAN, IMTIAZ A.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... LONG TERM IMMUNITY AGAINST TOXOPLASMOSIS....................... 258,541
R01AI040667-06................. VAN DER HEYDE, HENRI C............ LOUISIANA STATE UNIV HSC SHREVEPORT.......... Cell adhesion molecules in cerebral malaria.................... 253,750
R01AI040690-03................. QUAYLE, ALISON J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... HUMAN DEFENSIN-5 IN FEMALE GENITAL TRACT IMMUNE DEFENSE........ 142,804
R01AI042146-03................. MUGGERIDGE, MARTIN I.............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... ROLES OF HSV2 MEMBRANE PROTEINS IN MEMBRANE FUSION............. 180,021
R01AI042400-02................. DAVISON, BILLIE B................. TULANE UNIVERSITY OF LOUISIANA............... A RHESUS MONKEY MODEL OF MALARIA IN PREGNANCY.................. 454,121
R01AI042777-04................. CLEMENTS, JOHN D.................. TULANE UNIVERSITY OF LOUISIANA............... MECHANISM OF CHOLERA TOXIN AND E COLI LT ADJUVANTICITY......... 201,345
R01AI043000-03................. KOUSOULAS, KONSTANTIN GUS......... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... GENETICS & FUNCTIONS OF HSV1 GK IN VIRUS ENTRY & EGRESS........ 289,052
R01AI043693-05................. KHAN, IMTIAZ A.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ENCEPHALITOZOAN CUNICULI--HOST IMMUNITY AND PATHOGENESIS....... 221,460
R01AI045041-03................. HURLBURT, BARRY K................. U.S. AGRICULTURE RESEARCH SERVICE-MIDSOU..... MECHANISMS OF VIRULENCE GENE REGULATION IN S. AUREUS........... 180,762
R01AI045151-02................. FREYTAG, LUCIA C.................. TULANE UNIVERSITY OF LOUISIANA............... MUCOSAL IMMUNIZATION--PREVENTION OF SYSTEMIC CANDIDIASIS....... 222,750
R01AI045725-02................. GILLIS, THOMAS P.................. NATIONAL HANSEN'S DISEASE PROGRAM............ DEVELOP AND EVALUATE NEW LEPROSY AND TB VACCINES............... 113,583
R01AI046275-03................. Robinson, JAMES E................. TULANE UNIVERSITY OF LOUISIANA............... RHESUS MABS FROM SHIV INFECTED MACAQUES........................ 227,232
R01AI049080-01A1............... VEAZEY, RONALD S.................. TULANE UNIVERSITY OF LOUISIANA............... Mechanisms of CD4 Depletion and Proliferation in SIV........... 400,000
R01AI049139-01A1............... OBERHELMAN, RICHARD A............. TULANE UNIVERSITY OF LOUISIANA............... Diagnostics for AIDS-Related Pediatric TB, Peru................ 266,110
R01AI049976-01................. PHILIPP, MARIO T.................. TULANE UNIVERSITY OF LOUISIANA............... 'Lyme disease: A possible test for cure........................ 152,000
R01AR045982-04................. ALA-KOKKA, LEENA M................ TULANE UNIVERSITY OF LOUISIANA............... MUTATIONS CAUSING DISC DISEASE AND SCIATICA.................... 281,321
R01AR046976-03................. KIMPEL, DONALD L.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NOVEL IMAGING TECHNOLOGIES FOR RHEUMATOID ARTHRITIS............ 290,000
R01AR048323-01................. PROCKOP, DARWIN J................. TULANE UNIVERSITY OF LOUISIANA............... Osteoprogenitors for Potential Therapy of OI................... 371,250
R01CA054152-09S1............... HILL, STEVEN M.................... TULANE UNIVERSITY OF LOUISIANA............... NEUROENDOCRINE INFLUENCES ON MAMMARY CANCER.................... 37,431
R01CA065600-05................. JETER, JAMES R.................... TULANE UNIVERSITY OF LOUISIANA............... CARCINOGENESIS AND LOSS OF DIFFERENTIATION CONTROL............. 178,547
R01CA067372-07................. SIXBEY, JOHN W.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Epstein Barr Virus Induced Genomic Instability................. 326,250
R01CA075613-03................. HWANG, DANIEL H................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... CYCLOOXYGENASE AND TUMORIGENESIS............................... 191,184
R01CA078335-03................. GNARRA, JAMES R................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HGF/SF SIGNALING BY THE VHL TUMOR SUPPRESSOR................... 214,314
R01CA078335-03S1............... GNARRA, JAMES R................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HGF/SF SIGNALING BY THE VHL TUMOR SUPPRESSOR................... 72,221
R01CA080149-03................. MATHIS, J MICHAEL................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER........... 111,193
R01CA081125-03................. SCHWARZENBERGER, PAUL O........... LOUISIANA STATE UNIV HSC NEW ORLEANS......... IL-17 AND HEMATOPOIESIS........................................ 139,863
R01CA081506-02................. EHRLICH, MELANIE.................. TULANE UNIVERSITY OF LOUISIANA............... DNA HYPOMETHYLATION AND CANCER................................. 251,510
R01CA082689-03................. OCHOA, AUGUSTO C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... INDUCTION OF ANERGY AND ALTERED SIGNAL TRANSDUCTION............ 207,865
R01CA083823-02................. Levy, Laura S..................... TULANE UNIVERSITY OF LOUISIANA............... SELECTIVE FORCES OPERATIVE IN FELV INFECTION................... 248,883
R01CA085693-02................. HARRISON, LYNN.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DNA REPAIR OF MULTIPLY DAMAGED SITES IN CELLS.................. 195,750
R01CA088885-01................. OCHOA, AUGUSTO C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... IMMUNE DYSFUNCTION AND IMMUNOTHERAPY OF RENAL CANCER........... 288,024
R01CA089057-01A1............... LI, LI............................ OCHSNER CLINIC FOUNDATION.................... Stromal Cell Molecules Required for Lymphoma Generation........ 166,250
R01CA089121-01A1............... Dash, Srikanta A.................. TULANE UNIVERSITY OF LOUISIANA............... Hepatitis C Virus and Hepatocellular Carcinoma................. 233,888
R01CA095783-01................. JONES, FRANK E.................... TULANE UNIVERSITY OF LOUISIANA............... ErbB4 signaling in the normal and neoplastic breast............ 234,226
R01DA005084-14................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOID PEPTIDE SYNTHESIZING ENZYMES............................ 180,316
R01DA006013-09................. GOEDERS, NICHOLAS E............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... ENVIRONMENTAL INFLUENCES ON COCAINE SELF ADMINISTRATION........ 213,738
R01DA009820-06................. GLOWA, JOHN R..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DETERMINANTS OF DRUG EFFECTS ON DRUG MAINTAINED BEHAVIOR....... 387,962
R01DA011417-03................. Moerschbaecher, Joseph M.......... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CANNABINOID ABUSE EFFECTS ON LEARNING AND MEMORY............... 194,804
R01DA011417-03S1............... Moerschbaecher, Joseph M.......... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CANNABINOID ABUSE EFFECTS ON LEARNING AND MEMORY............... 31,460
R01DA011528-05................. TRUDELL, MARK L................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... SYNTHESIS OF POTENTIAL COCAINE ABUSE THERAPEUTICS.............. 257,932
R01DA011939-02................. Harlan, Richard E................. TULANE UNIVERSITY OF LOUISIANA............... THALAMOSTRIATAL MECHANISMS OF MORPHINE ACTION.................. 174,238
R01DA012267-03................. HARRISON, MURELLE G............... SOUTHERN UNIV A&M COL BATON ROUGE............ PREVENTING SUBSTANCE USE IN RURAL AFRICAN-AMERICAN YOUTH....... 598,668
R01DA012267-03S1............... HARRISON, MURELLE G............... SOUTHERN UNIV A&M COL BATON ROUGE............ PREVENTING SUBSTANCE USE IN RURAL AFRICAN-AMERICAN YOUTH....... 13,825
R01DA012427-02................. WINSAUER, PETER J................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... COCAINE SELF-ADMINSTRATION: EFFECTS ON LEARNING................ 97,643
R01DA012703-03................. TRUDELL, MARK L................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... NOVEL NICOTINIC RECEPTOR MEDIATED THERAPEUTIC AGENTS........... 285,517
R01DA013463-01A1............... GOEDERS, NICHOLAS E............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Role for the HPA Axis in Methamphetamine Reinforcement......... 310,794
R01DA013470-01A1............... STEKETEE, JEFFERY D............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Medial Prefrontal Cortex and Cocaine Sensitization............. 53,717
R01DA013899-01A1............... MORSE, EDWARD V................... TULANE UNIVERSITY OF LOUISIANA............... Risk Reduction for Young African American IDUs................. 562,493
R01DC003679-03................. Hood, Linda Jean.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... AUDITORY GENETIC STUDIES OF HEREDITARY HEARING LOSS............ 207,374
R01DC003792-03................. CAPRIO, JOHN T.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... ENCODING OF BIOLOGICALLY RELEVANT ODOR SIGNALS................. 319,975
R01DC003896-03................. Ricci, Anthony J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... ENDOGENOUS FACTORS REGULATING TRANSDUCER ADAPTATION............ 166,126
R01DC004196-03................. Keats, Bronya J................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ID OF THE MOUSE DEAFNESS (DN) GENE ON CHROMOSOME 19............ 224,047
R01DE008911-10................. WISE, GARY E...................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MOLECULAR BASIS OF TOOTH ERUPTION.............................. 173,814
R01DE012178-04................. FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ORAL IMMUNE DYSFUNCTION AND CANDIDIASIS IN HIV INFECTION....... ...........
R01DE012178-04S1............... FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ORAL IMMUNE DYSFUNCTION AND CANDIDIASIS IN HIV INFECTION....... 108,940
R01DE012178-04S2............... FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ORAL IMMUNE DYSFUNCTION AND CANDIDIASIS IN HIV INFECTION....... 26,240
R01DE012329-03................. CHEN, YIPING...................... TULANE UNIVERSITY OF LOUISIANA............... MOLECULAR MECHANISMS OF VERTEBRATE TOOTH INITIATION............ 180,242
R01DE012916-03................. AMEDEE, ANGELA M.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SIV MACAQUE MODEL FOR BREAST MILK TRANSMISSION OF HIV.......... 317,085
R01DK039232-12................. CARDELLI, JAMES A................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... REGULATION OF PHAGOCYTOSIS..................................... 185,261
R01DK041279-09A2............... GLASS, JONATHAN D................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... Molecular Mechanisms of Intestinal Iron Transport.............. 246,500
R01DK041868-11................. HWANG, DANIEL H................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DIETARY N 3 FATTY ACIDS AND EXPRESSION OF CYCLOOXYGENASE....... 191,169
R01DK042714-10................. HORNBY, PAMELA J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... CNS AUTONOMIC PATHWAYS AND GASTROINTESTINAL FUNCTION........... 182,394
R01DK043337-09................. KAPUSTA, DANIEL R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOIDS AND CENTRAL NEURAL REGULATION OF RENAL FUNCTION........ 146,731
R01DK044510-08................. AW, TAK Y......................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Glutathione redox control of intestinal cell responses......... 261,000
R01DK045278-09................. York, David A..................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... ENTEROSTATIN REGULATION OF FAT INTAKE.......................... 321,528
R01DK046935-07................. Lancaster, Jack R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... NITROGEN AND OXYGEN RADICAL INTERACTIONS IN SURGERY............ 198,912
R01DK046935-07S1............... Lancaster, Jack R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... NITROGEN AND OXYGEN RADICAL INTERACTIONS IN SURGERY............ 36,886
R01DK047211-07................. VEDECKIS, WAYNE V................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... REGULATION OF GLUCOCORTICOID RECEPTOR GENE EXPRESSION.......... 180,596
R01DK047348-08................. BERTHOUD, HANS-RUDOLF............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... AUTONOMIC REGULATION OF FOOD INTAKE AND METABOLISM............. 179,844
R01DK047663-07................. GRISHAM, MATTHEW B................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... ADHESION MOLECULE EXPRESSION IN CHRONIC GUT INFLAMMATION....... 177,703
R01DK048055-06A2............... MCCARTHY, KEVIN J................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... Proteoglycans in Diabetic Nephropathy.......................... 290,000
R01DK049703-05S3............... LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CONTROL OF PEPTIDE HORMONE BIOSYNTHESIS BY PC2 AND 7B2......... 71,500
R01DK052968-03................. Stephens, Jacqueline M............ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... REGULATION AND ACTIVATION OF STATS IN ADIPOCYTES............... 185,448
R01DK053113-03................. SMITH, BRENDA K................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... TASTE AND GENETIC MECHANISMS OF MACRONUTRIENT SELECTION........ 216,418
R01DK053697-04S1............... CORREA, PELAYO.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HELICOBACTER INFECTION AND GROWTH OF CHILDREN.................. 25,000
R01DK053697-05................. CORREA, PELAYO.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HELICOBACTER INFECTION AND GROWTH OF CHILDREN.................. 46,225
R01DK053981-04................. GETTYS, THOMAS W.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MECHANISMS OF UCP REGULATION BY LEPTIN......................... 198,992
R01DK054880-03................. KASTIN, ABBA J.................... TULANE UNIVERSITY OF LOUISIANA............... BLOOD/BRAIN BARRIER AND LEPTIN TRANSPORT IN OBESITY............ 321,158
R01DK054952-02................. HAMM, L. LEE...................... TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF CITRATE TRANSPORT................................ 198,450
R01DK055626-02................. AWAYDA, MOUHAMED S................ TULANE UNIVERSITY OF LOUISIANA............... KINASE REGULATION OF THE EPITHELIAL NA CHANNEL................. 222,750
R01DK056132-01A2............... SMITH, BRET N..................... TULANE UNIVERSITY OF LOUISIANA............... Neural Circuitry in the Caudal Solitary Complex................ 297,750
R01DK056264-02................. El-Dahr, Samir S.................. TULANE UNIVERSITY OF LOUISIANA............... INDUCIBLE DYSPLASTIC NEPHROPATHY IN B2-DEFICENT MICE........... 267,300
R01DK057242-02................. BERTHOUD, HANS-RUDOLF............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... FUNCTIONAL ORGANIZATION OF THE VAGAL-ENTERIC INTERFACE......... 209,153
R01DK057446-03................. LOVEJOY, JENNIFER C............... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... INTERNET-AIDED PREVENTION OF PREGNANCY-INDUCED OBESITY......... 141,699
R01DK057476-03................. MARTIN, PAMELA D.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... PRIMARY CARE OFFICE MANAGEMENT OF OBESITY...................... 186,088
R01DK058152-02................. KOZAK, LESLIE P................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... GENETICS OF DEVELOPMENTAL PLASTICITY IN THE ADIPOCYTE.......... 432,199
R01DK058499-01A1............... AGRAWAL, KRISHNA C................ TULANE UNIVERSITY OF LOUISIANA............... Protease Inhibitor Related Adipogenesis in HIV Infection....... 282,150
R01DK060412-01................. RAVUSSIN, ERIC.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Fat Cell Size, Muscle Lipid and Insulin Resistance............. 613,281
R01ES006766-08................. Brody, Arnold R................... TULANE UNIVERSITY OF LOUISIANA............... GROWTH FACTORS IN ASBESTOS INDUCED PULMONARY FIBROSIS.......... 250,931
R01ES008663-05................. FRIEDMAN, MITCHELL................ TULANE UNIVERSITY OF LOUISIANA............... BIOCHEMICAL MECHANISM FOR OZONE PATHOLOGY...................... 193,757
R01ES009158-05................. PRUETT, STEPHEN B................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... Mechanisms of Immunotoxcity of Chemical Stressors.............. 205,350
R01ES009870-02................. MEHENDALE, HARIHARA M............. UNIVERSITY OF LOUISIANA AT MONROE............ DIETARY RESTRICTION AND TOXICANT-INDUCED LIVER DISEASE......... 248,832
R01ES010046-02................. LASKY, JOSEPH A................... TULANE UNIVERSITY OF LOUISIANA............... DISRUPTION OF PDGF SIGNAL TRANSDUCTION IN LUNG FIBROSIS........ 222,750
R01EY002672-23................. KAUFMAN, HERBERT E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HERPES SIMPLEX VIRUS.................................... 346,750
R01EY003311-22................. KLYCE, STEPHEN D.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... INTEGRATED ASSESSMENT OF CORNEAL FORM AND FUNCTION............. 259,731
R01EY004928-19................. BAZAN, HAYDEE E................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CORNEAL LIPID METABOLISM AND RESPONSE TO INFLAMMATION.......... 197,171
R01EY005121-17A1............... BAZAN, NICOLAS G.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... RPE Messengers, Transcription and Photoreceptor Renewal........ 250,250
R01EY006311-15................. HILL, JAMES M..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HSV--LATENCY, REACTIVATION, AND RECURRENCE.............. 121,399
R01EY006311-16................. HILL, JAMES M..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Ocular HSV--Latency, Reactivation, and Recurrence.............. 160,875
R01EY006635-15................. BAZAN, HAYDEE E................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELL SIGNAL TRANSDUCTION IN CORNEAL WOUND HEALING.............. 223,276
R01EY007380-12................. MENERAY, MICHELE A................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... INTERACTIVE CELLULAR CONTROLS LACRIMAL GLAND FUNCTIONAL........ 286,000
R01EY008871-11................. HILL, JAMES M..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR PATHOGENESIS AND THERAPY OF BACTERIAL KERATITIS......... 301,534
R01EY010974-06................. O'CALLAGHAN, RICHARD J............ LOUISIANA STATE UNIV HSC NEW ORLEANS......... STAPH KERATITIS--MECHANISMS/ARRESTING OF CORNEAL DAMAGE........ 257,394
R01EY011610-04................. BURGOYNE, CLAUDE F................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... IOP RELATED FORCE AND FAILURE IN THE OPTIC NERVE HEAD.......... 328,054
R01EY012367-03................. JACOB, JEAN T..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... EPITHELIALIZATION OF TISSUE ENGINEERED CORNEAS................. 503,786
R01EY012416-03................. BEUERMAN, ROGER W................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... REGULATION OF PROTEIN SYNTHESIS IN THE LACRIMAL GLAND.......... 218,284
R01EY012540-03................. PALKAMA, ARTO K................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... AQUEOUS OUTFLOW AND STRUCTURAL CORRELATIONS.................... 337,419
R01EY012701-02................. CHANDRASEKHER, GUDISEVA........... LOUISIANA STATE UNIV HSC NEW ORLEANS......... GROWTH FACTOR RECEPTOR MEDITATED SIGNAL MECHANISMS LENS........ 175,955
R01EY012716-01A2............... GUIDO, WILLIAM.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... FUNCTIONAL STATE OF DEVELOPING RETINOGENICULATE SYNAPSE........ 204,137
R01EY012887-02................. KHOOBEHI, BAHRAM.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... RETINAL AND CHOROIDAL BLOOD FLOW IMAGING....................... 223,146
R01EY012961-02................. O'CALLAGHAN, RICHARD J............ LOUISIANA STATE UNIV HSC NEW ORLEANS......... MECHANISMS AND THERAPY OF BACTERIAL KERATITIS.................. 286,000
R01GM020818-27S1............... RHOADS, ROBERT E.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... REGULATION OF EUKARYOTIC PROTEIN SYNTHESIS INITITATION......... 94,237
R01GM039844-11................. WARNER, ISIAH M................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... Bioanalytical Separation Using Chiral Polymers................. 351,000
R01GM039844-11S1............... WARNER, ISIAH M................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... Bioanalytical Separation Using Chiral Polymers................. 15,817
R01GM045668-09................. DEININGER, Prescott L............. TULANE UNIVERSITY OF LOUISIANA............... HUMAN DIMORPHISMS BY SINE MASTER GENES......................... 241,319
R01GM047789-17................. TATCHELL, Kelly G................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... GENETIC ANALYSIS OF PROTEIN PHOSPHATASE 1 IN YEAST............. 279,098
R01GM048045-10................. FLEMINGTON, ERIK K................ TULANE UNIVERSITY OF LOUISIANA............... EBV BZLF1 GENE PRODUCT......................................... 239,669
R01GM051261-05................. WALDROP, GROVER L................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... CATALYTIC MECHANISM OF BIOTIN DEPENDENT ENZYMES................ 95,162
R01GM051521-08................. WITT, STEPHEN N................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... KINETICS AND MECHANISM OF THE HEAT SHOCK 70 PROTEIN DNAK....... 199,697
R01GM055420-11................. NEWCOMER, MARCIA E................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... ENZYMATIC ACTIVATION OF LIPOPHILIC SIGNALING MOLECULES......... 71,473
R01GM056835-04................. MCLAUGHLIN, MARK L................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... PEPTIDES ACTIVE AGAINST INTRACELLULAR PATHOGENIC DISEASE....... 171,443
R01GM058843-03................. LIMBACH, PATRICK A................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... IDENTIFICATION OF MODIFIED NUCLEOSIDES IN RIBOSOMAL RNA........ 130,415
R01GM059663-01A2............... WITTUNG-STAFSHEDE, PERNILLA E..... TULANE UNIVERSITY OF LOUISIANA............... COFACTOR ROLE IN BETA-SHEET PROTEIN FOLDING.................... 157,180
R01GM060000-01A2............... WIMLEY, WILLIAM C................. TULANE UNIVERSITY OF LOUISIANA............... Folding and design of beta sheets in membranes................. 173,500
R01GM061915-01A1............... STRONGIN, ROBERT M................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... Synthesis and Study of Novel Sensing Agents.................... 183,750
R01HD008431-26................. KOZAK, LESLIE P................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MOLECULAR GENETICS OF THERMOGENESIS............................ 311,940
R01HD036822-03................. WANG, YU-PING..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PLACENTAL FUNCTION IN PREECLAMPSIA............................. 141,187
R01HD037811-02................. GASSER, RAYMOND F................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... HUMAN EMBRYO SECTIONS ON COMPUTER DISKS FOR EDUCATION.......... 244,821
R01HD039104-02................. WILLIAMSON, DONALD A.............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... INTERNET-BASED OBESITY PREVENTION FOR BLACK ADOLESCENTS........ 158,490
R01HG001499-05................. SOPER, Steven A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... HIGH THROUGHPUT DNA SEQUENCING USING NANO-REACTORS............. 393,493
R01HG001499-05S1............... SOPER, Steven A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... HIGH THROUGHPUT DNA SEQUENCING USING NANO-REACTORS............. 31,605
R01HL026371-20................. Navar, L. Gabriel................. TULANE UNIVERSITY OF LOUISIANA............... RENAL FUNCTIONAL DERANGEMENTS IN HYPERTENSION.................. 327,703
R01HL026441-21................. GRANGER, D NEIL................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... TRANSCAPILLARY FLUID EXCHANGE.................................. 249,045
R01HL045670-10................. BOUCHARD, CLAUDE.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... HERITAGE-GENETICS, RESPONSE TO EXERCISE, RISK FACTORS-3........ 723,661
R01HL054797-08................. KORTHUIS, RONALD J................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... PRECONDITIONING: PMN ADHESION AND MICROVASCULAR INJURY......... 290,000
R01HL059699-04................. IMIG, JOHN D...................... TULANE UNIVERSITY OF LOUISIANA............... OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY.............. 27,519
R01HL059699-05................. IMIG, JOHN D...................... TULANE UNIVERSITY OF LOUISIANA............... OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY.............. 69,000
R01HL059724-05................. SHELLITO, JUDD E.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... T LYMPHOCYTE SUBSETS AND HOST DEFENSE AGAINST P CARINII........ 357,165
R01HL059879-03................. CLAYCOMB, WILLIAM C............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NOVEL GENE DISCOVERED IN THE HEART............................. 213,150
R01HL060300-05................. HE, JIANG......................... TULANE UNIVERSITY OF LOUISIANA............... EPIDEMIOLOGY STUDIES OF DIETARY FIBER AND BLOOD PRESSURE....... 104,421
R01HL060532-05................. Brody, Arnold R................... TULANE UNIVERSITY OF LOUISIANA............... EPITHELIAL GROWTH FACTORS IN ENVIRONMENTAL LUNG DISEASE........ 285,524
R01HL060849-03................. LEFER, DAVID J.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF MYOCARDIAL REPERFUSION INJURY--DIABETES.......... 180,586
R01HL061271-03................. Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NON CD4 HOST DEFENSE AGAINST P CARINII PNEUMONIA............... 76,076
R01HL061934-05................. MORRIS, CINDY A................... TULANE UNIVERSITY OF LOUISIANA............... MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS................ 222,750
R01HL062000-01A2S1............. HYMAN, ALBERT L................... TULANE UNIVERSITY OF LOUISIANA............... CARDIOPULMONARY SURGERY RESEARCH............................... 43,065
R01HL062000-02................. HYMAN, ALBERT L................... TULANE UNIVERSITY OF LOUISIANA............... CARDIOPULMONARY SURGERY RESEARCH............................... 302,940
R01HL062052-03S1............... Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA............. 4,976
R01HL062052-04................. Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA............. 255,226
R01HL062052-04S1............... Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA............. 4,976
R01HL062147-04................. PANDEY, KAILASH N................. TULANE UNIVERSITY OF LOUISIANA............... ANP RECEPTOR GENE--TARGETING AND EXPRESSION.................... 160,386
R01HL063128-02................. AGRAWAL, KRISHNA C................ TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF CARDIOVASCULAR COMPLICATIONS IN AIDS............. 291,666
R01HL063195-03................. TRAYANOVA, NATALIA A.............. TULANE UNIVERSITY OF LOUISIANA............... CARDIAC TISSUE STRUCTURE IN THE DEFIBRILLATION PROCESS......... 165,539
R01HL063778-01A1............... LASKY, JOSEPH A................... TULANE UNIVERSITY OF LOUISIANA............... CTGF IN LUNG FIBROGENESIS...................................... 253,813
R01HL064555-03................. CLARKSON, CRAIG W................. TULANE UNIVERSITY OF LOUISIANA............... MOLECULAR BASIS FOR DRUG INDUCED CARDIOTOXICITY IN AIDS........ 189,054
R01HL064577-03................. JOHNSON, ROBERT A................. TULANE UNIVERSITY OF LOUISIANA............... HEMODYNAMIC ROLES OF ENDOGENEOUS CARBON MONOXIDE............... 167,296
R01HL065997-01................. WANG, YU-PING..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... ENDOTHELIAL BARRIER FUNCTION IN PREECLAMPSIA................... 242,500
R01HL066158-01A1............... VEHASKARI, V M.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Prenatal and Perinatal Programming of Adult Hypertension....... 239,500
R01HL066432-01A1............... MAJID, DEWAN S.................... TULANE UNIVERSITY OF LOUISIANA............... Superoxide and nitric Oxide Interactions in the Kidney......... 247,750
R01NS009626-31................. LI, YU-TEH........................ TULANE UNIVERSITY OF LOUISIANA............... GLYCOSIDASES AS RELATED TO SPHINGOLIPIDOSES.................... 344,502
R01NS009626-31S1............... LI, YU-TEH........................ TULANE UNIVERSITY OF LOUISIANA............... GLYCOSIDASES AS RELATED TO SPHINGOLIPIDOSES.................... 27,716
R01NS025134-12................. HAYCOCK, JOHN W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR REGULATION OF TYROSINE HYDROXYLASE.................... 214,604
R01NS025987-14................. PHELPS, CAROL J................... TULANE UNIVERSITY OF LOUISIANA............... HYPOPHYSIOTROPIC NEURON DIFFERENTIATION--TARGET FEEDBACK....... 213,375
R01NS035370-09A1............... DUNN, ADRIAN J.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Cytokine Action on the CNS..................................... 283,070
R01NS036936-04................. ERICKSON, JEFFREY D............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... VESICULAR TRANSPORTER SPECIFICITY.............................. 207,749
R01NS037070-04................. ERZURUMLU, REHA S................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR MECHANISMS UNDERLYING PATTERN FORMATION............... 131,747
R01NS039033-01A2............... PHINNEY, DONALD G................. TULANE UNIVERSITY OF LOUISIANA............... Marrow stromal cells for Lysosomal Disease CNS Defects......... 259,875
R01NS039050-02................. ERZURUMLU, REHA S................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SOMATOSENSORY CORTICAL DEVELOPMENT AND PLASTICITY.............. 143,000
R01NS039099-02................. TASKER, JEFFREY G................. TULANE UNIVERSITY OF LOUISIANA............... HYPOTHALAMIC SYNCHRONIZATION BY LOCAL GLUTAMATE CIRCUITS....... 259,875
R01NS039458-02................. MAGEE, JEFFERY C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DENDRITIC INTEGRATION IN HIPPOCAMPAL PYRAMIDAL NEURONS......... 142,062
R01NS040373-01A1............... ARIMURA, AKIRA A.................. TULANE UNIVERSITY OF LOUISIANA............... Neuroprotection by PACAP in Stroke............................. 371,250
R01NS044000-01................. BASTIAN, FRANK O.................. TULANE UNIVERSITY OF LOUISIANA............... Spiroplasma 16S rDNA in TSE Brain Tissues...................... 181,745
R03AG019058-01................. MEHENDALE, HARIHARA M............. UNIVERSITY OF LOUISIANA AT MONROE............ AGING AND RESILIENCY TO LIVER TOXICITY......................... 66,844
R03AI043873-03................. Pincus, Seth H.................... CHILDREN'S HOSPITAL (NEW ORLEANS)............ ROLE OF MURINE LEUKEMIA VIRUS IN AUTOIMMUNITY.................. 70,000
R03CA083096-01A1............... JOHNSON, ERIC S................... TULANE UNIVERSITY OF LOUISIANA............... POSSIBLE OF ROLE OF AVIAN RETROVIRUSES IN HUMAN CANCER......... 71,513
R03CA086378-02................. HAGENSEE, MICHAEL E............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... DEVELOPMENT OF A URINE PCR ASSAY FOR HPV DNA DETECTION......... 71,500
R03CA088135-02................. SU, L. J.......................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... DIETARY SURVEY INSTRUMENT DEVELOPMENT FOR AN ETHNIC MINO....... 69,695
R03DA012547-02................. ROERIG, SANDRA C.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... SPINAL NITRIC OXIDE IN CHRONIC INFLAMMATORY PAIN............... 71,037
R03DA013421-02................. LAHOSTE, GERALD J................. LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... GAP JUNCTIONS AND DOPAMINE PLASTICITY.......................... 71,000
R03DA013546-02................. HUANG, TIEN L..................... XAVIER UNIVERSITY OF LOUISIANA............... NOVEL ANTI-PCP AGENTS WITH NEUROPROTECTIVE PROPERTIES.......... 69,975
R03DA013647-01A1............... SMAGIN, GENNADY N................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NEUROCHEMISTRY OF COCAINE REINFORCEMENT........................ 71,571
R03HD041052-01................. SCHMIDT-SOMMERFELD, EBERHARD...... LOUISIANA STATE UNIV HSC NEW ORLEANS......... PARENTERAL MEDIUM CHAIN TRIGLYCERIDES IN THE PREMATURE......... 71,500
R03MH061944-02................. NORTHUP, JOHN A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... STAR PROGRAM: EARLY & PREVENTIVE INTERVENTION OF ADHD.......... 73,500
R03MH063814-01................. SCARAMELLA, LAURA V............... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... PARENTING AND TEMPERAMENT RECIPROCITIES IN TODDLERHOOD......... 71,000
R03MH064587-01................. ULLER, CLAUDIA.................... UNIVERSITY OF LOUISIANA AT LAFAYETTE......... MENTAL STATE ATTRIBUTION IN INFANCY............................ 66,720
R13ES011296-01................. MCLACHLAN, JOHN A................. TULANE UNIVERSITY OF LOUISIANA CONFERENCE.... E.HORMONE 2001................................................. 10,000
R15CA086833-01A1............... SYLVESTER, PAUL W................. UNIVERSITY OF LOUISIANA AT MONROE............ ANTIPROLIFERATIVE & APOPTOTIC MECHANISMS OF TOCOTRIENOLS....... 124,500
R18AI033449-07................. FREY, DANIEL J.................... LOUISIANA ORGAN PROCUREMENT AGENCY........... ENHANCING DONOR REGISTRY TO INCREASE DONATION.................. 263,035
R21AR047796-02................. PROCKOP, DARWIN J................. TULANE UNIVERSITY OF LOUISIANA............... EXPANSION OF STEM CELLS FOR SKELETAL TISSUES................... 74,250
R21CA083198-02................. OCHOA, AUGUSTO C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... T CELL SIGNAL TRANSDUCTION TO MONITOR HPV VACCINES............. 143,000
R21CA084095-02................. HYMAN, LINDA E.................... TULANE UNIVERSITY OF LOUISIANA............... ELONGIN C: FUNCTION AND ROLE IN VHL DISEASE.................... 148,500
R21CA091785-02................. KEPPLER, DANIEL................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... ROLE OF CYSTATIN M IN BREAST TUMOR PROGRESSION................. 106,120
R21DC004994-01................. BOBBIN, RICHARD P................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DRUG MANIPULATION OF NOISE-INDUCED HEARING LOSS................ 143,000
R21DK057390-01A1............... HORNBY, PAMELA J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... VAGAL GASTRIC MOTOR CONTROL IN MICE............................ 143,000
R21NS043974-01................. EHRLICH, MELANIE.................. TULANE UNIVERSITY OF LOUISIANA............... FSHD SYNDROME--DNA REPEATS, METHYLATION, AND CHROMATIN......... 185,625
R21RR015016-02................. MURRAY, KERMIT K.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MADLI MASS SPECTROMETRY FOR MICROFLUIDIC CHIP DETECTION........ 99,440
R24CA084625-02................. SOPER, STEVEN A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MICRO-INSTRUMENT PLATFORMS FOR GENETIC-BASED ANALYSES.......... 548,672
R24DA007970-09................. KOMISKEY, HAROLD L................ XAVIER UNIVERSITY OF LOUISIANA............... MIDARP AT XAVIER UNIVERSITY OF LOUISIANA....................... 406,111
R24HL060808-04................. STRONG, JACK P.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... PDAY CARDIOVASCULAR SPECIMEN AND DATA LIBRARY.................. 128,074
R24RR012545-03................. BASKIN, GARY B.................... TULANE UNIVERSITY OF LOUISIANA............... ANIMAL MODEL FOR GENE THERAPY OF INHERITED DISORDERS........... 517,001
R25CA047877-14................. LOPEZ S, ALFREDO.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SHORT RESEARCH EXPERIENCES IN CANCER........................... 63,347
R25MH058560-04................. SAXENA, KRISHAN M................. GRAMBLING STATE UNIVERSITY................... NIMH HONORS MINORITY HIGH SCHOOL PROGRAM AT GSU................ 26,001
R29CA076186-04................. MEYERS, SHARI L................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MOLECULAR MECHANISM OF TRANSFORMATION BY AML1/ETO.............. 101,500
R29DC003280-04................. GARCIA, MEREDITH M................ TULANE UNIVERSITY OF LOUISIANA............... PROTEIN KINASE C IN CENTRAL AUDITORY PLASTICITY................ 100,289
R29DK050151-06................. LI, MING.......................... TULANE UNIVERSITY OF LOUISIANA............... LVA CALCIUM CHANNEL AND PANCREATIC B CELL DEATH................ 112,174
R29DK052148-05................. KALOGERIS, THEODORE J............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NEUROHORMONAL CONTROL OF INTESTINAL APOLIPOPROTEIN A IV........ 99,757
R29ES009055-04................. MILLER, CHARLES A................. TULANE UNIVERSITY OF LOUISIANA............... ARYL HYDROCARBON RECEPTOR STRUCTURE AND INTERACTIONS........... 91,084
R29EY012204-04................. GLEASON, EVANNA L................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... METABOTROPIC GLUTAMATE RECEPTORS ON AMACRINE CELLS............. 99,732
R29HD036310-06................. VEAZEY, RONALD S.................. TULANE UNIVERSITY OF LOUISIANA............... ONTOGENY OF THE NEONATAL MACAQUE IMMUNE SYSTEM................. 118,718
R29HD036421-05................. KUBISCH, HANS M................... TULANE UNIVERSITY OF LOUISIANA............... MARKER ASSISTED SELECTION OF BOVINE BLASTOCYSTS................ 133,523
R29MH055654-05................. FRICK, PAUL J..................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... CALLOUS/UNEMOTIONAL TRAITS AND CONDUCT PROBLEMS................ 86,984
R29NS035865-05................. MAGEE, JEFFERY C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DENDRITIC K+ AND IH CHANNELS IN HIPPOCAMPAL NEURONS............ 106,678
R37AG006168-16................. JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR AGING IN A YEAST MODEL SYSTEM......................... 410,300
R37DK032089-20................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DIETARY OBESITY................................................ 300,943
R37DK036013-15................. ORLANDO, ROY C.................... TULANE UNIVERSITY OF LOUISIANA............... ESOPHAGEAL CYTOPROTECTION-AGENTS AND MECHANISMS................ 208,830
R37MH051853-08................. MCCANN, SAMUEL M.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MECHANISM OF ACTION OF CYTOKINES ON BRAIN AND PITUITARY........ 290,105
R41AG018196-01A1............... NARDUCY, KENNETH W................ ST CHARLES PHARMACEUTICALS................... ANALGESICS FOR CHRONIC PAIN TREATMENT IN THE ELDERLY........... 100,000
R42CA083756-04................. PINCUS, SETH H.................... NORION DIAGNOSTIC INNOVATIONS, INC........... HIV INFECTIVITY TEST FOR ANTIVIRAL SUSCEPTIBILITY.............. 141,987
R43CA089772-01................. MORGAN, LEE R..................... DEKK-TEC, INC................................ A-007: IMMUNE MODULATION OF HPV--CERVICAL CANCER............... 191,517
R43CA090123-01................. GOTTLIEB, MARISE S................ ENDEAVOR CORPORATION......................... DNA BASED SENSITIVE ASSAY FOR LYMPOID MALIGNANCIES............. 122,123
R44CA083552-03................. MORGAN, LEE R..................... DEKK-TEC, INC................................ ISOPHOSPHORAMIDE MUSTARD--A PHASE 1 STUDY...................... 338,965
R44CA085021-02................. MORGAN, LEE R..................... DEKK-TEC, INC................................ DERIVATIVES OF DEMETHYLPENCLOMEDINE: ANTICANCER AGENTS......... 359,498
S06GM004531-12................. IFEANYI, FELIX I.................. GRAMBLING STATE UNIVERSITY................... MBRS SCORE PROGRAM AT GRAMBLING STATE UNIVERSITY............... 149,473
S06GM008008-30................. STEVENS, CHERYL L................. XAVIER UNIVERSITY OF LOUISIANA............... MBRS SCORE PROGRAM AT XAVIER UNIVERSITY........................ 570,861
S06GM008008-30S1............... STEVENS, CHERYL L................. XAVIER UNIVERSITY OF LOUISIANA............... MBRS SCORE RESEARCH AT XAVIER UNIVERSITY....................... 476,904
S06GM008025-28A1............... CHRISTIAN, FRED A................. SOUTHERN UNIV A&M COL BATON ROUGE............ MBRS SCORE PROGRAM AT SOUTHERN UNIVERSITY-BATON ROUGE.......... 55,505
S11ES009996-03................. BLAKE, ROBERT C................... XAVIER UNIVERSITY OF LOUISIANA............... ALTERATION OF GENE REGULATION BY ENVIRONMENTAL COMPOUNDS....... 970,632
S11ES010018-03................. MUGANDA, PERPETUA M............... SOUTHERN UNIV A&M COL BATON ROUGE............ CELLULAR & MOLECULAR TOXICOLOGY OF BUTADIENE................... 906,194
S21MD000100-01................. FRANCIS, NORMAN C................. XAVIER UNIVERSITY OF LOUISIANA............... XAVIER PHARMACY ENDOWMENT FOR MINORITY HEALTH.................. 2,300,000
T32AA007577-03................. BAGBY, GREGORY J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM................... 287,988
T32CA065436-05................. JAFFE, BERNARD M.................. TULANE UNIVERSITY OF LOUISIANA............... RESEARCH TRAINING IN SURGICAL ONCOLOGY (T32)................... 26,286
T32DA007311-03................. GOEDERS, NICHOLAS E............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... STRESS AND THE NEUROBIOLOGY OF DRUG AND ALCOHOL DEPENDE........ 282,094
T34GM007716-23................. BIRDWHISTELL, TERESA.............. XAVIER UNIVERSITY OF LOUISIANA............... MARC UNDERGRADUATE STUDENT TRAINING IN ACADEMIC RESEARCH....... 514,676
T34GM008714-03S1............... HIMAYA, M A....................... GRAMBLING STATE UNIVERSITY................... U STAR PROGRAM FOR MARC AT GRAMBLING STATE UNIVERSITY.......... 148,110
T34MH017102-19................. SAXENA, KRISHAN M................. GRAMBLING STATE UNIVERSITY................... NIMH COR HONORS UNDERGRADUATE PROGRAM AT GSU................... 157,376
U01AI032913-09S1............... VAN DYKE, RUSSELL B............... TULANE UNIVERSITY OF LOUISIANA............... TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT................. 884,360
U01AI038844-04S2............... LERTORA, JUAN J. L................ TULANE UNIVERSITY OF LOUISIANA............... AIDS CLINICAL TRIALS UNIT...................................... 318,973
U01AI042178-10................. MUSHATT, DAVID M.................. TULANE UNIVERSITY OF LOUISIANA............... LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA).............. 738,328
U01CA083014-03................. ZAKRIS, ELLEN L................... TULANE UNIVERSITY OF LOUISIANA............... TULANE AIDS-ASSOCIATED MALIGNANCY CONSORTIUM................... 151,039
U01DK048377-08................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... NIDDM PRIMARY PREVENTION TRIAL (DPT 2)......................... 700,258
U01DK056990-03................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... CLINICAL CENTER FOR LOOK AHEAD: HEALTH IN DIABETES............. 1,120,807
U01DK056990-03S1............... BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... CLINICAL CENTER FOR LOOK AHEAD: HEALTH IN DIABETES............. 7,350
U01DK060963-01................. HE, JIANG......................... TULANE UNIVERSITY OF LOUISIANA............... CLINICAL CENTER FOR PROSPECTIVE COHORT STUDY OF CRI............ 214,285
U01HD031315-08................. WILSON, JOHN T.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PEDIATRIC PHARMACOLOGY RESEARCH UNIT........................... 371,253
U01HD040470-01................. ABDALIAN, SUE E................... TULANE UNIVERSITY OF LOUISIANA............... ADOLESCENT MEDICINE TRIAL NETWORK FOR HIV/AIDS................. 347,686
U01HL038844-15................. BERENSON, GERALD S................ TULANE UNIVERSITY OF LOUISIANA............... EARLY NATURAL HISTORY OF ARTERIOSCLEROSIS...................... 1,129,399
U01HL060571-04................. HARSHA, DAVID W................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... PREMIER--LIFESTYLE INTERVENE FOR BLOOD PRESSURE CONTRL......... 344,746
U01HL066855-02................. WEBBER, LARRY S................... TULANE UNIVERSITY OF LOUISIANA............... TRIAL OF ACTIVITY FOR ADOLESCENT GIRLS (TAAG).................. 555,628
U10CA035272-18................. KARDINAL, CARL G.................. OCHSNER CLINIC FOUNDATION.................... OCHSNER COMMUNITY CLINICAL ONCOLOGY PROGRAM.................... 410,631
U10CA058658-09................. MILLS, GLENN M.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... SOUTHWEST ONCOLOGY GROUP....................................... 283,805
N01HR0R01650-000............... DEBOISBLANC, BENNETT.............. LOUISANA STATE UNIVERSITY BATON ROUGE........ ADULT RESPIRATOR DISTRESS SYNDROME STUDY....................... 230,082
U10CA063845-07A1............... VEITH, ROBERT W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... LSUHSC MINORITY BASED COMMUNITY CLINICAL ONCOLOGY.............. 240,283
U19AI045511-02S1............... BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... AFRICAN MALARIA VECTORS........................................ 40,000
U19AI045511-03................. BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... AFRICAN MALARIA VECTORS........................................ 606,005
U42RR015087-02................. ROWELL, THOMAS J.................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... ESTABLISHMENT/MAINTENANCE OF BIOMEDICAL RESEARCH COLONY........ 819,282
U42RR016026-01................. BLANCHARD, JAMES L................ TULANE UNIVERSITY OF LOUISIANA............... SPECIFIC PATHOGEN FREE INDIAN RHESUS MONKEY COLONY FOR A....... 725,069
U45ES010664-02................. WRIGHT, BEVERLY H................. XAVIER UNIVERSITY OF LOUISIANA............... WORKER HEALTH AND SAFETY TRAINING COOPERATIVE AGREEMENT........ 954,135
N01AO012747-000................ HASSELSCHWERT, DANA............... UNIVERSITY OF LOUISIANA AT LAFAYETTE......... DEVELOPMENT OF A SPF PIGTAIL MACAQUE BREEDING COLONY........... 1,175,750
N01NS092302-004................ ROWELL, THOMAS J.................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... SLOW, LATENT & TEMPERATE VIRUS INFECTIONS...................... 615,902
------------
TOTAL FY 2001............ .................................. ............................................. ............................................................... 85,845,703
============
FISCAL YEAR 2002
C06RR016483-01................. ROWELL, THOMAS J.................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... EXPANSION OF NIH CHIMPANZEE HOLDING FAC........................ 1,975,176
D43TW001086-04................. MATHER, FRANCES J................. TULANE UNIVERSITY OF LOUISIANA............... INTERNATIONAL TRAINING IN MEDICAL INFORMATICS.................. 152,358
D43TW001142-04................. BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... ACTIONS FOR BUILDING CAPACITY.................................. 100,000
F30DA015262-01................. KAILAS, SUDHA R................... TULANE UNIVERSITY OF LOUISIANA............... MORPHINE, SEROTONIN, AND PROTEIN KINASE C...................... 43,075
F31DA005907-03S1............... HORNER, KRISTEN A................. TULANE UNIVERSITY OF LOUISIANA............... CHANGES IN ENDOMORPHINS DURING OPIATE TOLERANCE................ 3,026
F31DA006040-03................. GREENWELL, THOMAS N............... TULANE UNIVERSITY OF LOUISIANA............... ENDOMORPHIN-NEUROIMMUNE INTERACTIONS........................... 22,895
F31DA014155-02................. BANNER, EDITH J................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... TOTAL SYNTHESIS OF NOVEL DECAHYDROQUINOLINES................... 24,177
F31GM019387-05................. HAMILTON, KIMBERLY Y.............. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... CHIRAL SELECTOR IN CAPILLARY ELECTROPHORESIS................... 24,556
F31GM019876-04................. BURSE, JEANINE R.................. TULANE UNIVERSITY OF LOUISIANA............... PAST AND PRESENT BIOINDICATION OF RIVER POLLUTION.............. 6,189
F31GM020437-04................. CEDILLO, BERTHA M................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... DEVELOPMENT OF A CHIRAL SELECTOR SYSTEM........................ 26,643
F31GM020603-02................. WILLIAMS, BRIDGET D............... TULANE UNIVERSITY OF LOUISIANA............... THE ROLE OF TRACT STABILITY IN TELOMERE MAINTENANCE............ 20,300
F31GM020915-02................. GUTIERREZ, YANIRA I............... TULANE UNIVERSITY OF LOUISIANA............... PI3K-MEDIATED HYPOXIA SURVIVAL SIGNALING PATHWAYS.............. 22,356
F31GM020928-02................. AUSTIN, JOSEPH.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MINORITY PRE-DOCTORAL FELLOWSHIP PROGRAM....................... 9,226
F31HD041928-01................. TRUJILLO, LEA A................... TULANE UNIVERSITY OF LOUISIANA............... MINORITY PREDOCTORAL FELLOWSHIP PROGRAM........................ 26,160
F31HL068296-02................. ANDERSON, KIMBERLY M.............. TULANE UNIVERSITY OF LOUISIANA............... STUDIES OF A NOVEL A AND B BLOOD GROUP CLEAVING ENZYME......... 22,206
F31MH012816-02................. SANTUZZI, ALECIA M................ TULANE UNIVERSITY OF LOUISIANA............... PREDOCTORAL FELLOWSHIP PROGRAM (DISABILITY).................... 22,986
F31NS011180-02................. CLAYTON BAUCOM, CATHERINE A....... TULANE UNIVERSITY OF LOUISIANA............... HUMAN HAND PREFERENCE-STRUCTURAL FUNCTIONAL MRI STUDIES........ 24,176
F32AR048481-01................. POCHAMPALLY, RADHIKA R............ TULANE UNIVERSITY OF LOUISIANA............... MARROW STROMAL CELLS IN OSTEOGENESIS IMPERFECTA MODEL.......... 37,820
F32DA014162-02................. DANIEL, JILL M.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... EFFECTS OF ESTROGEN AND CANNABINOIDS ON LEARNING............... 38,320
F32DC005284-01A1............... LEBLANC, CHRISTOPHER S............ LOUISIANA STATE UNIV HSC NEW ORLEANS......... HAIR BUNDLE MOVEMENTS AND OTOACOUSTIC EMISSIONS................ 38,320
F32DK010151-02................. WHITE, CHRISTY L.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... LEPTIN RESPONSIVENESS IN A DIETARY MODEL OF OBESITY............ 50,116
F32DK061137-01................. SAIFUDEEN, ZUBAIDA R.............. TULANE UNIVERSITY OF LOUISIANA............... TRANSCRIPTION FACTOR P53 IN TERMINAL NEPHRON DIFFERENT......... 50,116
F32EY013651-02................. MARQUART, MARY E.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... PSEUDOMONAS PROTEASES AS OCULAR VIRULENCE FACTORS.............. 48,148
F32MH064248-01A1............... DAVIS, SCOTT F.................... TULANE UNIVERSITY OF LOUISIANA............... BRAINSTEM CIRCUITS INVOLVED IN ADRENAL REGULATION.............. 38,320
F32MH065092-01A1............... BLUMER, JOE B..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... DEFINING THE ROLE OF AGS3 IN G PROTEIN SIGNAL PROCESSING....... 38,320
G11HD034961-05................. ISLAND, GLENDA J.................. GRAMBLING STATE UNIVERSITY................... GSU RESEARCH INFRASTRUCTURE--PHASE II.......................... 91,800
G11HD041839-01................. ORBAN, JOSEPH I................... SOUTHERN UNIVERSITY SHREVEPORT-BOSSIER....... BIOMEDICAL RESEARCH CENTER, SOUTHERN UNIVERSITY AT SHRE........ 27,000
G20RR017029-01................. BLANCHARD, JAMES L................ TULANE UNIVERSITY OF LOUISIANA............... BUILDING C RENOVATION WEST WING................................ 699,655
K01CA078318-04................. HEMENWAY, CHARLES S............... TULANE UNIVERSITY OF LOUISIANA............... BMI1 INTERACTING PROTEINS IN NEOPLASTIC TRANSFORMATION......... 140,282
K01ES000358-02................. HUNT, JAY D....................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... MUTATION AND ENVIRONMENTAL EXPOSURES........................... 104,372
K01GM000707-03................. CHETTY, KOTHAPA N................. GRAMBLING STATE UNIVERSITY................... HYPERCHOLESTEROLEMIA AND REPERFUSION INJURY.................... 23,994
K02DA000204-10................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOID PEPTIDE PROCESSING ENZYMES.............................. 118,991
K02DK002605-04................. KAPUSTA, DANIEL R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOIDS AND CENTRAL NEURAL REGULATION OF RENAL FUNCTION........ 100,440
K02MH000967-09................. HAYCOCK, JOHN W................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HUMAN TYROSINE HYDROXYLASE AND SCHIZOPHRENIA................... 112,497
K08AI001467-05................. MASON, ANDREW L................... OCHSNER CLINIC FOUNDATION.................... RETROVIRAL ETIOLOGY OF PRIMARY BILIARY CIRRHOSIS............... 118,800
K08AI049790-03................. PARADA, NEREIDA A................. TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF IL-2 RECEPTOR BY THE CD4 LIGAND IL-16............ 118,800
K08MH001706-05................. SCHEERINGA, MICHAEL S............. TULANE UNIVERSITY OF LOUISIANA............... TRAUMATIZED YOUNG CHILDREN-RISK FOR MALADAPTATION.............. 149,858
K12HD043451-01................. WHELTON, PAUL K................... TULANE UNIVERSITY OF LOUISIANA............... TULANE BIRCWH.................................................. 435,408
K22ES011025-02................. DUGAS, TAMMY R.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... COX-2 MEDIATED VASCULAR TOXICITY OF METHYLENEDIANILINE......... 108,000
K22HD001339-02................. DONZE, DAVID...................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... ANALYSIS OF CHROMOSOMAL INSULATOR/BOUNDARY ELEMENTS............ 134,200
K23RR016076-04................. BERGGREN, RUTH E.................. TULANE UNIVERSITY OF LOUISIANA............... MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW....... 123,390
K30HL004521-03................. FRIEDMAN, MITCHELL................ TULANE UNIVERSITY OF LOUISIANA............... CLINICAL RESEARCH CURRICULUM AWARD............................. 200,000
M01RR005096-13................. WHELTON, PAUL K................... TULANE UNIVERSITY OF LOUISIANA............... GENERAL CLINICAL RESEARCH CENTER............................... 2,588,372
P01DK043785-11A1............... GRANGER, D NEIL................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PATHOPHYSIOLOGY OF ISCHEMIA-REPERFUSION INJURY................. 1,486,250
P20RR016456-02................. WISCHUSEN, EVERETT W.............. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... LOUISANA BIOMEDICAL RESEARCH NETWORK........................... 1,807,933
P20RR016816-01................. BAZAN, NICOLAS G.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... MENTORING NEUROSCIENCE IN LOUISIANA............................ 1,949,343
P20RR017659-01................. NAVAR, L. GABRIEL................. TULANE UNIVERSITY OF LOUISIANA............... TULANE COBRE IN HYPERTENSION AND RENAL BIOLOGY................. 2,346,364
P30EY002377-24................. KAUFMAN, HERBERT E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... CORE GRANT FOR VISION RESEARCH................................. 519,951
P50AA009803-09................. NELSON, STEVE..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, HIV INFECTION AND HOST DEFENSE........................ 1,645,309
P50AA009803-09S1............... NELSON, STEVE..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, HIV INFECTION AND HOST DEFENSE........................ 126,708
P51RR000164-41................. WHELTON, PAUL K................... TULANE UNIVERSITY OF LOUISIANA............... REGIONAL PRIMATE RESEARCH CENTER............................... 7,879,003
R01AA009505-07................. PRUETT, STEPHEN B................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF IMMUNOSUPPRESSION BY ONE DOSE OF ETHANOL......... 181,208
R01AA009876-08................. WOLCOTT, ROBERT M................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... FETAL ALCOHOL EFFECTS AND IMMUNE DEVELOPMENT................... 218,115
R01AA010384-07................. KOLLS, JAY K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ALCOHOL, IMMUNOSUPPRESSION, AND TACE........................... 286,000
R01AA012865-02................. KASTIN, ABBA J.................... TULANE UNIVERSITY OF LOUISIANA............... PEPTIDES AND ALCOHOL INTERACT AT THE BLOOD-BRAIN BARRIER....... 189,000
R01AA013543-01................. MOLINA, PATRICIA E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... CHRONIC ALCOHOL & AIDS IMPACT ON MUSCLE WASTING................ 191,969
R01AA013563-01................. VEAZEY, RONALD S.................. TULANE UNIVERSITY OF LOUISIANA............... THE EFFECT ALCOHOL ON SIV PATHOGENESIS......................... 283,392
R01AG016592-03................. BERENSON, GERALD S................ TULANE UNIVERSITY OF LOUISIANA............... EVOLUTION OF CARDIOVASCULAR RISK WITH NORMAL AGING............. 697,574
R01AG017887-03................. JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NUTRITIONAL AND METABOLIC MECHANISMS OF AGING.................. 286,000
R01AG017983-03................. HAMMER, ROBERT P.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... INHIBITION OF FIBRILLOGENESIS WITH B-STRAND MIMICS............. 291,180
R01AG018031-02................. LUKIW, WALTER J................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... GENE EXPRESSION IN ALZHEIMER'S DISEASE......................... 237,738
R01AG018239-03................. GEISELMAN, PAULA J................ LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... OBESITY PREVENTION AFTER SMOKING CESSATION IN MENOPAUSE........ 183,416
R01AG018869-02................. SUITOR, JILL J.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... PARENT-ADULT CHILD RELATIONS: WITHIN FAMILY DIFFERENCES........ 401,481
R01AI022001-18A1............... O'CALLAGHAN, DENNIS J............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NUCLEIC ACIDS OF HERPES VIRUS-INFECTED CELLS................... 468,495
R01AI022186-17................. KLIMSTRA, WILLIAM B............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MOLECULAR BASIS OF ALPHAVIRUS NEUROVIRULENCE................... 312,535
R01AI024030-15................. ROBINSON, JAMES E................. TULANE UNIVERSITY OF LOUISIANA............... HIV-1 NEUTRALIZING HUMAN MABS.................................. 297,000
R01AI024912-15................. CUTLER, JIM E..................... CHILDREN'S HOSPITAL (NEW ORLEANS)............ CANDIDA ALBICANS SURFACE ANTIGENS.............................. 315,000
R01AI031567-08................. CHERVENAK, ROBERT P............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DEVELOPMENTAL BIOLOGY OF T CELL PRECURSORS..................... 188,942
R01AI032556-08................. FIDEL, PAUL L..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... MUCOSAL CELL MEDIATED IMMUNITY IN VAGINAL CANDIDIASIS.......... 203,775
R01AI039968-04A1............... DIDIER, ELIZABETH SCHMIDT......... TULANE UNIVERSITY OF LOUISIANA............... MICROPORIDIOSIS IN AIDS........................................ 182,954
R01AI040667-07................. VAN DER HEYDE, HENRI C............ LOUISIANA STATE UNIV HSC SHREVEPORT.......... CELL ADHESION MOLECULES IN CEREBRAL MALARIA.................... 253,750
R01AI042146-04................. MUGGERIDGE, MARTIN I.............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... ROLES OF HSV2 MEMBRANE PROTEINS IN MEMBRANE FUSION............. 185,394
R01AI042400-03................. DAVISON, BILLIE B................. TULANE UNIVERSITY OF LOUISIANA............... A RHESUS MONKEY MODEL OF MALARIA IN PREGNANCY.................. 501,878
R01AI043000-04................. KOUSOULAS, KONSTANTIN GUS......... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... GENETICS & FUNCTIONS OF HSV1 GK IN VIRUS ENTRY & EGRESS........ 295,109
R01AI044596-05................. MARX, PRESTON A................... TULANE UNIVERSITY OF LOUISIANA............... SIV-RCM AND RELATED PRIMATE LENTIVIRUSES IN WEST AFRICA........ 542,776
R01AI045041-04................. HURLBURT, BARRY K................. U.S. AGRICULTURE RESEARCH SERVICE-MIDSOU..... MECHANISMS OF VIRULENCE GENE REGULATION IN S. AUREUS........... 272,803
R01AI045151-03................. FREYTAG, LUCIA C.................. TULANE UNIVERSITY OF LOUISIANA............... MUCOSAL IMMUNIZATION--PREVENTION OF SYSTEMIC CANDIDIASIS....... 222,750
R01AI045725-03................. GILLIS, THOMAS P.................. NATIONAL HANSEN'S DISEASE PROGRAM............ DEVELOP AND EVALUATE NEW LEPROSY AND TB VACCINES............... 116,990
R01AI046275-04................. ROBINSON, JAMES E................. TULANE UNIVERSITY OF LOUISIANA............... RHESUS MABS FROM SHIV INFECTED MACAQUES........................ 234,049
R01AI047693-03................. BUNNELL, BRUCE A.................. TULANE UNIVERSITY OF LOUISIANA............... INTRAMARROW GENE TRANSFER IN NEONATES.......................... 327,456
R01AI049080-01A1S1............. VEAZEY, RONALD S.................. TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV........... 11,499
R01AI049080-02................. VEAZEY, RONALD S.................. TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV........... 442,426
R01AI049139-02................. OBERHELMAN, RICHARD A............. TULANE UNIVERSITY OF LOUISIANA............... PRACTICAL DIAGNOSTICS FOR AIDS-RELATED PEDIATRIC TB, PERU...... 206,190
R01AI049193-01A1............... PETERSON, KENNETH M............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... SIGNAL TRANS. AND INTESTINAL COLONIZATION BY V. CHOLERAE....... 278,750
R01AI049293-01A2............... RAMAMOORTHY, RAMESH............... TULANE UNIVERSITY OF LOUISIANA............... RPOS AND GENE EXPRESSION IN BORRELIA BURGDORFERI............... 200,000
R01AI049744-01A2............... BEILKE, MARK A.................... TULANE UNIVERSITY OF LOUISIANA............... RETROVIRAL CO-INFECTIONS: HIV, HTLV AND DRUG ABUSE............. 359,125
R01AI049976-01S1............... PHILIPP, MARIO T.................. TULANE UNIVERSITY OF LOUISIANA............... 'LYME DISEASE: A POSSIBLE TEST FOR CURE........................ 24,000
R01AI049976-02................. PHILIPP, MARIO T.................. TULANE UNIVERSITY OF LOUISIANA............... 'LYME DISEASE: A POSSIBLE TEST FOR CURE........................ 160,000
R01AI050027-01A1............... ADAMS, LINDA B.................... NATIONAL HANSEN'S DISEASE PROGRAM............ GENE KNOCK-OUT MICE AS MODELS FOR THE LEPROSY SPECTRUM......... 150,000
R01AI051677-01................. SHELLITO, JUDD E.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... IL-17 AND KLEBSIELLA PNEUMONIA................................. 315,026
R01AR045982-05................. ALA-KOKKA, LEENA M................ TULANE UNIVERSITY OF LOUISIANA............... MUTATIONS CAUSING DISC DISEASE AND SCIATICA.................... 288,509
R01AR046976-04................. KIMPEL, DONALD L.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... NOVEL IMAGING TECHNOLOGIES FOR RHEUMATOID ARTHRITIS............ 290,000
R01AR048323-02................. PROCKOP, DARWIN J................. TULANE UNIVERSITY OF LOUISIANA............... OSTEOPROGENITORS FOR POTENTIAL THERAPY OF OI................... 371,250
R01CA054152-10A2............... HILL, STEVEN M.................... TULANE UNIVERSITY OF LOUISIANA............... NEUROENDOCRINE INFLUENCES ON MAMMARY CANCER.................... 291,199
R01CA067372-08................. SIXBEY, JOHN W.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... EPSTEIN BARR VIRUS INDUCED GENOMIC INSTABILITY................. 326,250
R01CA074731-04A2............... LEVY, LAURA S..................... TULANE UNIVERSITY OF LOUISIANA............... PATHOBIOLOGY OF SAIDS-ASSOCIATED LYMPHOMAS..................... 257,753
R01CA078335-04................. GNARRA, JAMES R................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... HGF/SF SIGNALING BY THE VHL TUMOR SUPPRESSOR................... 295,132
R01CA080149-04................. MATHIS, J MICHAEL................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... ADENOVIRUS BASED P53 GENE THERAPY FOR OVARIAN CANCER........... 114,527
R01CA081125-04................. SCHWARZENBERGER, PAUL O........... LOUISIANA STATE UNIV HSC NEW ORLEANS......... IL-17 AND HEMATOPOIESIS........................................ 177,500
R01CA081506-03................. EHRLICH, MELANIE.................. TULANE UNIVERSITY OF LOUISIANA............... DNA HYPOMETHYLATION AND CANCER................................. 259,058
R01CA082689-04................. OCHOA, AUGUSTO C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... ARGININE REGULATES T CELL SIGNAL TRANSDUCTION & FUNCTION....... 248,500
R01CA083823-03................. LEVY, LAURA S..................... TULANE UNIVERSITY OF LOUISIANA............... SELECTIVE FORCES OPERATIVE IN FELV INFECTION................... 246,155
R01CA085693-03................. HARRISON, LYNN.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... DNA REPAIR OF MULTIPLY DAMAGED SITES IN CELLS.................. 195,750
R01CA088885-02................. OCHOA, AUGUSTO C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... IMMUNE DYSFUNCTION AND IMMUNOTHERAPY OF RENAL CANCER........... 225,602
R01CA089057-02................. LI, LI............................ OCHSNER CLINIC FOUNDATION.................... STROMAL CELL MOLECULES REQUIRED FOR LYMPHOMA GENERATION........ 166,250
R01CA089121-02................. DASH, SRIKANTA A.................. TULANE UNIVERSITY OF LOUISIANA............... HEPATITIS C VIRUS AND HEPATOCELLULAR CARCINOMA................. 233,888
R01CA092126-01A1............... CHOI, YONG S...................... OCHSNER CLINIC FOUNDATION.................... LYMPHOMAGENESIS................................................ 221,113
R01CA095783-02................. JONES, FRANK E.................... TULANE UNIVERSITY OF LOUISIANA............... ERBB4 SIGNALING IN THE NORMAL AND NEOPLASTIC BREAST............ 217,390
R01DA005084-15................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OPIOID PEPTIDE SYNTHESIZING ENZYMES............................ 181,401
R01DA011417-04................. MOERSCHBAECHER, JOSEPH M.......... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CANNABINOID ABUSE EFFECTS ON LEARNING AND MEMORY............... 200,650
R01DA011939-03................. HARLAN, RICHARD E................. TULANE UNIVERSITY OF LOUISIANA............... THALAMOSTRIATAL MECHANISMS OF MORPHINE ACTION.................. 179,465
R01DA012267-03S2............... HARRISON, MURELLE G............... SOUTHERN UNIV A&M COL BATON ROUGE............ PREVENTING SUBSTANCE USE IN RURAL AFRICAN-AMERICAN YOUTH....... 38,856
R01DA012267-04................. HARRISON, MURELLE G............... SOUTHERN UNIV A&M COL BATON ROUGE............ PREVENTING SUBSTANCE USE IN RURAL AFRICAN-AMERICAN YOUTH....... 382,294
R01DA012267-04S1............... HARRISON, MURELLE G............... SOUTHERN UNIV A&M COL BATON ROUGE............ PREVENTING SUBSTANCE USE IN RURAL AFRICAN-AMERICAN YOUTH....... 112,134
R01DA012427-03................. WINSAUER, PETER J................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... COCAINE SELF-ADMINSTRATION: EFFECTS ON LEARNING................ 100,570
R01DA012703-04................. TRUDELL, MARK L................... LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... NOVEL NICOTINIC RECEPTOR MEDIATED THERAPEUTIC AGENTS........... 311,219
R01DA013463-02................. GOEDERS, NICHOLAS E............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... ROLE FOR THE HPA AXIS IN METHAMPHETAMINE REINFORCEMENT......... 320,554
R01DA013899-02................. MORSE, EDWARD V................... TULANE UNIVERSITY OF LOUISIANA............... RISK REDUCTION FOR YOUNG AFRICAN AMERICAN IDUS................. 566,386
R01DC003679-04................. HOOD, LINDA JEAN.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... AUDITORY GENETIC STUDIES OF HEREDITARY HEARING LOSS............ 213,503
R01DC003792-04................. CAPRIO, JOHN T.................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... ENCODING OF BIOLOGICALLY RELEVANT ODOR SIGNALS................. 329,574
R01DC003896-04................. RICCI, ANTHONY J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... ENDOGENOUS FACTORS REGULATING TRANSDUCER ADAPTATION............ 170,977
R01DC003896-04S1............... RICCI, ANTHONY J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... ENDOGENOUS FACTORS REGULATING TRANSDUCER ADAPTATION............ 54,450
R01DC004196-04................. KEATS, BRONYA J................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... ID OF THE MOUSE DEAFNESS (DN) GENE ON CHROMOSOME 19............ 230,769
R01DE008911-11................. WISE, GARY E...................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MOLECULAR BASIS OF TOOTH ERUPTION.............................. 178,924
R01DE012329-04................. CHEN, YIPING...................... TULANE UNIVERSITY OF LOUISIANA............... MOLECULAR MECHANISMS OF VERTEBRATE TOOTH INITIATION............ 185,282
R01DE012916-04................. AMEDEE, ANGELA M.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SIV MACAQUE MODEL FOR BREAST MILK TRANSMISSION OF HIV.......... 257,756
R01DE014044-01A1............... CHEN, YIPING...................... TULANE UNIVERSITY OF LOUISIANA............... GROWTH FACTOR SIGNALING IN MOUSE PALATOGENESIS................. 297,000
R01DK041279-10................. GLASS, JONATHAN D................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... MOLECULAR MECHANISMS OF INTESTINAL IRON TRANSPORT.............. 246,500
R01DK041868-11S1............... HWANG, DANIEL H................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DIETARY N 3 FATTY ACIDS AND EXPRESSION OF CYCLOOXYGENASE....... 85,260
R01DK044510-09................. AW, TAK Y......................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... GLUTATHIONE REDOX CONTROL OF INTESTINAL CELL RESPONSES......... 261,000
R01DK045278-10................. YORK, DAVID A..................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... ENTEROSTATIN REGULATION OF FAT INTAKE.......................... 330,750
R01DK046935-08................. LANCASTER, JACK R................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... NITROGEN AND OXYGEN RADICAL INTERACTIONS IN SURGERY............ 204,820
R01DK047211-08................. VEDECKIS, WAYNE V................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... REGULATION OF GLUCOCORTICOID RECEPTOR GENE EXPRESSION.......... 186,014
R01DK047348-09................. BERTHOUD, HANS-RUDOLF............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... AUTONOMIC REGULATION OF FOOD INTAKE AND METABOLISM............. 185,241
R01DK047663-08................. GRISHAM, MATTHEW B................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... ADHESION MOLECULE EXPRESSION IN CHRONIC GUT INFLAMMATION....... 182,736
R01DK048055-07................. MCCARTHY, KEVIN J................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... PROTEOGLYCANS IN DIABETIC NEPHROPATHY.......................... 290,000
R01DK049703-06A1............... LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CONTROL OF PEPTIDE HORMONE BIOSYNTHESIS BY PC2 AND 7B2......... 310,483
R01DK050550-09................. LACKNER, ANDREW A................. TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF INTESTINAL DYSFUNCTION IN SIMIAN AIDS............ 468,334
R01DK050736-04S1............... LOVEJOY, JENNIFER C............... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MENOPAUSE EFFECT ON OBESITY, ENERGY BALANCE AND INSULIN........ 167,018
R01DK052142-05A1............... ROGERS, RICHARD C................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... TNF, VAGAL TONE AND GASTRIC MOTILITY........................... 328,897
R01DK052968-04................. STEPHENS, JACQUELINE M............ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... REGULATION AND ACTIVATION OF STATS IN ADIPOCYTES............... 189,070
R01DK053872-05................. CLARKE, STEVEN D.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... CONTROL OF GENE TRANSCRIPTION BY ESSENTIAL FATTY ACIDS......... 159,475
R01DK054880-04................. KASTIN, ABBA J.................... TULANE UNIVERSITY OF LOUISIANA............... BLOOD/BRAIN BARRIER AND LEPTIN TRANSPORT IN OBESITY............ 328,290
R01DK054952-03................. HAMM, L. LEE...................... TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF CITRATE TRANSPORT................................ 198,450
R01DK055626-03................. AWAYDA, MOUHAMED S................ TULANE UNIVERSITY OF LOUISIANA............... KINASE REGULATION OF THE EPITHELIAL NA CHANNEL................. 222,750
R01DK056132-02................. SMITH, BRET N..................... TULANE UNIVERSITY OF LOUISIANA............... NEURAL CIRCUITRY IN THE CAUDAL SOLITARY COMPLEX................ 222,750
R01DK056264-03................. EL-DAHR, SAMIR S.................. TULANE UNIVERSITY OF LOUISIANA............... INDUCIBLE DYSPLASTIC NEPHROPATHY IN B2-DEFICENT MICE........... 267,300
R01DK056373-05................. ROGERS, RICHARD G................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... BRAINSTEM ESOPHAGEAL--GASTRIC CONTROL REFLEXES................. 138,630
R01DK057242-03................. BERTHOUD, HANS-RUDOLF............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... FUNCTIONAL ORGANIZATION OF THE VAGAL-ENTERIC INTERFACE......... 191,739
R01DK058152-03................. KOZAK, LESLIE P................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... GENETICS OF DEVELOPMENTAL PLASTICITY IN THE ADIPOCYTE.......... 445,163
R01DK058499-02................. AGRAWAL, KRISHNA C................ TULANE UNIVERSITY OF LOUISIANA............... PROTEASE INHIBITOR RELATED ADIPOGENESIS IN HIV INFECTION....... 282,150
R01DK059326-01A1............... BRISKI, KAREN P................... UNIVERSITY OF LOUISIANA AT MONROE............ CAUDAL BRAIN STEM LACTATE AVAILABILITY REGULATES FEEDING....... 81,699
R01DK060412-02................. RAVUSSIN, ERIC.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... FAT CELL SIZE, MUSCLE LIPID INFILTRATION AND INSULIN RE*....... 560,060
R01DK062003-01................. HARRISON-BERNARD, LISA M.......... TULANE UNIVERSITY OF LOUISIANA............... AT1 RECEPTORS IN RENAL MICROVASCULAR PHYSIOLOGY................ 283,635
R01DK063453-01................. WILLIAMSON, DONALD A.............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... WISE MIND: ENVIRONMENTAL APPROACH FOR OBESITY PREVENTION....... 220,500
R01DK063669-01................. ORLANDO, ROY C.................... TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF ACID RESISTANCE IN BARRETT'S ESOPHAGUS........... 311,100
R01DK064156-01................. CLARKE, STEVEN D.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DELTA-6 AND DELTA-5 DESATURASES................................ 280,770
R01EB000242-03................. KHOOBEHI, BAHRAM.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... RETINAL AND CHOROIDAL BLOOD FLOW IMAGING....................... 207,586
R01EB000739-01................. MCSHANE, MICHAEL J................ LOUISIANA TECHNOLOGICAL UNIVERSITY........... FLUORESCENT GLUCOSE SENSORS FROM POLYION MICROSHELLS........... 292,116
R01ES004344-11A1............... BACKES, WAYNE L................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... TOXICOLOGICAL SIGNIFICANCE OF ALKYLBENZENE METABOLISM.......... 315,300
R01ES006766-09................. BRODY, ARNOLD R................... TULANE UNIVERSITY OF LOUISIANA............... GROWTH FACTORS IN ASBESTOS INDUCED PULMONARY FIBROSIS.......... 255,518
R01ES009158-06................. PRUETT, STEPHEN B................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF IMMUNOTOXCITY OF CHEMICAL STRESSORS.............. 207,375
R01ES009870-03................. MEHENDALE, HARIHARA M............. UNIVERSITY OF LOUISIANA AT MONROE............ DIETARY RESTRICTION AND TOXICANT-INDUCED LIVER DISEASE......... 188,055
R01ES010046-03................. LASKY, JOSEPH A................... TULANE UNIVERSITY OF LOUISIANA............... DISRUPTION OF PDGF SIGNAL TRANSDUCTION IN LUNG FIBROSIS........ 259,875
R01ES010497-03................. MURRAY, KERMIT K.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... REAL TIME MASS SPECTROMETRY OF BIOAEROSOLS..................... 147,000
R01ES010859-01A1............... ORTIZ, LUIS A..................... TULANE UNIVERSITY OF LOUISIANA............... TNF-ALPHA SIGNALING IN SILICA-INDUCED LUNG FIBROSIS............ 289,725
R01EY002672-24................. KAUFMAN, HERBERT E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HERPES SIMPLEX VIRUS.................................... 336,000
R01EY003311-23................. KLYCE, STEPHEN D.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... INTEGRATED ASSESSMENT OF CORNEAL FORM AND FUNCTION............. 315,720
R01EY004928-20................. BAZAN, HAYDEE E................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CORNEAL LIPID METABOLISM AND RESPONSE TO INFLAMMATION.......... 203,086
R01EY005121-18................. BAZAN, NICOLAS G.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... RPE MESSENGERS, TRANSCRIPTION AND PHOTORECEPTOR RENEWAL........ 250,250
R01EY006311-17................. HILL, JAMES M..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HSV-LATENCY, REACTIVATION, AND RECURRENCE............... 387,224
R01EY007380-13................. MENERAY, MICHELE A................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... INTERACTIVE CELLULAR CONTROLS LACRIMAL GLAND FUNCTIONAL........ 286,000
R01EY011610-05................. BURGOYNE, CLAUDE F................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... IOP-RELATED FORCE AND FAILURE IN THE OPTIC NERVE HEAD.......... 616,605
R01EY012416-04................. BEUERMAN, ROGER W................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... REGULATION OF PROTEIN SYNTHESIS IN THE LACRIMAL GLAND.......... 224,832
R01EY012540-04................. PALKAMA, ARTO K................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... AQUEOUS OUTFLOW AND STRUCTURAL CORRELATIONS.................... 300,113
R01EY012701-03................. CHANDRASEKHER, GUDISEVA........... LOUISIANA STATE UNIV HSC NEW ORLEANS......... GROWTH FACTOR RECEPTOR MEDITATED SIGNAL MECHANISMS LENS........ 176,170
R01EY012716-02................. GUIDO, WILLIAM.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... FUNCTIONAL STATE OF DEVELOPING RETINOGENICULATE SYNAPSE........ 178,750
R01EY012961-03................. O'CALLAGHAN, RICHARD J............ LOUISIANA STATE UNIV HSC NEW ORLEANS......... MECHANISMS AND THERAPY OF BACTERIAL KERATITIS.................. 286,000
R01EY013176-01A2............... ALLIEGRO, MARK C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... NOVEL GENES EXPRESSED IN PROLIFERATING ENDOTHELIAL CELLS....... 204,690
R01EY013325-01A1............... KWON, BYOUNG S.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... OCULAR HSV-1, STROMAL KERATITIS, & T CELL COSTIMULATION........ 315,415
R01GM020818-28A1............... RHOADS, ROBERT E.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... REGULATION OF EUKARYOTIC PROTEIN SYNTHESIS INITIATION.......... 320,850
R01GM039844-12................. WARNER, ISIAH M................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... BIOANALYTICAL SEPARATION USING CHIRAL POLYMERS................. 273,533
R01GM045668-10A1............... DEININGER, PRESCOTT L............. TULANE UNIVERSITY OF LOUISIANA............... SINE RETROTRANSPOSITION........................................ 259,875
R01GM047789-18................. TATCHELL, KELLY G................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... GENETIC ANALYSIS OF PROTEIN PHOSPHATASE 1 IN YEAST............. 228,375
R01GM051521-09................. WITT, STEPHEN N................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... KINETICS AND MECHANISM OF THE HEAT SHOCK 70 PROTEIN DNAK....... 205,446
R01GM055420-12................. NEWCOMER, MARCIA E................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... ENZYMATIC ACTIVATION OF LIPOPHILIC SIGNALING MOLECULES......... 235,200
R01GM059663-02................. WITTUNG-STAFSHEDE, PERNILLA E..... TULANE UNIVERSITY OF LOUISIANA............... COFACTOR ROLE IN BETA-SHEET PROTEIN FOLDING.................... 175,770
R01GM060000-02................. WIMLEY, WILLIAM C................. TULANE UNIVERSITY OF LOUISIANA............... FOLDING AND DESIGN OF BETA SHEETS IN MEMBRANES................. 185,625
R01GM061915-02................. STRONGIN, ROBERT M................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... SYNTHESIS AND STUDY OF NOVEL SENSING AGENTS.................... 183,750
R01HD008431-27................. KOZAK, LESLIE P................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MOLECULAR GENETICS OF THERMOGENESIS............................ 321,299
R01HD036822-04................. WANG, YU-PING..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PLACENTAL FUNCTION IN PREECLAMPSIA............................. 145,425
R01HD037811-03................. GASSER, RAYMOND F................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... HUMAN EMBRYO SECTIONS ON DVDS FOR EDUCATION.................... 326,032
R01HD039104-03................. WILLIAMSON, DONALD A.............. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... INTERNET-BASED OBESITY PREVENTION FOR BLACK ADOLESCENTS........ 160,073
R01HG001499-06................. SOPER, STEVEN A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... HIGH THROUGHPUT DNA SEQUENCING USING NANO-REACTORS............. 428,179
R01HL018426-28................. NAVAR, L. GABRIEL................. TULANE UNIVERSITY OF LOUISIANA............... REGULATION OF RENAL HEMODYNAMICS............................... 334,125
R01HL022252-26................. ROSELLI, CHARLES E................ LOUISIANA STATE UNIV A&M COL BATON ROUGE..... SYNTHESES OF HEMES FOR PROTEIN STUDIES......................... 367,500
R01HL026371-21................. NAVAR, L. GABRIEL................. TULANE UNIVERSITY OF LOUISIANA............... RENAL FUNCTIONAL DERANGEMENTS IN HYPERTENSION.................. 336,341
R01HL026441-22................. GRANGER, D NEIL................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... TRANSCAPILLARY FLUID EXCHANGE.................................. 255,138
R01HL032788-16................. CHILIAN, WILLIAM M................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... MICROCIRCULATORY DYNAMICS IN THE CORONARY CIRCULATION.......... 320,215
R01HL045670-11................. BOUCHARD, CLAUDE.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... HERITAGE-GENETICS, RESPONSE TO EXERCISE, RISK FACTORS-3........ 749,187
R01HL054797-09................. KORTHUIS, RONALD J................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... PRECONDITIONING: PMN ADHESION AND MICROVASCULAR INJURY......... 290,000
R01HL057531-05A1............... PANDEY, KAILASH N................. TULANE UNIVERSITY OF LOUISIANA............... ANP Receptor: Molecular approach of signaling mechanisms....... 222,750
R01HL060532-06................. Brody, Arnold R................... TULANE UNIVERSITY OF LOUISIANA............... TGF-B in Interstitial Lung Disease............................. 334,125
R01HL060849-04................. LEFER, DAVID J.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MECHANISMS OF MYOCARDIAL REPERFUSION INJURY--DIABETES.......... 184,285
R01HL061271-04................. Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... NON CD4 HOST DEFENSE AGAINST P CARINII PNEUMONIA............... 78,314
R01HL061934-06................. MORRIS, CINDY A................... TULANE UNIVERSITY OF LOUISIANA............... MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS................ 222,750
R01HL062000-03................. HYMAN, ALBERT L................... TULANE UNIVERSITY OF LOUISIANA............... CARDIOPULMONARY SURGERY RESEARCH............................... 302,940
R01HL062052-05................. Kolls, Jay K...................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CD8 AND GAMMA/DELTA T CELLS IN P CARINII PNEUMONIA............. 255,226
R01HL063128-03................. AGRAWAL, KRISHNA C................ TULANE UNIVERSITY OF LOUISIANA............... MECHANISMS OF CARDIOVASCULAR COMPLICATIONS IN AIDS............. 299,899
R01HL063195-04................. TRAYANOVA, NATALIA A.............. TULANE UNIVERSITY OF LOUISIANA............... CARDIAC TISSUE STRUCTURE IN THE DEFIBRILLATION PROCESS......... 171,030
R01HL063778-02................. LASKY, JOSEPH A................... TULANE UNIVERSITY OF LOUISIANA............... CTGF IN LUNG FIBROGENESIS...................................... 259,875
R01HL064577-04................. JOHNSON, ROBERT A................. TULANE UNIVERSITY OF LOUISIANA............... HEMODYNAMIC ROLES OF ENDOGENEOUS CARBON MONOXIDE............... 166,634
R01HL065997-02................. WANG, YU-PING..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... ENDOTHELIAL BARRIER FUNCTION IN PREECLAMPSIA................... 217,500
R01HL066158-02................. VEHASKARI, V M.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Prenatal and Perinatal Programming of Adult Hypertension....... 214,500
R01HL066432-02................. MAJID, DEWAN S.................... TULANE UNIVERSITY OF LOUISIANA............... Superoxide and nitric Oxide Interactions in the Kidney......... 222,750
R01HL068057-01A1............... HE, JIANG......................... TULANE UNIVERSITY OF LOUISIANA............... Clinical Trial of Dietary Protein on Blood Pressure............ 655,198
R01HL069029-01................. FEELISCH, MARTIN.................. LOUISIANA STATE UNIV HSC SHREVEPORT.......... Redox-activation of vascular stores of NO by vitamin C......... 340,000
R01HL073774-01................. FARLEY, THOMAS A.................. TULANE UNIVERSITY OF LOUISIANA............... ATTENDED CITY SCHOOLYARDS TO INCREASE PHYSICAL ACTIVITY........ 222,750
R01LM007591-01................. CORK, ROBERT J.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Enhancements to a human embryo, serial-section database........ 101,460
R01MH059931-03................. LANIER, STEPHEN M................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... A TRANSDUCTION COMPLEX FOR G PROTEIN COUPLED RECEPTORS......... 240,693
R01MH061192-05................. LACKNER, ANDREW A................. TULANE UNIVERSITY OF LOUISIANA............... CHEMOKINE RECEPTORS IN THE NEUROPATHOGENESIS OF AIDS........... 284,869
R01MH062640-01A2............... LEIDENHEIMER, NANCY J............. LOUISIANA STATE UNIV HSC SHREVEPORT.......... Regulation of GABAA Receptor Cell Surface Expression........... 264,961
R01NS009626-32................. LI, YU-TEH........................ TULANE UNIVERSITY OF LOUISIANA............... GLYCOSIDASES AS RELATED TO SPHINGOLIPIDOSES.................... 382,466
R01NS023002-16A1............... BAZAN, NICOLAS G.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... Phospholipid and Arachidonic Acid Signaling in Epilepsy........ 270,275
R01NS024821-13................. LANIER, STEPHEN M................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... STRUCTURAL ANALYSIS OF THE ALPHA 2 ADRENERGIC RECEPTOR......... 213,269
R01NS025987-15................. PHELPS, CAROL J................... TULANE UNIVERSITY OF LOUISIANA............... HYPOPHYSIOTROPIC NEURON DIFFERENTIATION--TARGET FEEDBACK....... 219,774
R01NS030769-11................. LACKNER, ANDREW A................. TULANE UNIVERSITY OF LOUISIANA............... NEUROPATHOGENESIS OF PEDIATRIC AIDS: A SIV MODEL............... 345,144
R01NS035370-10................. DUNN, ADRIAN J.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Cytokine Action on the CNS..................................... 253,750
R01NS037963-04A1............... CANAVIER, CARMEN C................ LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... Firing Pattern in Midbrain Dopamine Neurons.................... 168,625
R01NS039033-02................. PHINNEY, DONALD G................. TULANE UNIVERSITY OF LOUISIANA............... Marrow stromal cells for Lysosomal Disease CNS Defects......... 259,875
R01NS039033-02S1............... PHINNEY, DONALD G................. TULANE UNIVERSITY OF LOUISIANA............... Marrow stromal cells for Lysosomal Disease CNS Defects......... 72,765
R01NS039050-03................. ERZURUMLU, REHA S................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SOMATOSENSORY CORTICAL DEVELOPMENT AND PLASTICITY.............. 143,000
R01NS039099-03................. TASKER, JEFFREY G................. TULANE UNIVERSITY OF LOUISIANA............... HYPOTHALAMIC SYNCHRONIZATION BY LOCAL GLUTAMATE CIRCUITS....... 259,875
R01NS039458-03................. MAGEE, JEFFERY C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DENDRITIC INTEGRATION IN HIPPOCAMPAL PYRAMIDAL NEURONS......... 230,823
R01NS039458-03S1............... MAGEE, JEFFERY C.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... DENDRITIC INTEGRATION IN HIPPOCAMPAL PYRAMIDAL NEURONS......... 50,000
R01NS040373-02................. ARIMURA, AKIRA A.................. TULANE UNIVERSITY OF LOUISIANA............... Neuroprotection by PACAP in Stroke............................. 371,250
R01NS044000-02................. BASTIAN, FRANK O.................. TULANE UNIVERSITY OF LOUISIANA............... Spiroplasma 16S rDNA in TSE Brain Tissues...................... 185,625
R01NS045694-01................. ZHANG, JOHN H..................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Anti-apoptosis as a new therapy for cerebral vasospasm......... 253,750
R01NS045954-01................. TAYLOR, BRADLEY K................. TULANE UNIVERSITY OF LOUISIANA............... NEUROPEPTIDERGIC INHIBITION OF SPINAL PAIN TRANSMISSION........ 352,688
R03CA083096-02................. Johnson, Eric S................... TULANE UNIVERSITY OF LOUISIANA............... POSSIBLE OF ROLE OF AVIAN RETROVIRUSES IN HUMAN CANCER......... 74,250
R03CA091185-01A1............... RAJ, MADHWA H..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... A new tumor marker for Ovarian Cancer.......................... 71,208
R03CA097778-01................. MANDAL, DIPTASRI M................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... Genetics of Prostate Cancer in an Af-Am Population............. 35,500
R03DA013647-02................. GOEDERS, NICHOLAS E............... LOUISIANA STATE UNIV HSC SHREVEPORT.......... Neurochemistry of Cocaine Reinforcement........................ 72,500
R03DA015618-01................. PHADTARE, SHASHIKANT K............ XAVIER UNIVERSITY OF LOUISIANA............... NEW PHENYL NUCLEOSIDES AS ANTI-HIV AGENTS...................... 72,554
R03DC004957-01A2............... FOUNDAS, ANNE L................... TULANE UNIVERSITY OF LOUISIANA............... Developmental Stuttering: MRI Studies in Children.............. 74,250
R03EY014021-01................. JACOB, JEAN T..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Capillary Electrophoresis Profiling of Tears in Dry Eye........ 135,619
R03EY014135-01................. NAUMAN, ERIC A.................... TULANE UNIVERSITY OF LOUISIANA............... Intraocular Pressure-Mediated Damage to the Optic Nerve........ 141,225
R03HD041052-02................. SCHMIDT-SOMMERFELD, EBERHARD...... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Parenteral Medium Chain Triglycerides in the Premature......... 71,500
R03HD042003-01................. VANLANDINGHAM, MARK J............. TULANE UNIVERSITY OF LOUISIANA............... Migration Effects on Health of Working Age Vietnamese.......... 74,250
R03MH065943-01................. STAFFORD, BRIAN S................. TULANE UNIVERSITY OF LOUISIANA............... Validity of Reactive Attachment Disorder....................... 74,250
R13AA013578-01................. MOLINA, PATRICIA E................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... Alcoholism and Disease: Immune/Pathological Mechanisms......... 38,100
R13AG021441-01................. GRISHAM, MATTHEW B................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... Ninth Annual Oxygen Society Meeting............................ 15,000
R13DA015297-01................. Harlan, Richard E................. TULANE UNIVERSITY OF LOUISIANA............... Workshop on Steroid Hormones and Brain Function................ 15,650
R13HL069204-01................. GRISHAM, MATTHEW B................ LOUISIANA STATE UNIV HSC SHREVEPORT.......... Eighth Annual Oxygen Society Meeting........................... 20,000
R15DA013512-01A2............... MANDAL, TARUN K................... XAVIER UNIVERSITY OF LOUISIANA............... SR Drug Delivery for the Treatment of Drug Abuse............... 68,113
R15ES011279-01A1............... ASRABADI, BADIOLLAH R............. NICHOLLS STATE UNIVERSITY.................... Air Pollution and Asthma in Southeast Louisiana................ 151,000
R18AI033449-08................. FREY, DANIEL J.................... LOUISIANA ORGAN PROCUREMENT AGENCY........... ENHANCING DONOR REGISTRY TO INCREASE DONATION.................. 387,407
R21AA013555-01A1............... McDonough, Kathleen H............. LOUISIANA STATE UNIV HSC NEW ORLEANS......... Alcohol Enhances HIV-1 Induced Cardiac Depression.............. 139,903
R21AA013828-01................. MACLEAN, ANDREW G................. TULANE UNIVERSITY OF LOUISIANA............... Alcohol and SIV neuroinvasion in vivo and in vitro............. 160,000
R21AI051414-01................. HALFORD, WILLIAM P................ TULANE UNIVERSITY OF LOUISIANA............... ROLE OF THE LAT-ICP0 LOCUS IN REGULATING HSV LATENCY........... 284,875
R21AI053290-01................. RAMSAY, ALISTAIR J................ LOUISIANA STATE UNIV HSC NEW ORLEANS......... Generation of protection against 'stealth' poxviruses.......... 210,900
R21AI053517-01................. LINDBERG, IRIS.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Blockade of Anthrax Cytotoxicity Using Furin Inhibitors........ 204,600
R21CA089348-01A2............... SINGAL, RAKESH.................... U.S. DEPT/VETS AFFAIRS MED CTR(SHREVPRT)..... GSTP1 gene repression in prostate cancer....................... 75,000
R21DA016029-01................. MOHAMADZADEH, MANSOUR............. TULANE UNIVERSITY OF LOUISIANA............... Dendritic cell targeted hepatitis c virus immunotherapy........ 148,500
R21DC004994-02................. BOBBIN, RICHARD P................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... Drug manipulation of noise-induced hearing loss................ 143,000
R21DC005470-01................. Ricci, Anthony J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... Mature mouse cochlea culture model for physiological inv....... 71,500
R21DC005514-01................. WATSON, GLEN M.................... UNIVERSITY OF LOUISIANA AT LAFAYETTE......... Target Proteins for Linkages in Membranes of Hair Cells........ 62,320
R21DE015051-01................. HAGENSEE, MICHAEL E............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Prevalence of HPV in the Oral Cavity of HIV+ Individuals....... 206,700
R21DK057390-02................. PARTOSEOEDARSO, ELITA R........... LOUISIANA STATE UNIV HSC NEW ORLEANS......... VAGAL GASTRIC MOTOR CONTROL IN MICE............................ 143,000
R21ES012026-01................. REISER, JAKOB..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Protein trapping tools for mammalian cells..................... 213,000
R21GM065612-01................. POLLOCK, DAVID D.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... Protein sequence, structure, and computational analysis........ 138,348
R21NS042736-01................. BRISKI, KAREN P................... UNIVERSITY OF LOUISIANA AT MONROE............ Microscopic Quantitative Mapping Ion Flux in Rat Brain......... 99,500
R21NS043974-02................. EHRLICH, MELANIE.................. TULANE UNIVERSITY OF LOUISIANA............... FSHD Syndrome: DNA Repeats, Methylation, & Chromatin........... 185,625
R21RR015016-03................. MURRAY, KERMIT K.................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MADLI Mass Spectrometry for Microfluidic Chip Detection........ 89,570
R24CA084625-03................. SOPER, Steven A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MICRO-INSTRUMENT PLATFORMS FOR GENETIC-BASED ANALYSES.......... 537,986
R24CA084625-03S1............... SOPER, Steven A................... LOUISIANA STATE UNIV A&M COL BATON ROUGE..... MICRO-INSTRUMENT PLATFORMS FOR GENETIC-BASED ANALYSES.......... 33,075
R24HL060808-05................. STRONG, JACK P.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... PDAY CARDIOVASCULAR SPECIMEN AND DATA LIBRARY.................. 131,915
R24RR015395-01A2............... BAVISTER, BARRY D................. LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS..... EMBRYO TECHNOLOGIES FOR PROPAGATION OF RHESUS MONKEYS.......... 250,176
R24RR016986-01A1............... Marx, Preston A................... TULANE UNIVERSITY OF LOUISIANA............... AN IMPROVED MACAQUE MODEL FOR SIV AND SHIV..................... 683,168
R25CA047877-15................. LOPEZ-S, ALFREDO.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SHORT RESEARCH EXPERIENCES IN CANCER........................... 66,965
R25CA087994-03................. GREGORY, PAULA E.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... SCIENCE FOR THE NEW MILLENNIUM--HS CANCER RES PARTNER.......... 63,334
R25GM060926-01A2............... STEVENS, CHERYL L................. XAVIER UNIVERSITY OF LOUISIANA............... MBRS RISE Program at Xavier University......................... 137,138
R25MH058560-05................. Duhon, Stacey A................... GRAMBLING STATE UNIVERSITY................... NIMH HONORS MINORITY HIGH SCHOOL PROGRAM AT GSU................ 26,001
R29CA076186-05................. MEYERS, SHARI L................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... MOLECULAR MECHANISM OF TRANSFORMATION BY AML1/ETO.............. 101,500
R29DC003280-05................. Garcia, Meredith M................ TULANE UNIVERSITY OF LOUISIANA............... PROTEIN KINASE C IN CENTRAL AUDITORY PLASTICITY................ 102,566
R29ES009055-05................. MILLER, CHARLES A................. TULANE UNIVERSITY OF LOUISIANA............... ARYL HYDROCARBON RECEPTOR STRUCTURE AND INTERACTIONS........... 94,724
R29EY012204-05................. GLEASON, EVANNA L................. LOUISIANA STATE UNIV A&M COL BATON ROUGE..... METABOTROPIC GLUTAMATE RECEPTORS ON AMACRINE CELLS............. 99,231
R29HD036421-06................. KUBISCH, HANS M................... TULANE UNIVERSITY OF LOUISIANA............... MARKER ASSISTED SELECTION OF BOVINE BLASTOCYSTS................ 152,674
R37AG006168-17................. JAZWINSKI, S MICHAL............... LOUISIANA STATE UNIV HSC NEW ORLEANS......... CELLULAR AGING IN A YEAST MODEL SYSTEM......................... 327,656
R37DK032089-21................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... DIETARY OBESITY................................................ 308,966
R37DK036013-16................. ORLANDO, ROY C.................... TULANE UNIVERSITY OF LOUISIANA............... ESOPHAGEAL CYTOPROTECTION--AGENTS AND MECHANISMS............... 215,096
R37MH051853-09................. MCCANN, SAMUEL M.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... MECHANISM OF ACTION OF CYTOKINES ON BRAIN AND PITUITARY........ 290,105
R43CA094566-01A1............... MORGAN, LEE R..................... DEKK-TEC, INC................................ Clinical Development of 4-Hydroperoxyifosfamide................ 185,641
R44CA085021-03................. MORGAN, LEE R..................... DEKK-TEC, INC................................ DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS.......... 122,592
R44GM061508-02................. SINHA, SUDHIR K................... RELIAGENE TECHNOLOGIES, INC.................. Dimorphic ALU repeats- Application in identity testing......... 469,306
R44NS038358-02................. NARDUCY, KENNETH W................ ST CHARLES PHARMACEUTICALS................... Development of Novel Therapeutics for Postsurgical Pain........ 435,340
S06GM008008-31................. STEVENS, CHERYL L................. XAVIER UNIVERSITY OF LOUISIANA............... MBRS SCORE PROGRAM AT XAVIER UNIVERSITY........................ 761,051
S06GM008025-29................. CHRISTIAN, FRED A................. SOUTHERN UNIV A&M COL BATON ROUGE............ MBRS SCORE PROGRAM AT SOUTHERN UNIVERSITY-BATON ROUGE.......... 44,708
S07RR018185-01................. WHELTON, PAUL K................... TULANE UNIVERSITY OF LOUISIANA............... Technology for Electronic Submission of IRB Protocols.......... 123,500
S10RR016963-01................. VEAZEY, RONALD S.................. TULANE UNIVERSITY OF LOUISIANA............... High-speed cell sorter......................................... 427,553
S11ES009996-04................. BLAKE, ROBERT C................... XAVIER UNIVERSITY OF LOUISIANA............... ALTERATION OF GENE REGULATION BY ENVIRONMENTAL COMPOUNDS....... 593,981
S11ES010018-04................. MUGANDA, PERPETUA M............... SOUTHERN UNIV A&M COL BATON ROUGE............ CELLULAR & MOLECULAR TOXICOLOGY OF BUTADIENE................... 985,060
S21MD000231-01................. FRANCIS, NORMAN C................. XAVIER UNIVERSITY OF LOUISIANA............... Xavier Pharmacy Endowment for Minority Health.................. 5,000,000
T32AA007577-03S1............... BAGBY, GREGORY J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM................... 49,758
T32AA007577-04................. BAGBY, GREGORY J.................. LOUISIANA STATE UNIV HSC NEW ORLEANS......... BIOMEDICAL ALCOHOL RESEARCH TRAINING PROGRAM................... 273,978
T34GM007716-24................. BIRDWHISTELL, TERESA T............ XAVIER UNIVERSITY OF LOUISIANA............... MARC U*STAR Training Program at Xavier University.............. 534,181
T34GM008714-04................. HIMAYA, M A....................... GRAMBLING STATE UNIVERSITY................... MARC U STAR at Grambling State University...................... 278,345
T34MH017102-20................. DUHON, STACEY A................... GRAMBLING STATE UNIVERSITY................... NIMH COR HONORS UNDERGRADUATE PROGRAM AT GSU................... 227,971
U01AG020478-01................. RAVUSSIN, ERIC.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Metabolic Adaptations to Two Year Caloric Restriction.......... 1,432,621
U01AG020478-01S1............... RAVUSSIN, ERIC.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Metabolic Adaptations to Two Year Caloric Restriction.......... 147,000
U01AG020478-01S2............... RAVUSSIN, ERIC.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Metabolic Adaptations to Two Year Caloric Restriction.......... 915,000
U01AI032913-10................. VAN DYKE, RUSSELL B............... TULANE UNIVERSITY OF LOUISIANA............... Tulane/LSU Pediatric AIDS Clinical Trials Unit................. 815,476
U01AI038844-04S3............... Lertora, Juan J. L................ TULANE UNIVERSITY OF LOUISIANA............... AIDS CLINICAL TRIALS UNIT...................................... 285,956
U01AI042178-11................. MUSHATT, DAVID M.................. TULANE UNIVERSITY OF LOUISIANA............... LOUISIANA COMMUNITY AIDS RESEARCH PROGRAM (CPCRA).............. 853,801
U01CA083014-04................. ZAKRIS, ELLEN L................... TULANE UNIVERSITY OF LOUISIANA............... TULANE AIDS-ASSOCIATED MALIGNANCY CONSORTIUM................... 154,826
U01DK048377-09................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... NIDDM PRIMARY PREVENTION TRIAL (DPT 2)......................... 304,921
U01DK056990-04................. BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Clinical Center for Look AHEAD: Health in Diabetes............. 1,312,399
U01DK056990-04S1............... BRAY, GEORGE A.................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Clinical Center for Look AHEAD: Health in Diabetes............. 7,350
U01DK060963-02................. HE, JIANG......................... TULANE UNIVERSITY OF LOUISIANA............... Clinical Center for Prospective Cohort Study of CRI............ 316,100
U01DK060963-02S1............... HE, JIANG......................... TULANE UNIVERSITY OF LOUISIANA............... Clinical Center for Prospective Cohort Study of CRI............ 250,000
U01HD031315-09................. WILSON, JOHN T.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PEDIATRIC DRUG EVALUATION RESOURCE............................. 383,323
U01HD031315-09S1............... WILSON, JOHN T.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... PEDIATRIC DRUG EVALUATION RESOURCE............................. 178,033
U01HD040470-02................. ABDALIAN, SUE E................... TULANE UNIVERSITY OF LOUISIANA............... NEW ORLEANS ADOLESCENT MEDICINE TRIALS UNIT.................... 762,602
U01HL060571-05................. HARSHA, DAVID W................... LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... PREMIER--LIFESTYLE INTERVENE FOR BLOOD PRESSURE CONTRL......... 163,892
U01HL066855-03................. Webber, Larry S................... TULANE UNIVERSITY OF LOUISIANA............... TRIAL OF ACTIVITY FOR ADOLESCENT GIRLS (TAAG).................. 763,926
U01HL072274-01................. LEISSINGER, CINDY A............... TULANE UNIVERSITY OF LOUISIANA............... Hemostasis Clinical Research Network Protocols................. 300,000
U01HL072507-01................. HE, JIANG......................... TULANE UNIVERSITY OF LOUISIANA............... Genetic Epidemiology of Blood Pressure Intervention............ 1,432,730
U01HL072510-01................. LEFEVRE, MICHAEL.................. LSU PENNINGTON BIOMEDICAL RESEARCH CTR....... Diet, genetics, and CVD risk factor response in Blacks......... 2,098,725
U10CA035272-19................. KARDINAL, CARL G.................. OCHSNER CLINIC FOUNDATION.................... OCHSNER COMMUNITY CLINICAL ONCOLOGY PROGRAM.................... 467,005
U10CA058658-10................. MILLS, GLENN M.................... LOUISIANA STATE UNIV HSC SHREVEPORT.......... SOUTHWEST ONCOLOGY GROUP....................................... 324,550
U10CA063845-08................. Gilbert, Jill..................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... LSUHSC Minority Based Community Clinical Oncology.............. 211,735
U10NS044471-01................. RAO, JAYARAMAN.................... LOUISIANA STATE UNIV HSC NEW ORLEANS......... Nicotine and Neuroprotection in Parkinson's Disease............ 104,197
U19AI045511-03S1............... BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... AFRICAN MALARIA VECTORS........................................ 76,005
U19AI045511-04................. BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... AFRICAN MALARIA VECTORS........................................ 680,483
U19AI045511-04S1............... BEIER, JOHN C..................... TULANE UNIVERSITY OF LOUISIANA............... AFRICAN MALARIA VECTORS........................................ 40,189
U24RR018111-01................. BOHM, RUDOLF P.................... TULANE UNIVERSITY OF LOUISIANA............... ESTABLISHMENT AND EXPANSION OF A SPF RHESUS COLONY............. 769,149
U42RR015087-03................. ROWELL, THOMAS J.................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... ESTABLISHMENT/MAINTENANCE OF BIOMEDICAL RESEARCH COLONY........ 843,593
N01NS992302.................... ROWELL, THOMAS J.................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... SLOW, LATENT & TEMPERATE VIRUS INFECTIONS...................... 1,171,906
N01HR16150..................... DEBOISBLANC, BENNETT.............. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... ADULT RESPIRATORY DISTRESS SYNDROME STUDY...................... 125,337
N01AO12747..................... HASSELSCHWERT, DANA............... UNIVERSITY OF LOUISIANA AT LAFAYETTE......... MAINTENANCE OF A SPF PIGTAIL BREEDING COLONY................... 1,922,466
N01AO22751..................... FONTENOT, BABETTE................. UNIVERSITY OF LOUISIANA AT LAFAYETTE......... BREEDING,HOUSING AND MAINTENANCE OF RHESUS MACAQUES IN SUPPORT 1,349,886
OF AIDS.
N01AO22754..................... HASSELSCHWERT, DANA............... UNIVERSITY OF LOUISIANA AT LAFAYETTE......... LEASING OF CHIMPANZEES FOR THE CONDUCT OF RESEARCH............. 1,360,000
U42RR016026-02................. BLANCHARD, JAMES L................ TULANE UNIVERSITY OF LOUISIANA............... SPECIFIC PATHOGEN FREE INDIAN RHESUS MONKEY COLONY FOR A....... 1,311,873
U45ES010664-03................. WRIGHT, BEVERLY H................. XAVIER UNIVERSITY OF LOUISIANA............... WORKER HEALTH AND SAFETY TRAINING COOPERATIVE AGREEMENT........ 993,562
------------
TOTAL FY 2002............ .................................. ............................................. ............................................................... 117,481,005
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
BIOTERRRORISM
Senator Specter. Mr. Secretary, coming back to the
bioterrorism, the budget has a figure of $3.6 billion. How is
help going to be given to the States on dealing with
bioterrorism? I have traveled my State. I know my colleagues
have traveled their States. But there are no funds which are
being devoted. The University of Pittsburgh Medical Center, for
example, has a very elaborate system where they have plans to
bring people in in the event of bioterrorism attack, showers,
quarantines, response to anthrax or smallpox or whatever else
may occur. But what is being done about distributing funds from
the Federal Government to the States?
Secretary Thompson. Last year, Senator, we had $918 million
that we could send out for the State departments and local
health departments and communities for biopreparedness. And we
had an additional $125 million that was sent out for hospitals
in order to find ways in which they might be able to expand
their surge capacity, and that was distributed on a formula
throughout all of the States in America.
But in addition to that, we asked them to make some
planning because we knew that we were going to ask for some
additional money in fiscal year 2003, which is $518 million,
which has been appropriated, less a reduction, I think, of
about 1 percent in the appropriation language. So there is $518
million, less that reduction for balancing the budget, that is
going to be sent out to the hospitals based upon their plans.
Senator Specter. How much money is that again?
Secretary Thompson. $518 million.
Senator Specter. Is that remotely enough?
Secretary Thompson. We are expecting that to be replicated
again this year in fiscal year 2004 and fiscal year----
Senator Specter. Do you have an estimate on how much money
it will take?
Secretary Thompson. We have lots of estimates, but I cannot
tell you off the top of my head right now exactly. I know it is
a lot more than----
Senator Specter. Could you provide for us what it will
cost? It seems to me that to adequately prepare the hospitals
in America for bioterrorism is a gigantic figure. I know you
are working on it. But would you provide for the subcommittee
what it is?
Secretary Thompson. Sure, absolutely.
[The information follows:]
Bioterrorism
We are providing $518 million, roughly the full authorization level
in Section 319C-1 of the Public Health Service Act, to improve and
expand the capacity of our Nation's hospitals to respond to biological,
chemical, and radiological terrorist attacks and situations involving
large scale casualties. These funds will supplement the $515 million
appropriated for these activities in fiscal year 2003, and $135 million
in fiscal year 2002, bringing the total to $1.2 billion over 3 years--a
significant investment. The fiscal year 2003 appropriation for the
District of Columbia also included $10 million for related hospital
preparedness activities. We believe that our investment is
significantly contributing to meeting the need of hospitals to
adequately prepare to deal with bioterrorism. We are working with the
States, the American Hospital Association, American Association of
Poison Control Centers, American College of Emergency Physicians,
American Academy of Pediatrics, National Association of EMS Physicians,
National Association of State EMS Directors, Association of State and
Territorial Health Officials, National Rural Health Association,
National Association of Community Health Centers, National Association
of Social Workers, and the American Nurses Association. Each State has
developed a plan for preparing their hospitals and other health care
facilities. These funds will be expended consistent with these State
plans and assessments.
Senator Specter. So we have some idea as to what it is and
how we are getting there.
Mr. Secretary, there is an enormous----
Secretary Thompson. If I could.
Senator Specter. Yes, go ahead.
Secretary Thompson. Pennsylvania has got an obligation of
$33 million, and they have only drawn down $9.5 million. There
are still $23 million undrawn for the State of Pennsylvania as
of right now.
Senator Specter. That is the 19 percent drawdown you have
talked about?
Secretary Thompson. Yes. Pennsylvania has drawn down a
little bit more, but it still has $23 million.
Senator Specter. And that is a simple matter for them to
draw it down?
Secretary Thompson. Yes. But this is before we sent out the
additional $1.5 billion, which we are in the process of sending
out right now.
Senator Specter. Well, that is important to move ahead on,
and we will assist on that.
Secretary Thompson. Thank you.
Senator Specter. I was about to say, Mr. Secretary, there
is enormous anxiety everywhere as to what is going to happen in
the course of the next several days. You are in the command
center. You have the responsibility for a big chunk of
preparedness on bioterrorism. Can you provide any insights as
to what people might expect as we have the countdown to war?
Secretary Thompson. We have, of course, gone from code
yellow to code orange, and there is a possibility we will be
going to code red. I am not sure about that, but there is a
possibility.
Senator Specter. Are you consulted? Is your Department a
party to that determination?
Secretary Thompson. The determination is by the Department
of Justice and the Department of Homeland Security, but we have
very close cooperation and communications with both of those
Departments. We work very closely with them.
What we are anticipating is, Senator, that there could
definitely be attacks, bioterrorism, chemical, radiological,
nuclear, whatever the case may be. We have placed some of our
DMAT teams on alert so that they can be moved very quickly.
Senator Specter. When you say radiological, what do you
mean by that?
Secretary Thompson. That is a dirty bomb, a nuclear bomb.
We have divided up the country into 10 regions. We have
approximately 8,000 medical doctors, nurses, morticians, and
veterinarians that can be called up. We have 600 tons of
medical supplies and equipment strategically located in 12
sites around America that we can move to any city in America
within 7 hours.
Senator Specter. And what kind of paraphernalia do you have
in these sites?
Secretary Thompson. All kinds of things from masks, to
antibiotics, to antidotes, to mark I kits for chemicals.
Vaccines are in a different place. There are also masks, other
kind of equipment to be used, stretchers and so on, if need be.
They are strategically located in 12 sites around America.
Senator Specter. Do you have adequate resources to handle
that particular issue?
Secretary Thompson. We think at this point in time we do,
Senator. I think we could allay your concerns tremendously if
you would come over and just take a look at what we have, how
we are set up to deploy people, equipment, and supplies, and
how we are able to monitor everything and stay in communication
with every State and local health department.
In our GIS, we are I believe the only one that has in our
database every hospital, every fire station, every police
station, all of the first responders. We have all the railroad
lines in our GIS system. We know daily how many beds are
available in each hospital. We can set up plume modeling for
any kind of chemical or any kind of gas that is exploded. On a
street level, we have every street in America in our GIS
database so that we can----
Senator Specter. Every street in America?
Secretary Thompson. Every street in every city.
Senator Specter. Okay. I am going to come take a look.
Secretary Thompson. I think you would be very impressed by
what we have done.
Senator Specter. I want to see the markings on Senator
Craig's street.
I want to see how closely you have him tabbed.
Senator Craig. Mr. Chairman, when you get ready to go, I
will go with you. I would like to see that too.
Secretary Thompson. It is absolutely amazing. I would love
to have you come over.
Senator Craig. The problem is my hometown does not have any
streets.
It has a road that goes to it.
Secretary Thompson. We have the capacity in our
communication room to hook up to any one of 4,000 local TV
stations across America so that if something would happen in
Idaho, we could bring up the TV stations and find out what is
happening on site in that particular area.
Senator Craig. That is very impressive.
Mr. Secretary, were you involved in a briefing with the
Governors in the last couple of days?
Secretary Thompson. No, I was not.
Senator Craig. Mr. Chairman, in relation to your express
concern here--and it is mine--as to the next 24 to 48 hours,
Homeland Security and I believe CIA were involved in a briefing
with all of our Governors in the last 24 hours that my Governor
tells me was the most comprehensive detail he has yet had and
he was very pleased about it. That kind of communication is
improving greatly, and the ability now for you all to tie, as
you are telling us you can, is a very real advancement.
Secretary Thompson. I think if you came over, you would be
very impressed.
Senator Craig. I will do that. I will make a point to do
it.
Secretary Thompson. We are in weekly, if not daily, contact
with all the State health departments through CDC and through
our communication room. So we are keeping everybody very well
up to speed as to what is going on, Senator.
Senator Craig. Thank you.
OBESITY AND LIFESTYLE
Senator Specter. On the issue of obesity and lifestyle,
this subcommittee held a hearing in San Francisco during the
last recess and developed a lot of fascinating information. A
big part of the problem may originate in fast foods where
people are encouraged to eat foods which are very harmful, so
it is said. There recently was a lawsuit against McDonald's
which was dismissed.
What can be done by way of so-called jawboning to try to
get fast food chains to do something about the kind of food
they serve?
Secretary Thompson. I held a meeting, Senator, with several
members of the fast food industry and the national restaurant
organization. We had a difficult but I think productive meeting
and got pledges from them that they would be helpful in trying
to put healthier items on their menu.
[The information follows:]
Fast Food Industry
Secretary Thompson has made it clear that obesity is a problem that
requires a multi disciplinary approach to address this unprecedented
epidemic. HHS has reached out to both public and private organizations,
including the fast food industry to find unique ways to establish
partnerships that will impact this epidemic.
HHS has strongly encouraged the fast food industry to provide
healthy choices on menus, aggressively market those choices to
consumers, and reduce portion sizes.
Senator Specter. Anything concrete? Anything specific?
Secretary Thompson. Nothing specific at this point in time.
That is why we are going to try and have this prevention
summit. I believe it is in April. I will let you know the date,
Senator, and hopefully you can come.
Senator Specter. What do you think of the litigation on the
analogy to smoking, to dangers in smoking? I see the Justice
Department just this week has taken a very strong position
about fraud on the tobacco companies in enticing juveniles to
smoke, put an enormous figure, into the hundreds of millions of
dollars. Is there any analogy to subjecting people to the risks
of adverse health from foods which are unhealthy?
Secretary Thompson. Well, as you know, there was a lawsuit
started and it was dismissed. I am not sure that that is the
most correct way to go, Senator. I think that a better way to
do it is to bring them in and try and convince them to do it. I
spent a half a day at Hamburger University, which is at the
McDonald's campus in northern Illinois, and they were willing
to be quite supportive to try and get healthier items on their
menus.
Senator Specter. Well, we would be very interested to see
what results you have.
Let me move to a couple of other subjects quickly and
terminate the hearing because we have kept you here a long
time.
TAX CREDITS FOR HEALTH INSURANCE
You talk about tax credits for health insurance. Is that an
administration position?
Secretary Thompson. No. It is mine.
Senator Specter. It would be a good idea. We see the number
of uninsured Americans. If you had a tax credit, that would be
a very effective way of dealing with the issue.
Senator Craig. Mr. Chairman?
Senator Specter. Senator Craig.
Senator Craig. Mr. Secretary, you did tie that comment,
though, to long term, did you not?
Secretary Thompson. Yes.
Senator Craig. Thank you. I agree with both, but clearly to
introduce long-term health care insurance into our economy
would be a tremendous advantage to get people investing in
insurance that carries them through to death of that kind.
Secretary Thompson. I would also like to see health
insurance charge lower premiums for people that lead healthier
lifestyles like they do on automobiles.
Senator Craig. I agree.
Secretary Thompson. It is something that we could work on.
TAX CREDITS ON MALPRACTICE INSURANCE
Senator Specter. On the issue of tax credits, one of our
colleagues in the Senate is talking about a tax credit on
malpractice insurance. We had a hearing last week on that
subject, and this is a new idea which is being considered. What
would you think of that, which could be tailored to the areas
which have the greatest problem at the present time?
Secretary Thompson. Senator, I have not looked at it. I am
not knowledgeable about that subject. I would like to read it.
It seems like it has got some possibilities.
Senator Specter. We had a lengthy hearing, Mr. Secretary,
and we had responses from Deputy Secretary Claude Allen. I
would appreciate it if you could find the time to review
Secretary Allen's testimony and give a response to the
subcommittee as to whether you think it was adequate in
answering the questions which we posed.
Secretary Thompson. Okay.
Senator Specter. I would appreciate that.
[The information follows:]
Tax Credit on Malpractice Insurance
I do not believe that the crisis can be fixed by giving doctors tax
credits to help pay the cost of malpractice insurance. This would
simply require the taxpayers to pay even more for the cost of the
excesses of the litigation system. They already are paying $70 billion
as patients and insured for the problems caused by the litigation
system. At the same time, a tax credit would do nothing to address the
underlying problems of the litigation system. It would feed, not fix,
the broken litigation system. We believe the Congress should enact
reasonable reforms such as those passed by the House in H.R. 5.
MEDICAL LIABILITY
Senator Specter. In looking at medical liability--and there
is a lot of concern. Pennsylvania has a very, very serious
problem. Quite a number of States do. When we talk about
frivolous lawsuits, we are talking about a subject matter which
I think really is containable. We have had testimony that 70
percent of the lawsuits are won, but even if the defendants
win, the cost of litigation is so high that it boosts rates.
There are ways to deal with that, sanctions on lawyers,
requirement of a certification by doctors from a panel that
there is something to be submitted to the court.
We have taken a look at the insurance industry. There was a
problem in Texas on homeowners insurance. Nobody could buy
homeowners insurance because there had been so many hurricanes
and the insurance companies had invested the money and the
stock market had gone down.
MEDICAL ERRORS
The medical errors issue. We are anxiously awaiting your
report on medical errors to see to what extent that impacts.
When you talk about caps, you are on a very sensitive subject,
but I think there is some latitude, if it is done carefully. I
think there has to be some exclusion for cases like the
transplant victim in North Carolina, something which is
catastrophic or something like we had a witness testify about a
double mastectomy which was erroneous. They got the wrong x-ray
slides. There is a lot of complaint and understandably about
the lottery, so to speak, with minor cases coming in with
gigantic verdicts.
Would you think that there could be some careful pruning?
There are some State laws on liability, for example, of
governmental units which exclude what they call catastrophic
cases, permanent impairment of bodily function or death or
major disfigurement. Would you think that would be an
appropriate line to make?
Secretary Thompson. Senator, the administration feels very
strongly that we need to have cap on noneconomic damages, but
what you are looking at are many new ideas that certainly
should be explored. I am willing to look at each and every one
of them.
We are looking at something in the Department that we are
going to try administratively and that is first offer. We do
not know if it is going to work, but we are going to try in
some of our cases to be able to offer money to a patient that
has been harmed and pay for their expenses. We are trying to
set it up administratively so that we could do it outside of
litigation. They still would have the right to appeal.
Senator Specter. First offer by the Government, by the
Department of Health and Human Services?
Secretary Thompson. That is correct. To see if we could
somehow show that this is a new procedure. We are working with
a professor I believe in North Carolina that has come up with
this new mechanism on how we might be able to reduce
litigation.
Senator Specter. Well, we would be interested to see the
details on that.
Senator Craig, anything more?
Senator Craig. I do not have anything more. Thank you, Mr.
Secretary, Mr. Chairman.
Senator Specter. Thank you very much, Mr. Secretary.
Secretary Thompson. Thank you, Senator.
Senator Specter. We will be working with you on this.
Secretary Thompson. Please do, and I appreciate it.
Senator Craig, thank you.
Senator Craig. Thank you.
Secretary Thompson. Thank you for your leadership on long-
term. That is great.
PREPARED STATEMENT RECEIVED
Senator Specter. We have received the prepared statement of
Senator Thad Cochran which will be placed in the record.
[The statement follows:]
Prepared Statement of Senator Thad Cochran
Mr. Chairman, thank you for holding this hearing on the 2004 budget
for the Department of Health and Human Services. At this important
time, we must ensure that we are setting clear priorities and investing
wisely in the health and safety of all Americans. Thank you, Secretary
Thompson for appearing before us today and for the excellent job you
are doing as Secretary of HHS. I appreciated your visit to my state
last May.
As we consider the 2004 budget, I think our first priority should
be protecting the safety of our country's citizens. While the defense
of our country comes frist, we must make increased investments in the
health infrastructure of our nation. I am pleased to see the overall
commitment of over $3.5 billion in research and infrastructure funding
aimed at detecting and responding to a national emergency. This is a
wise investment because these public health capacities and research
findings improve our ability to respond to naturally occurring disease
outbreaks even if no bioterrorist incident ever occurs.
We must also remember that cooperation and coordination between HHS
and the Departments of Homeland Security, Agriculture, and Defense are
vital to our response to a biological or chemical attack. We must build
these relationships before an attack occurs.
We must not forget that our nation also faces other pressing health
problems. The biomedical research conducted by HHS has dramatically
improved the health of Americans. While the amazing growth of the NIH's
budget could not be sustained, the President's budget provides a 2
percent increase. I hope this figure can be increased so that we
continue the progress NIH and other agencies have made in understanding
disease.
The funding for the Centers for Disease Control also provides for
important public health research, especially with regard to chronic
diseases. The budget provides an additional $100 million for the
prevention of chronic diseases. This initiative has the potential to
provide tremendous returns. However, we must not shortchange the other
important areas such as infectious disease, birth defects, and
occupational injuries.
We must also continue to make investments in clinical and research
technology. NIH has been leading this effort. Biomedical technology
provides the great promise in the detection, treatment and prevention
of disease. It also provides our best opportunity to confront the
challenges of medical errors and patient safety.
The budget also provides for those in our country most in need of
health. The $1.6 billion provided for Community Health Centers will
create access to health care for over 1 million Americans, according to
the Department.
The budget also provides $47 million for the Office of Minority
Health and $193 million for the National Center for Minority Health and
Health Disparities. While it is important for us to continue to
increase these funding levels, it is also important for us to continue
to work to make sure that this research and outreach takes place in
those areas of the country where it is most needed.
Mr. Secretary, thank you for the leadership you continue to
provide. We look forward to helping you as you oversee the vital
programs that provide us a safe and healthy country.
ADDITIONAL COMMITTEE QUESTIONS
Senator Specter. There will be some additional questions
which will be submitted for your response in the record.
[The following questions were not asked at the hearing, but
were submitted to the Department for response subsequent to the
hearing:]
Questions Submitted by Senator Arlen Specter
MEDICAID DRUG REBATE PROGRAM
Question. You are proposing a Medicaid drug rebate program that is
estimated to save $13.2 billion over the next ten years, and save
states a similar amount. How much do you estimate will be saved in
Fiscal 2004?
Answer. CMS actuaries have estimated that the adjustment to the
Medicaid drug rebate formula will save the Federal Government $800
million in fiscal year 2004.
Question. Could this component of Medicaid reform be enacted as a
separate, free-standing initiative? Provide bill language that would
accomplish this rebate program.
Answer. Yes this legislation could be enacted as a separate free-
standing initiative. The savings I just gave you reflect what would be
the case without Medicaid and SCHIP modernization. As we have stated
previously there are some problems with the current formulation of the
drug rebate. There have been a number of suggestions on how the rebate
formula might be improved. One option suggested was to change the
rebate formula from the difference between Average Manufacturer's Price
(AMP) and best price, to the difference between Average Wholesale Price
(AWP) and best price. Another was to simply set the rebate equal to a
percentage of AMP. Both of these proposals, and others, would save us
money. We wish to work with Congress to come up with the plan that best
advances the interests of the Federal Government and the American
taxpayer.
MEDICAL LIABILITY REFORM LEGISLATION
Question. Last week, you issued a press release applauding the
House of Representatives for passage of Medical Liability Reform
Legislation. The statement said you looked forward to working with the
Senate to pass complementary legislation this year. I chaired a hearing
on this subject last week, and the matter of capping non-economic
awards at $250,000, without exceptions, for egregious cases, was very
controversial. Do you have a compromise plan to gain bi-partisan
support in the Senate?
Answer. The Department's report entitled: ``Addressing the New
Health Care Crisis: Reforming the Medical Litigation System to Improve
the Quality of Health Care,'' shows how problems associated with
medical litigation have worsened significantly in the past year.
Premiums charged to specialists in 18 states without reasonable limits
on non-economic damages increased by 39 percent between 2000 and 2001.
Premiums in these states have since gone up an additional 51 percent.
This report also documents the spiraling cost of insurance for health
care providers, which is impairing patients' access to care, as well as
the cost and quality of care.
Therefore, reasonable caps on non-economic damages increase
doctors; hospitals' and nursing homes' ability to stay in business,
which leads to greater access to care. In addition, caps on non-
economic damages reduce the growth of medical liability costs and
insurance premiums. Over the last two years, states with limits of
$250,000 or $350,000 on non-economic damages have seen increases in
premium quotes for specialists increase only 18 percent. States without
reasonable limits on non-economic damages, in states representing
almost half of the entire U.S. population, have seen average increases
of 45 percent. Since California implemented a reasonable cap on non-
economic damages and other critical procedural reforms 25 years ago,
liability premiums have increased by less than one-third as much as in
the rest of the country. It is important to implement caps at $250,000
for the sake of affordability and access to quality health care.
MEDICARE PAYMENT POLICY
Question. MedPAC considers the implementation of a transition
method as an important aspect of any new payment system design when
establishing its framework for assessing Medicare payment policy
issues. Payment corridors, hold-harmless methods, blend approaches as
well as phase-in periods have been adopted in different circumstances
in order to cushion the impact of payment changes on individual
providers and prevent service disruptions. Did CMS consider
incorporating any of these methods when designing its new outlier
policy?
Answer. Extensive discussions were held on the best approach to
solving the problems caused by hospitals exploiting vulnerabilities in
the determination of outlier payments.
It must be kept in mind that the goal of Medicare is to make fair
and accurate payments for services rendered, these higher payments were
made because of a vulnerability in the determination of payments not as
a result of the true costs of services provided. The proposed outlier
rule will allow CMS to ensure that only hospitals that are truly
experiencing higher then expected costs can receive reimbursement.
HOSPITAL COST COMPUTATION
Question. In its September, 1988 rulemaking process, HCFA (now CMS)
received a number of comments expressing concern about the timeliness
of the data used to compute hospital specific cost-to-charge ratios,
the issue that is at the core of the problem addressed by the newly
proposed regulatory change. In 1988 some suggested that data from the
latest filed cost report be used. CMS dismissed that suggestion stating
that Medicare costs are often overstated on the filed cost report and
are subsequently reduced by audit; CMS elected to use data from a
hospital's final settled cost report to establish the pertinent cost-
to-charge ratios. Now CMS is proposing to use information from a
hospital's tentatively settled cost reports to calculate hospital
specific ratios. To what extent do hospitals costs change between
tentative and final settlement?
Answer. Hospital costs can either increase or decrease between
tentative and final settlement. When a cost report is received by the
FI they ensure the cost report is complete before accepting it. Once
the cost report is accepted the FI has 60 days to make a tentative
settlement on this cost report. The tentative settlement process
usually entails looking at the providers past cost report history and
making any necessary adjustment to the current cost report based on
prior year data. In order to final settle the cost report, the FI will
perform a desk or field review of the cost report. Based on the review,
adjustments are made to costs, charges, and reimbursement in order to
final settle the cost report. This final settlement represents final
payment to the provider.
There is a variation in the change of hospital costs between
tentative and final settlement, depending on the areas reviewed and the
results of the review. However, it is highly unlikely that the cost
from the tentative to the final settled cost reports would change as
much as the latest changes in the cost per case (over 12 percent from
2001 to 2002). With this amount of year-to-year change in charges, it
is imperative to use the latest available cost-to-charge ratio.
Reconciliation at final settlement will take care of any large
differences used for payment and the actual ratio.
Question. Is the concern expressed by CMS in 1988 any less valid
today?
Answer. No, this issue is still pertinent, filed cost reports have
not been reviewed and if necessary audited, and are not an appropriate
basis of final payment. For this reason the proposed outlier rule uses
tentative cost reports which can include adjustments for ``known''
issues, to determine the initial payments. Final settlements are used
to adjust the initial payments and if necessary an adjustment for the
time value of money will be made if the initial payments were
inaccurate.
Our goal is always to make the most accurate payment possible. The
proposed outlier rule highlights that a change was necessary to prevent
hospitals from exploiting vulnerabilities in the determination of
outlier payments. Using tentative cost reports will help eliminate a
vulnerability in the system, and using the final settled cost reports
to determine final payments ensure their accuracy.
MEDICARE DRUG BENEFIT
Question. The President's budget dedicates $400 billion over ten
years for targeted improvements and modernization of Medicare,
including providing access to subsidized prescription drug coverage.
The Senate Budget Resolution also contains a $400 billion reserve fund
for Medicare. What would your proposal offer in prescription drug
coverage for those who stay in the traditional fee-for-service Medicare
program, compared to those who opt for a managed care plan?
Answer. The President's Framework to Modernize and Improve Medicare
gives beneficiaries immediate help with their prescription drug bills
starting in 2004, for beneficiaries in both traditional fee-for-service
and Medicare+Choice plans. A drug discount card will allow all
beneficiaries to save 10-25 percent off retail prices on their
medicines. Low-income beneficiaries will also get a $600 benefit added
to the drug card.
Beginning in 2006, beneficiaries will have three options for their
Medicare benefit: Traditional Medicare, Enhanced Medicare, and Medicare
Advantage. Under, the first option, Traditional Medicare, beneficiaries
could continue receiving their care through the existing program, while
getting a drug discount card that will allow them to save 10-25 percent
on their prescription drug bills. For no additional premium, fee-for-
service beneficiaries will also get protection from high out-of-pocket
drug costs.
Under the second option, Enhanced Medicare, beneficiaries could
choose to receive integrated benefits and drug coverage offered through
a FFS/PPO plan, like FEHBP or TRICARE. Plans would bid to serve one or
more of 10 different regions in the country, and the three best
qualified bids in each region would be awarded the opportunity to
compete for beneficiaries' business. All beneficiaries in a region
would be guaranteed access to all plans serving a region. Beneficiaries
who enroll in the plan submitting the middle-priced bid in their region
would pay a premium equal to the Part B premium in traditional
Medicare. Those choosing the plan with the low-priced bid would receive
most of the savings, while those choosing the high-priced bid would pay
a supplemental premium. All beneficiaries would pay an additional
premium for drug coverage, except for those with low incomes. New
benefits in the enhanced package include a combined deductible for Part
A & B services, free preventive benefits, and protection from high out-
of-pocket medical costs.
Under the third option, Medicare Advantage, beneficiaries could
choose to receive the integrated benefits and drug coverage through a
managed care plan. Plans in competitive markets would bid to provide
the enhanced benefit package. Beneficiaries who select the most
efficient plan could share in the premium savings (and possibly pay no
premium). Beneficiaries could select a plan without drug coverage if
they are satisfied with their current coverage. Like Enhanced Medicare,
beneficiaries would pay an additional premium for drug coverage, unless
they are low-income.
Question. What additional coverage are you suggesting for
preventive health services, such as nutrition education?
Answer. Beneficiaries enrolled in Enhanced Medicare and Medicare
Advantage will be able to receive preventive services absolutely free--
all current co-pays will be waived. As you may know, the Medicare
currently covers screening mammography, screening pap smears and pelvic
exams, colorectal cancer screening, prostate cancer screening, glaucoma
screening, diabetes self-management, medical nutrition therapy, bone
mass measurements, and certain vaccines. The President's Framework
promises that the cost of a co-pay will never stand in the way of this
potentially life-saving preventive care.
PHYSICIANS' PAY
Question. Congress replaced a 4.4 percent cut this year in Medicare
payments for physicians, with a 1.6 percent increase. Will this
correction be sufficient to avoid a payment cut in 2004?
Answer. The enactment of the Consolidated Appropriations Resolution
(CAR) corrected a statutory flaw in the physician payment formula
resulting in multi-year, permanent changes in Medicare expenditures for
physicians' services. The CAR provision increased Medicare spending by
an estimated $49.6 billion over 10 years by allowing the Centers for
Medicare and Medicaid Services (CMS) to revise the fiscal years 1998
and 1999 sustainable growth rates (SGRs) and establish a 1.6 percent
update to physician fee schedule rates for March 1 to December 31 in
place of the 4.4 percent reduction announced in our December 31, 2002
final rule. The revisions CMS made to the fiscal year 1998 and fiscal
year 1999 SGRs allow the physician fee schedule update and SGR system
to work as originally intended by the Balanced Budget Act of 1997.
While CMS had previously estimated positive updates for 2004 and
later years, we now estimate physician fee schedule updates will be
negative for 2004-2007 as a result of higher spending in 2002 for
physicians' services and lower real GDP per capita for both 2002 and
2003 than previously estimated. The revisions made to the fiscal year
1998 and fiscal year 1999 SGRs will result in higher physician fee
schedule updates for years beginning with 2004 than would have occurred
had the CAR of 2003 not been enacted.
Question. What would be the impact on the pay update of excluding
the cost of outpatient prescription drugs from the calculation of
spending targets for physician services?
Answer. We previously estimated a physician fee schedule update of
1.7 percent for 2004. However, more recent data on actual spending in
2002 and new figures for real per capita GDP changed this estimate to
4.2 percent. We estimate that 44 percent of the change is the result of
higher physician spending (other than for drugs). Another 41 percent of
change is the result of lower GDP figures for 2002 and 2003. Another 10
percent of the change is the result of higher spending for drugs and
the remaining 5 percent is the result of a small reduction in the
estimated Medicare Economic Index (MEI). More information on 2003
spending and real per capita GDP growth will likely change this figure
further. The 2004 update would be somewhat less negative if spending
for currently covered drugs were removed from the measurement of
spending under the 2003 sustainable growth rate.
SMALLPOX VACCINATION PROGRAM
Question. Public health groups are now estimating that the cost of
implementing the Smallpox Vaccination Program would range between $154
and $284 per vaccination with a median cost of $204. Does the
Administration plan to request an appropriation in the emergency
supplemental to provide states with resources so that they may carry
out the Smallpox Vaccination Plan without diverting funding from other
bioterrorism preparedness or core public health activities?
Answer. We understand that these estimates include a range of costs
over and above the direct costs of running an immunization campaign.
They include, for example, costs of infrastructure that States should
be building with the funds they have already received, costs of the
added epidemiologists that funds have been appropriated to cover, and a
range of potential indirect costs that State public health departments
would not have to pay. CDC is making every effort to assist States in
implementing the smallpox vaccination program including providing
training to the States, offering technical assistance on administering
the smallpox vaccine, and providing education to clinicians, public
health groups, and State health officers and organizations. To help
implement these plans, CDC and HHS is allowing States to request
immediate use of 20 percent of their fiscal year 2003 Bioterrorism
grant allocation to be used for immediate needs including implementing
the smallpox vaccination program. Although this may not cover all the
costs associated with the vaccination, CDC is committed to helping the
states in every way possible.
HEAD START
Question. Mr. Secretary, the Administration's budget proposal has
identified the fiscal year 2004 as the transfer transition year for
Head Start, with the Department of Education taking over administration
in 2005. Please provide the specific evidence available that indicates
that the Head Start program would better achieve its goals under the
stewardship of the Department of Education and therefore support this
proposed transfer?
Answer. What I can assure you is that as long as Head Start is in
the Department of Health and Human Services, I am going to do
everything I possibly can to improve it an make it better.
Over the past two years we have increased our efforts to help Head
Start programs enhance school readiness and the development of early
literacy skills. In April 2002, the President announced his Good Start/
Grow Smart initiative which is designed to assure that every Head Start
teacher has the training skills they will need to provide Head Start
children the early literacy, language, and numeracy skills they will
need to be successful in school. The Strategic Teacher Education
Program, knows as STEP, launched last summer, was designed to ensure
that every Head Start program and every classroom teacher has a
fundamental knowledge of early development and literacy, and of state-
of-the-art early literacy teaching techniques. Good Start, Grow Smart
calls for not only the improvement and strengthening of Head Start
through intense, large-scale efforts in the areas of early language and
literacy, but also for a method to track the results of this effort.
This fall we will begin implementing the Congressionally mandated
assessments of the school readiness of all the four-year old children
in Head Start.
Question. What specific actions are being taken by either
Department related to this transition year?
Answer. Under the proposal to transfer Head Start to the Department
of Education, fiscal year 2004 would be a transition and planning year
with implementation in fiscal year 2005. An Interagency Task Force was
created in 2001 to consider issues related to the transfer. However,
our Department is currently focusing its main efforts on the existing
fiscal year 2003 priorities, such as improving early literacy skills in
Head Start and developing a national reporting system to better assess
child outcomes. This will create a stronger program and we anticipate
improvements will continue, should the administration of Head Start be
transferred. We are prepared to do the necessary transition planning in
fiscal year 2004.
HEAD START FACES AND IMPACT STUDY
Question. Mr. Secretary, in your prepared statement for testimony
before this subcommittee on March 19, 2003, you indicated that:
``Children in Head Start enter school further ahead than other
economically disadvantaged children. But unfortunately--even after 30
years--Head Start children do not enter school at the same level as
more economically advantaged children.'' This subcommittee has
allocated substantial resources for HHS to carry out evaluations of the
Head Start program, including FACES and the National Head Start Impact
Study. Please provide the subcommittee with a summary of the latest
school readiness-related, program quality, and child development
findings from the FACES evaluation, as well as a status report on
progress made related to the Impact Study.
Answer. The Head Start Family and Child Experiences Survey (FACES)
is an ongoing, longitudinal study of Head Start program quality and
child outcomes, which currently has two nationally representative
cohorts (1997, 2000) and plans for a third. While it does not have a
control group of children who are not in Head Start, it does provide
important information on program quality over time, and child outcomes
from program entry through kindergarten follow-up. FACES uses a sample
of classrooms, children, and families that is scientifically
representative of all Head Start programs. Child outcomes can be
compared with national averages for children of all income levels on a
range of standardized assessments. From FACES we find:
The average Head Start classroom is of ``good'' quality as an early
childhood learning environment, consistently over several years of
measurement. On the Early Childhood Environment Rating Scale (ECERS), a
widely used and well-respected instrument for evaluating quality of
early childhood programs, scores can range from 1 (meaning
``inadequate'') to 7 (meaning ``excellent''). In both FACES 1997 and
FACES 2000, typical Head Start classrooms received ratings just below
5, or ``good.''
Few classrooms scored below minimal quality. In FACES 1997, no Head
Start classroom in the national sample received a mean ECERS score in
the ``inadequate'' range (1 or 2). In 2000, a few classrooms (two-
percent) scored in that range.
The use of integrated curriculum is linked to program quality. In
FACES 2000, Head Start programs using the two most widely used
integrated early childhood curricula--Creative Curriculum (39 percent)
and High Scope (20 percent)--were found to have higher average ECERS
language and overall quality factor scores than programs that used
``other'' curricula.
In addition, FACES 2000 has found that Head Start teachers have
higher levels of educational attainment than teachers studied in 1997-
1998.
The FACES study allows comparisons of Head Start scores with
national averages for children of all income levels. Children enter
Head Start with vocabulary scores that are at about the 16th percentile
nationally. They made significant progress over the Head Start year, in
both the 1997 and 2000 cohorts. For example, English proficient
children in FACES 2000 gained 3.8 points in standard scores from 85.3
to 89.1. Methodologists have called such gains ``educationally
meaningful'' and they are greater than the gains made by the typical
child of this age, regardless of income level. However, they do not
raise Head Start children to the national average in vocabulary scores.
Adding in children who were not proficient in English on entry into the
program, the average standard score in vocabulary changes from 81.4 to
85.7, representing a gain of 4.3 standard score points over the 2000-
2001 year.
In another important literacy area, pre-writing, Head Start
children make significant gains relative to national norms (in FACES
2000, 85.1 to 87.1), but are still below national averages. This gain
in early writing is slightly smaller than that seen in FACES 1997,
although still significant.
In FACES 2000, Head Start children are scoring higher on
assessments of letter recognition and book knowledge, areas in which
they lagged in 1997-1998. First, Head Start children in FACES 2000 are
making more progress in the area of letter recognition than they did in
1997-1998. Their scores meant that children learned the equivalent of 5
additional letters in Head Start and knew an average of 9 letters at
the end of the program year. In relation to national norms on the
Letter-Word sub-test, Head Start children advanced about as much as the
typical preschool-age child, and performed better than the 1997 cohort
but still remained below the national norm.
Second, Head Start children are performing better in the area of
book knowledge. Book and print concepts do not have national norms
available, but in FACES 1997, children did not show advances in this
type of knowledge from fall to spring. By contrast, in FACES 2000, mean
scores showed a significant gain, from 1.61 in the fall to 2.46 in the
spring.
In addition, Head Start children showed growth in social skills and
reduction in hyperactive behavior during the Head Start year, according
to teacher ratings of behavior. Behavior in Head Start is a predictor
of the child's adjustment and performance in early elementary school.
Children whose teachers rated them higher on social skills at the end
of Head Start were also rated higher by Kindergarten teachers. Children
whose teachers rated them higher on social skills and lower on behavior
problems also scored better on cognitive assessments at the end of
Kindergarten, even when their Head Start assessments were taken into
account.
The Head Start Impact Study is a longitudinal study involving
approximately 5,000 three- and four-year old children across 75
nationally representative grantee/delegate agencies (in communities
where there are more eligible children and families than can be served
by the program). The participating children have been randomly assigned
to either a Head Start group (that receives Head Start program
services) or a control group (that does not receive Head Start services
but may enroll in other available services selected by their parents or
be cared for at home). Every effort was made to minimize the burden on
individual programs and not to significantly change typical enrollment
and recruitment procedures.
Children enrolled in Early Head Start, Migrant Head Start, and
programs operated by Tribal organizations, as well as those considered
extremely new (i.e., in operation approximately less than 2 years), and
those considered severely out of compliance were not included in the
study.
Great care was taken to include only programs that were not able to
serve all of the eligible children in their community. It was important
to have a sufficient number of unserved, eligible children available
who could be randomly assigned to a control group, without causing any
fewer children to be served by the program than would otherwise be the
case. These ``saturation'' determinations were based on grantee/
delegate agencies' own reports of enrollment levels in the fall of
2001, along with other available information.
Data collection began in the fall of 2002 and is scheduled to
continue through 2006, following children through the spring of their
first grade year. It includes twice yearly in-person interviews with
parents, in-person child assessments, annual surveys with care
providers and teachers, direct observations of the quality of different
care settings, and teacher ratings of children. Data collection will
include:
--Individual child data in areas related to school readiness, such as
physical well-being and motor development, social and emotional
development, approaches to learning, language usage and
emerging literacy, cognition and general knowledge;
--Information pertaining to parenting practices, family resources and
risk factors, demographic and socio-economic data, and family
structure, including parents' descriptions of the types of
literacy activities they engage in with children at home;
--Information on structure, process, and quality of Head Start, child
care, and school settings through first grade, including
teachers' reports on their credentials and experience. Trained
observers will assess the quality of different care settings,
including assessments of classroom resources and instructional
practices; and
--Community level data relating to the availability and means of
formal and informal family support services.
An interim report is scheduled for September 2003 and the final
report in December 2006.
EARLY LEARNING FUND
Question. The Performance Assessment Rating Tool for the Head Start
program, stated that Head Start is not well coordinated with other
early education and care programs. However, the Administration has once
again proposed to eliminate funding for the Early Learning Fund, a
program that seeks to remove barriers to the provision of an accessible
system of early childhood learning programs in communities throughout
the United States and facilitate the development of community-based
systems of collaborative service delivery models characterized by
resource sharing, linkages between appropriate supports, and local
planning for services. Why does the Administration oppose funding for
this program, when it could help states and local communities meet the
stated goals of coordination, program improvement, and early care and
education services?
Answer. No funds are being requested in fiscal year 2004 for the
Early Learning Opportunities Program because the fiscal year 2004
budget provides funding for similar activities in the Department of
Education through the Early Reading First program and the Early
Childhood Educator Professional Development Grants.
COMPASSION CAPITAL FUND
Question. On December 12, 2002, I was in Philadelphia with
President Bush for the White House Conference on Faith-based and
Community Initiatives. It was an appropriate setting, as members of the
Philadelphia community, in particular Public/Private Ventures, have
been leaders in the area of faith-based and community initiatives.
During his remarks, President Bush highlighted the Amachi program run
by Public/Private Ventures, which is serving as the model for the
Mentoring Children of Prisoners proposal. As you know, this
subcommittee has been very supportive of the faith-based agenda, and
just last year, funding for authorized programs received an increase of
almost 50 percent. Can you provide the subcommittee with an update on
the early lessons learned through grant funding provided by the
compassion capital fund, and explain how these lessons are informing
planning and implementation for the mentoring program and the
President's new substance abuse voucher program, as well as the broader
issue of providing an appropriate opportunity for faith and small
community based programs to compete for grants programs administered by
your Department?
Answer. Although we are in the early stages of implementation for
the Compassion Capital Fund, we have already contracted with two
research and development firms to begin the necessary work toward
performance measurement. Those firms will assess best practices in
faith-based organizations through several CCF demonstration project
grantees within a sample of eight to 10 intermediary organizations.
This effort is part of a comprehensive strategy to develop measures
that will not only assess the outcomes of the program's efforts, but
will also highlight what strategies work in utilizing this group of
organizations to provide services. Using information culled from the
assessment of grantees, the contractors will develop and maintain the
National Resource Center. The National Resource Center will document
programs operated under the Compassion Capital Fund so that practices
are measured, and successes emulated or expanded. We will share our
findings and experiences across government with interested agencies and
programs, including those involved in mentoring programs and the
President's substance abuse voucher program.
The Family and Youth Services Bureau (FYSB) within the
Administration on Children and Families has been assigned the
responsibility for implementing the Mentoring Children of Prisoners
program. FYSB has developed a program announcement soliciting
applications for grant funding for the program and expects to publish
the announcement in the Federal Register early this summer. While no
funding has been obligated to date, we anticipate making all grant
awards and obligating all funding by September 30, 2003. We expect to
make awards to a wide range of eligible applicants, including community
and faith-based organizations, State and local units of government, and
Tribes.
The President's new substance abuse voucher program, Access to
Recovery, is an innovative client-based program to increase access to
substance abuse treatment. We recognize there are several pathways to
recovery. Access to Recovery will increase substance abuse treatment
capacity by allowing an individual to use Federal substance abuse
dollars to choose effective treatment organizations, including faith-
based organizations. Individuals in need of treatment will first be
assessed and then will receive a voucher to pay for an appropriate
level treatment. This program emphasizes consumer choice and will
reward treatment effectiveness.
More broadly, the department has been busy eliminating the barriers
that in the past have prevented faith-based and community-based
organizations entry into the Federal funding stream. The Compassion
Capital Fund program, for example, supports intermediary organizations
to assist faith-based and community organizations in helping faith-
based and community organizations expand their capacity to provide
needed services to the community. Intermediaries assist these small
groups in their efforts to improve effectiveness and organizational
management, access funds from diverse sources and manage those funds,
develop and train staff, expand the types and reach of social services
programs in their communities and develop promising collaboration among
organizations dedicated to social service delivery. A National Resource
Center is also being established by the Compassion Capital Fund for
small faith-based and community organizations. Other accomplishments
include making applications more user-friendly, promoting diversity in
the grant review panels, and eliminating preference points for
organizations previously awarded grants. With these efforts, and the
assistance of intermediary organizations, the Department is building a
bridge between the federal government and small faith-based and
community organizations in the provision of needed services to
distressed individuals and communities.
UNACCOMPANIED CHILDREN TRANSFER TO ORR
Question. Mr. Secretary, as you know, section 462 of the Homeland
Security Act of 2002 transferred the INS Unaccompanied Alien Children
program to the HHS Office of Refugee Resettlement. Please provide the
subcommittee with your plan, including timeline and budget
requirements, for appropriately implementing this provision of the law.
Answer. The UAC program was transferred from INS to the Office of
Refugee Resettlement (ORR) on March 1, 2003. Along with this transfer,
the fiscal year 2003 funding base of $34.2 million was established for
this program. Unobligated fiscal year 2003 funds in the amount of
$20.142 million were transferred from INS to ORR on February 28, 2003,
in a Determination Order. Much of the transferred balance was committed
by INS for shelter care grants and contracts for secure detention prior
to the transfer of this program to HHS. These previously existing
grants and contracts were transferred to ORR. Twenty-one full-time
positions also transferred to ORR.
Consistent with Section 462 of the Homeland Security Act and the
Flores v. Reno settlement agreement, ORR will provide care and
placement for these children in the least restrictive setting possible.
To this end, we are (1) scheduling site visits to review all existing
facilities under contract to the former INS, (2) entering into
cooperative agreements with the two agencies experienced in the refugee
unaccompanied minor program to expand shelter and foster care capacity,
and (3) developing training for all staff on the assessment of the
children and the facilities.
ORR is currently working with the Department of Homeland Security
to finalize a Memorandum of Understanding to specify roles and
responsibilities for each agency under the transfer.
The fiscal year 2004 President's Budget includes $34 million in ACF
to support the UAC program. This funding level represents an estimate
developed before the transfer had been completed. The UAC budget
request does not include costs associated with activities not
previously performed by INS, newly authorized in the Homeland Security
Act, or to reach full compliance with the Flores v. Reno settlement
agreement. We look forward to working with Congress to ensure that
adequate support is provided for the care of these children.
MEDICARE HEARINGS TRANSFER
Question. What planning and transition activities are being
undertaken with SSA to ensure that a timely and smooth transition
occurs, if legislation is enacted that transfers the Medicare appeals
function effective October 1, 2003, as proposed in the President's
budget?
Answer. The Department and SSA have agreed in principle to transfer
this function currently performed by SSA's Office of Hearings and
Appeals. Negotiations over the details and timing of the transfer are
on-going. CMS is preparing a Memorandum of Agreement that will reflect
these decisions.
We can transfer the responsibility by October 1, 2003, but to
transfer the work itself would be a monumental task to accomplish. For
one thing, the existing moratorium on hiring new administrative law
judges has not been lifted. For another, CMS's fiscal year 2003 budget
did not include funding for appeals reform so they have not been able
to begin building the framework of systems and operational support that
needs to be in place before this transfer can occur. These activities
would normally require 12 to 15 months. Given the delays and costs of
the existing process, we would ideally like to have sufficient time and
resources to design a process that provides fair and timely hearings
for our Medicare beneficiaries.
HEALTH WELLNESS
Question. Under what circumstances would you support funding a
chiropractic demonstration project on health (Wellness) enhancement
rather than merely the treatment of pain or disease?
Answer. AHRQ has supported research in the area of chiropractic
care. One study found that chiropractic care is the most commonly used
alternative therapy for back problems, and is as effective as medical
care alone for reducing disability and pain in patients with low back
pain. To date, the Agency has not supported the wellness aspect of
chiropractic care. To continue to build the evidence-base in the area
of chiropractic care, AHRQ would give research proposal(s) in this area
every consideration under its peer review process.
Question. Given the growing support for lower healthcare costs with
evidence--board wellness care. Under what circumstances would you
support projects that develop wellness models for health delivery?
Answer. Evidence on effectiveness of care should drive the
implementation of wellness models that have been shown to improve
health outcomes and quality of life. AHRQ could evaluate the results of
biomedical and behavior change research in this area.
______
Questions Submitted by Senator Tom Harkin
HEAD START
Question. Mr. Secretary, under the Administration's Head Start
reauthorization proposal, funding for training and technical assistance
in fiscal year 2004 would be reduced by approximately $65,000,000 at
the same time that Head Start programs are being asked to implement new
child and family literacy and other school readiness activities
proposed in the Good Start/Grow Smart initiative, as well as a new
outcomes-based accountability system. Please explain specifically how
much training/technical assistance funding will be allocated to support
these initiatives, as well as identify specifically what costs will be
borne by local programs and what source(s) of funds will be available
to them to pay for related activities. In addition, what types of
training are currently being conducted by local Head Start programs
that will have to be foregone in fiscal year 2004 in order to perform
these new initiatives?
Answer. The training and technical assistance budget has grown
dramatically in the last several years when compared to the number of
children served. Since fiscal year 1990, for example, funding for
training and technical assistance has grown 300 percent, while
enrollment has increased by only 58 percent. Moreover, grantees have
received considerable training and technical assistance resources as
part of the allocation of quality improvement funds. For example,
grantees currently receive $80 million annually for training and
related costs designed to increase the number of teachers with college
degrees. Allowing the Secretary discretion to best target these funds
means that in fiscal year 2004, we will be able to serve almost 10,500
additional disadvantaged children and families in areas of the country
which have the greatest unmet need for Head Start services.
The full costs to grantees of implementing the national reporting
system will be made available to grantees from the fiscal year 2003
increase, so grantees will not need to reduce any current activities to
pay for those costs. Further, much of the early literacy training has
been and will continue to be allocated directly to grantees to cover
travel and other costs associated with this training, so again there
will not be large costs being incurred by grantees.
Grantees, in fiscal year 2004, will continue to be able to address
important T&TA issues. We will work with all of our grantees to assure
that they have adequate resources to meet their priority needs and
will, as necessary, make adjustments in the amount of T&TA resources
expended on other areas to assure that this can happen.
CHILD CARE DEVELOPMENT BLOCK GRANT
Question. A recent report by the Southern Regional Initiative on
Child Care after interviewing administrators in 15 states and the
District of Columbia found that states and localities were
collaborating successfully with Head Start in many areas. The Child
Care and Development Block Grant currently gives states a great deal of
flexibility and they can choose to take advantage of this flexibility
to encourage collaboration by aligning their policies with Head Start
in areas such as eligibility, eligibility redetermination,
reimbursement rates, hours of care, etc. However, the report found that
the major barriers to collaboration were not related to Head Start
policies but rather were caused by state policies for subsidized child
care. How does the administration plan to provide states with the
resources necessary to improve their child care policies in order to
strengthen collaboration?
Answer. The Administration is committed to promoting collaboration
across early childhood programs. Head Start, child care, and other
programs can best meet the needs of families and children by working
together.
However, we do not believe that barriers to collaboration are
solely caused by State policies for subsidized child care. The Southern
Institute on Children and Families report found that ``respondents
generally agreed that polices were not a barrier to collaboration, but
a few State child care policies were cited as burdensome to Head Start
providers because they required programs to operate differently
(emphasis added, p.6).'' From the perspective of a child care provider
wanting to collaborate, Head Start policies might seem burdensome
because they are different from child care policies.
There are fundamental differences between the Child Care and
Development Fund (CCDF)--which awards monies to States for child care
subsidies and quality improvements--and the Head Start program. CCDF
supports parental choice by primarily giving families vouchers that
they can use with an array of providers in the private child care
market while Head Start is a single-design, center-based program
operating within prescriptive Federal parameters [Note: Early Head
Start (EHS) has a home-based option, a center-based option and a
combined option]. CCDF dollars are awarded to States while Head Start
grants go directly to local entities. As a condition of eligibility,
CCDF requires families to work or attend training or education while
Head Start does not. Head Start requires parent involvement in services
to their children, CCDF does not. Head Start focuses on serving
families below the poverty level, while CCDF concentrates on families
transitioning from or at-risk of needing public assistance (some of
whom are above poverty). These and other differences make collaboration
between the two programs a challenge, but as the Southern Institute
report found, not an insurmountable one.
Under President Bush's plan to better prepare children for
kindergarten, the Administration has proposed a statutory change that
would allow States to better coordinate early childhood programs.
States would be given the option to manage Head Start funding, allowing
them to coordinate Head Start with other preschool programs in exchange
for meeting certain accountability requirements.
Additionally, the Child Care and Head Start Bureaus are taking
steps to encourage coordination. For example:
--The Child Care Bureau (CCB) has been charged with implementing
aspects of the President's Good Start, Grow Smart initiative to
help prepare children for school. This includes working with
States to develop early learning guidelines, professional
development plans, and collaboration plans. CCB's technical
assistance effort, including a recent series of regional
planning workshops, is designed to meet the needs of the entire
array of child care settings and providers and to encourage
collaboration across programs.
--The Child Care and Head Start Bureaus jointly fund the Quality in
Linking Together (QUILT) technical assistance initiative to
support full-day, full-year partnerships among childcare, Head
Start, prekindergarten, and other early education programs.
QUILT provides training, on-site consultation, written
materials, and a website of resources (www.quilt.org), and is
particularly adept at strategies to blend or braid funding.
--The Child Care and Head Start Bureaus encourage collaboration
between Early Head Start grantees and infant/toddler child care
providers, for example, by sponsoring joint training
institutes. The Child Care Bureau's new National Infant and
Toddler Child Care Initiative will provide technical assistance
and consultation to help teams of State stakeholders achieve
system-wide improvement in infant and toddler care.
Question. Mr. Secretary, in your prepared statement for your
Department's budget hearing on March 19, 2003, with respect to Welfare
Reform, you wrote: ``we are committed to working with both the House
and Senate to ensure legislation moves quickly and is consistent with
the President's budget.'' Before the Senate Committee on Finance, you
stated your support for additional child care funding in fiscal year
2004. Given that Senate Budget resolution assumes a discretionary
spending increase in the Child Care Development Block Grant of $214
million, while the President requested level funding, and the
resolution assumes a mandatory spending increase in the Child Care
Development Block Grant of $200 million, will the Administration put
forth a budget amendment consistent with these proposals? If not, does
the Administration support these increased resources and will it
propose appropriate offsets?
Answer. The Administration would support increased child care
funding, such as proposed in the House-passed TANF reauthorization bill
(H.R. 4), as it is accompanied by strengthened TANF work requirements
and improvements to the overall TANF program, and is accommodated
within the context of the overall budget.
INDEPENDENT LIVING VOUCHER PROGRAM
Question. Mr. Secretary, I applaud the Administration's awareness
of the unique circumstances faced by individuals who will age out of
foster care, and its goal to help improve upon this situation with the
new Independent Living Voucher program. As you are aware, the Congress
provided approximately $42 million in the Department of Health and
Human Services Appropriations Act, 2003 to support this new program.
Please explain your plan for implementing this new program,
specifically how federal funds will be used efficiently and effectively
in conjunction with the base Independent Living program and other
programs and nonfederal funding streams to better serve the needs such
individuals.
Answer. As you mentioned, several purposes of the base Chafee
Foster Care Independent Living Program (CFCIP) focus on services and
supports to improve the educational outcomes for individuals aging out
of foster care. A recent survey indicates States are providing a wide
range of services to ensure that youth will stay in and complete high
school in order to be eligible for the newly available post secondary
education and training vouchers. These services include tutoring,
remedial instruction, the purchase of books, equipment, supplies and
school related travel and transportation.
Presently, we are developing guidance to the States to direct the
effective implementation of the Education and Training Voucher program
(ETV). The guidance requires States to submit an application amending
and expanding the base CFCIP plan, specifically the educational
assistance component. This application requires States to describe how
they will implement the new voucher program and its required
conditions, including strengthening the educational activities already
in place.
States are also being encouraged to coordinate their program with
other appropriate education, training and dropout prevention programs.
These programs include, but are not limited to, the Department of
Education's Upward Bound program, the Department of Labor's Workforce
Investment Programs for out-of-school youth, and private sector
initiatives such the Orphan Foundation of America's Scholarship program
and the Community College Foundation's Peer Counseling program in
California.
Another way we hope to ensure efficiency is by encouraging States
to work with the student financial offices of educational and training
institutions to certify an individual's eligibility for the voucher
program. In the guidance, we specifically reference the Free
Application for Student Financial Assistance (FASFA) as a resource to
assist jurisdictions in certifying eligibility for the ETV program.
States are encouraged to use the FASFA as it may be a helpful tool for
identifying youth eligible for the ETV program as a part of the case
planning activities specifically related to preparation for post
secondary education and training; and as a method for certifying the
youth's financial status.
______
Question Submitted by Senator Ernest F. Hollings
STROKE
Question. Mr. Secretary, I would like to spend a minute discussing
your agency's stroke-related activities. As you know, stroke is the
third leading cause of death in United States and a major cause of
permanent disability. My home state of South Carolina falls within the
group of Southeastern states known as the ``Stroke Belt'' where stroke
death rates are significantly higher than the national average. More
than half of my state falls within the ``Stroke Buckle,'' a part of the
``Stroke Belt'' where stroke death rates are twice the national
average. South Carolina is at the epicenter of an epidemic. We have the
highest stroke death rate in the nation and have held that unfortunate
distinction for the past five decades.
I noted with great interest the recent release of the CDC's the
``Atlas of Stroke Mortality: Racial, Ethnic, and Geographic Disparities
in the United States.'' The document does a great job defining the
extent of the problem but does not prescribe a solution to the.
problem. For that we need a larger portfolio at the NIH. I am concerned
given the significant impact that stroke has on the lives of so many
citizens, the NIH invests only 1 percent of its budget on stroke
research. At the encouragement of this Subcommittee, the National
Institute of Neurological Disorders and Stroke's Stroke Progress Review
Group identified critical gaps in stroke knowledge and outlined 5
research priorities and 7 resource priorities. Mr. Secretary, what can
you tell us about your plans to implement these recommendations? I
would also appreciate hearing any additional plans you may have to
alleviate and prevent stroke in the ``Stroke Belt'' and the ``Stroke
Buckle?''
Answer. NIH continues to place a high priority on stroke-related
research. The stroke program of the National Institute of Neurological
Disorders and Stroke (NINDS) ranges from basic investigation of stroke
mechanisms through large studies of risk factors and clinical trials
aimed at prevention or treatment. Interventions under investigation
besides the ``clot-buster,'' t-PA, include drugs, surgery, vitamins,
physical therapy, and psychosocial modalities. Research is also
targeted to special issues of stroke in minority populations, women,
and children, and in geographic regions such as the ``stroke belt.''
The NINDS has formed a Stroke Working Group (SWG) of Institute
Program Directors who work on stroke to implement the recommendations
of the Stroke Progress Review Group (SPRG). This group matched current
NINDS stroke activities to SPRG goals, including basic genetic studies,
research to understand the process of stroke recovery, development of
better animal models of stroke, expansion of stroke imaging research,
and development of new designs and methods for stroke clinical trials.
The NINDS Stroke Working Group continues to meet regularly to review
progress in implementing the recommendations of the SPRG, and to
discuss plans for future activities.
The NINDS already supports, or is planing, a variety of stroke
center programs that address a number of SPRG recommendations. A new
initiative, Specialized Program of Translational Research in Acute
Stroke (``SPOTRIAS'') will facilitate translation of basic research
findings into clinical practice, in settings where patients are
evaluated and treated very rapidly after the onset of their symptoms.
The intent of the SPOTRIAS is to support a collaboration of clinical
researchers from different specialties whose collective efforts will
lead to new approaches to early diagnosis and treatment of acute stroke
patients. Training and career development will be part of the SPOTRIAS
program.
Other ongoing efforts are focusing on expanding education and
training of stroke medical and research personnel, a resource priority
identified by the SPRG. Initiatives in this area include the Mentored
Clinical Scientist Development Award, Mentored Patient-Oriented
Research Career Development Award, NINDS Career Transition Award, and
the Mid-Career Investigator Award in Patient-Oriented Research.
We know the ``Stroke Belt'' is an area in the Southeastern United
States with stroke mortality rates approximately 25 percent above the
rest of the nation, and contains a region of even higher stroke
mortality (the ``Stroke Buckle''). African American stroke mortality is
50 percent higher than in whites. The NINDS has initiated several
studies to address this phenomena. The NINDS, NHLBI and NCRR are
jointly supporting a Stroke Prevention/Intervention Research Program at
Morehouse School of Medicine in Atlanta. The goals are to further
understand the etiology of stroke among rural and urban African
Americans who reside in the Stroke Belt. Based on the data obtained,
community-specific stroke prevention and intervention projects will be
crafted and evaluated. Additionally, the Institute supports a study,
``Etiology of Geographic and Racial Differences in Stroke'' in Alabama.
The role of geographic and racial differences in incidence as
contributors to the differences in mortality rates will be examined and
risk factors estimated. Also, the role of candidate genes for stroke
will be investigated. This study addresses the wide range of
hypothesized causes of the excess stroke mortality in the Southeastern
US and among African Americans, and will provide information to design
interventions to reduce the excess stroke mortality in these
populations.
______
Questions Submitted by Senator Robert C. Byrd
MEDICARE PLUS CHOICE
Question. As I hear all this rhetoric about injecting competition
and choice into Medicare to save the program, I must ask myself,
where's the competition and choice in my State? There are only two
Medicare HMOs in the whole State of West Virginia, and they enroll less
than two percent of the entire State's Medicare population. The seniors
in my State depend on a strong and viable traditional, fee-for-service
Medicare program. ``Choice'' seems to be a favorite theme of this
Administration. In the Medicare program, right now, seniors have the
choice of their individual doctor. That's what most people in West
Virginia think about when they think about choice. The last thing
seniors in my State need is a forced choice between the family doctor
they know and trust and the prescriptions drugs they need to live. Mr.
Secretary, what happens under the Administration's current deregulation
scheme, to the poorest and sickest seniors in West Virginia who are
left in a Fee-For-Service Medicare plan, without drug coverage, facing
skyrocketing premiums, and with no HMOs or private health plans coming
to their rescue?
Answer. Senator, President Bush is not about to let that happen,
and the Framework to Modernize and Improve Medicare takes steps to
ensure that all Medicare beneficiaries have access to an Enhanced
Medicare plan with meaningful prescription drug coverage.
Enhanced Medicare will be a system of PPO-style plans that will be
awarded contracts to serve entire multi-state regions. Under those
contracts, the PPOs will be required to take all beneficiaries--those
in the cities, as well as those in the rural areas. This structure will
be fundamentally different than the county-by-county contracts you are
familiar with in Medicare+Choice. This system of regional contracting
has worked successfully for TRICARE in the military health system.
That's why we believe that the regional PPO approach is right for
Medicare.
PPOs have been a growing form of health insurance and are now the
most popular type of coverage in the private market. Among individuals
with employer group coverage, 52 percent are enrollees of PPOs as of
2002. Today's workers will age into Medicare with experience with PPO
coverage. Indeed, 78 percent of large employers offer a PPO option to
pre-65 retirees.
So all Medicare beneficiaries will have the option of Traditional
Medicare or Enhanced Medicare as described above. In addition, for
those who choose to stay in Traditional Medicare, the Framework
protects them from undue premium increases. Part B premiums would
continue to be calculated as though current law were in effect.
MEDICARE PRESCRIPTION DRUG PROPOSAL
Question. Mr. Secretary, you have repeatedly stated that the
Administration's proposal to reform Medicare is modeled after the
Federal Employees Health Benefit Plan (FEHBP), which offers several
different health plans for Federal employees. However, in States like
West Virginia, comparing Federal employees participating in the FEHBP
to Medicare beneficiaries participating in the Medicare program is like
comparing ``apples and oranges.'' The Federal employees in West
Virginia are much younger, wealthier, and healthier than the Medicare
beneficiaries in West Virginia. Medicare beneficiaries in West Virginia
are either elderly or disabled, and tend to be heavy utilizers of
costly health care services. Further, the health plans offered to
Federal employees in West Virginia through the FEHBP are all
concentrated in only small pockets of my State, the Northern and
Eastern Panhandle regions, which are less rural. There are very few
Federal health plans offered in southern West Virginia. Mr. Secretary,
can you offer an explanation as to how a Medicare prescription drug
proposal, modeled after the Federal Employees Health Benefit Plan,
would work in West Virginia?
Answer. The difference, Senator, is in how Enhanced Medicare
defines its service areas. Under Enhanced Medicare, beneficiaries could
choose to receive integrated benefits and drug coverage offered through
a FFS/PPO plan, like FEHBP or TRICARE. The plans would bid to serve one
or more of 10 multi-state regions, and by doing so they would agree to
serve the entire region, cities and rural areas alike. In addition, all
beneficiaries in a region are guaranteed access to any of the three
plans that are entrusted to serve the region. Beneficiaries who enroll
in an average-priced plan in their region would pay a premium equal to
the Part B premium in traditional Medicare. Those choosing the plan
with the low-priced bid would receive most of the savings, while those
choosing the high-priced bid would pay a supplemental premium.
Beneficiaries would pay an additional premium for drug coverage, except
for those with low incomes. New benefits in the enhanced package
include a combined deductible for Part A & B services, free preventive
benefits, and protection from high out-of-pocket medical costs.
In designing the framework, the President is looking toward other
federal programs that have successfully brought coverage to federal
workers in big city offices, to forest rangers in remote areas, and all
federal workers and their dependents in between.
PRESCRIPTION DRUG COST
Question. Mr. Secretary, according to an article in The Wall Street
Journal on February 24, 2003, it appears that taxpayers as well as
Medicaid are being significantly overcharged for prescription
medications by certain pharmaceutical companies. The article states
that ``despite a 1990 law requiring drug makers to report to Medicaid
the lowest prices they charge anyone, some big pharmaceutical companies
simply aren't doing so.'' The result is taxpayers and Medicaid are
paying more than their fair share for prescription drugs. Mr.
Secretary, I find this matter deeply troubling and wonder why the
Administration has chosen to ignore this glaring loophole in the law in
its current Medicaid proposal?
Answer. This administration has by no means ignored the
complications surrounding prescription drug pricing. In fact, the
President's budget proposes to work to work with congress to improve
the Medicaid drug rebate system. There are many means by which we can
generate program savings. We look forward to working with you to
determine the course of action that will best address the concerns of
the American taxpayer.
MEDICAID PROPOSAL
Question. Mr. Secretary, I am concerned that the Administration may
be trying to take advantage of the current fiscal crisis facing States
in order to sneak out of the Federal government's financial obligations
to the poor and disabled and to cap what is now a guarantee of specific
health benefits. The Administration's Medicaid proposal would
essentially eliminate the federal guarantee of certain health benefits
for a significant portion of the Medicaid population. Why is the
Administration dismantling this health care safety net at a time when
many Americans are vulnerable from the struggling economy and rising
health care costs?
Answer. The Administration has proposed State Health Care
Partnership Allotments to deal directly with the problems of coverage
being eliminated due to constrained State budgets. States can currently
eliminate coverage for non-mandatory populations and many states have
already made cuts. We are not eliminating any guarantees that currently
exist.
The Medicaid reform package gives States alternatives to merely
cutting the rolls. Instead of solving budgetary dilemmas by cutting
whole populations, the allotment model would allow States to
strategically construct services in ways that most ably address the
specific needs of their unique Medicaid and SCHIP populations.
Once again let me stress, mandatory services for mandatory
populations will not be affected by the reform package. We are not
allowing States to cut any populations they can't already cut through
State Plan Amendments. We hope that we have given States a more humane
alternative to eliminating benefits for needy Americans.
SCIENTIFIC ADVISORY COMMITTEE
Question. Mr. Secretary, I found it extremely disturbing to read on
the front page of The Washington Post last Fall that the Bush
Administration has been quietly overhauling the 250 scientific advisory
committees that guide the Department of Health and Human Services (HHS)
on a wide range of health issues. I am concerned that the Presidents
message to scientific advisory committees within his Administration
reads: either you're with us or you're against us. While the
Administration talks about supporting programs that are shown by
science to be effective, at the same time, the Administration is
reshuffling the independent panels and stacking them with handpicked,
partisan choices. Mr. Secretary, why should the general public have any
confidence in the recommendations of these advisory panels when their
independence and objectivity appear to have been compromised?
Answer. There are over 250 Secretarial Advisory Committees at the
Department of Health and Human Services. By Congressional charge the
Office of the Secretary is responsible for making appointments to these
committees. Vacancies on these committees occur regularly for a variety
of reasons including resignations and expiring terms. We are also
charged with maintaining the charters of these committees and from time
to time we must update charters as they also expire. As a result, we
will make hundred of appointments in the course of any year and update
several charters in the same time frame.
Let me assure you that this Department fully supports and
understands the need to select members for scientific advisory
committees who are the best suited to promote health in our nation.
Under the General Services Administration manual's chapter on Advisory
Committee Management, we are required to adhere to certain policies.
For example, we must ensure that the nomination, selection, and
appointment process results in selections that are balanced in terms of
views represented. I am confident that we have in place procedures to
ensure that we select members who are not only experts, but whom we
believe will provide objective assessments on important scientific
matters without prejudice or prejudgment.
SUBCOMMITTEE RECESS
Senator Specter. Thank you all very much. The subcommittee
will stand in recess to reconvene at 9:30 a.m., Thursday, March
27, in room SD-192. At that time we will hear testimony from
the Honorable Roderick Paige, Secretary, Department of
Education.
[Whereupon, at 10:27 a.m., Wednesday, March 19, the
subcommittee was recessed, to reconvene at 9:30 a.m., Thursday,
March 27.]